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INTRODUCTION 
Over the past two decades, a dramatic worldwide increase in the number of 
people with the metabolic syndrome has been observed. The term “metabolic 
syndrome” defines the clustering of risk factors that often accompany obesity 
and associate with increased risk for cardiovascular disease and type 2 di-
abetes. Although a constellation of closely related metabolic risk factors for 
cardiovascular disease was first recognized more than 80 years ago, it was re-
introduced by Reaven in the Banting lecture in 1988, under the term Syndrome 
X or insulin resistance syndrome (1). The present common designation is “me-
tabolic syndrome”. 
The cluster of metabolic abnormalities associated with the metabolic syndrome 
includes insulin resistance, central obesity, disturbed glucose homeostasis 
(type 2 diabetes, impaired fasting glucose or impaired glucose tolerance), athe-
rogenic dyslipidemia, hypertension, and a pro-thrombotic and pro-
inflammatory state (2-5). These are all well documented risk factors for cardi-
ovascular disease. With advancing medical science, other diseases are being 
linked to the metabolic syndrome including non-alcoholic fatty liver disease, 
polycystic ovarian syndrome, cancer, gallstones, gout, and obstructive sleep 
apnoea (6).  
 
 
DEFINITION OF THE METABOLIC SYNDROME 
The ultimate importance of defining the metabolic syndrome is to identify 
subjects at high risk for cardiovascular disease. There has been much discus-
sion and several attempts by experts groups to define standardized diagnostic 
criteria. The World Health Organisation (WHO) was the first to publish their 
definition in 1998 (7), which was slightly modified in 1999 (8). A mandatory 
criterion of the WHO was insulin resistance and/or disturbed glucose homeos-
tasis. In addition two of the following four risk factors needed to be present: 
hypertension, dyslipidemia, central obesity and microalbuminuria. The Euro-
pean Group for Study of Insulin Resistance (EGIR) published their criteria in 
1999 (9). They excluded people with type 2 diabetes, but analogous to the 
WHO-criteria put forward insulin resistance, reflected by hyperinsulinemia, as 
the central mandatory component. In addition, presence of two of four other 
risk factors (hyperglycemia, hypertension, dyslipidemia and central obesity) 
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needed to be fulfilled (9). The National Cholesterol Education Program Adult 
Treatment Panel III (NCEP:ATPIII) criteria were published in 2001(10). These 
criteria did not make insulin resistance strictly required for diagnosis. Instead, 
three of the following five risk factors (Increased waist circumference, low 
HDL-cholesterol, high triglycerides, hypertension and impaired fasting glu-
cose), needed to be present to meet the diagnostic criteria for the metabolic 
syndrome. The NCEP:ATPIII-criteria were more suitable for clinical practice as 
it required only fasting assessment of blood glucose, whereas WHO and EGIR 
required an oral glucose tolerance for their diagnostic procedure. In 2003, the 
American Association of Clinical Endocrinology (AACE) refocused on insulin 
resistance as the primary cause of metabolic risk factors, and used the name 
“insulin resistance syndrome”(11). Remarkably, the AACE statement delibe-
rately does not provide a specific definition of the syndrome and allows the 
diagnosis to rely on clinical judgment, irrespective of the number of risk fac-
tors present. Also according to the AACE’s definition, once a person develops 
type 2 diabetes mellitus, the term insulin resistance syndrome no longer ap-
plies. 
The different definitions described above reflect the discussion in the scientific 
world on the conceptual framework that underlies the metabolic syndrome. 
Due to an incomplete understanding of the biological background, opinions 
vary on whether the metabolic syndrome should be defined to mainly indicate 
insulin resistance, consequences of obesity, risk for cardiovascular disease, or 
just a collection of statistically related factors. The parallel use of different 
definitions led to confusion and hampered the comparability of studies. In 
May 2004 the International Diabetes Federation (IDF) convened a workshop 
with representatives from the WHO, the NCEP-ATPIII, and members from all 
IDF regions to attempt to establish a new unified definition for the metabolic 
syndrome (12). Put first was that the new definition should be simple for clini-
cal practice and easily to be used in any country worldwide. From this prere-
quisite, the clinically simple NCEP-ATPIII criteria were chosen as a starting 
point. Furthermore it was considered that abdominal obesity is so highly cor-
related with insulin resistance that other, more laborious measures of insulin 
resistance are unnecessary. Abdominal obesity, assessed by waist circumfe-
rence, was the mandatory central trait in the new diagnosis. Importantly, waist 
circumference cut-off values were specified by nationality or ethnicity based 
on best available population estimates. Two additional risk factors from the 
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NCEP-ATPIII criteria are sufficient to establish the diagnosis “metabolic syn-
drome” (12).  
It is certain that the most recent criteria from the IDF are not the final word. 
Almost simultaneously with the new IDF consensus, the National Heart Lung 
and Blood Institute (NHLBI), together with the American Heart Association 
(AHA) reaffirmed the utility of ATPIII criteria, with minor modifications (13). 
Although the last ATPIII-update and the IDF criteria harmonize more on the 
clinical diagnosis than all previous definitions, the ultimate goal of one global 
definition has apparently not been achieved yet. Despite the fact that defini-
tions differ in detail, and handle different cut-off levels for several components 
of the metabolic syndrome, they agree on the following central traits: obesity, 
disturbed glucose homeostasis, dyslipidemia and hypertension. 
 
Part of the scientific community is sceptical about the term “metabolic syn-
drome”, especially the ill-considered use thereof. They agree that the term may 
have some utility to refer to a cluster of correlated risk factors for cardiovascu-
lar disease, but are strongly set against its representation as a specific algo-
rithm that should be used to diagnose a unique disease. Their view is sup-
ported by the absence of scientific observations, showing that the risk im-
parted by the metabolic syndrome is higher than the simple additive effects of 
its separate components (14, 15). On the contrary, several reports document 
that the risk of cardiovascular disease, associated with the metabolic syn-
drome, can be fully explained by the presence of the separate factors (16-19). In 
spite of all this, most important from a clinicians perspective is to realize that 
occurrence of one risk factor may portend the presence of others, and that each 
of these risk factors confer additional cardiovascular risk.   
 
 
PREVALENCE OF THE METABOLIC SYNDROME 
The prevalence of the metabolic syndrome varies between different popula-
tions and is highly age-dependent. In studies that include subjects of 20 years 
and older, the prevalence in men varies from 8% in urban populations in India 
to 24% in the USA, and for women from 7% in France to 43% in Iran (3). Nota-
bly, in age categories of 60 years and older the prevalence can rise to 67% (3). 
Obesity is the driving force behind the pandemic proportions of the metabolic 
syndrome and type 2 diabetes. In 2005, about 1.6 billion adults (15 years and 
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older) were overweight (BMI≥25) and approximately 400 million were obese 
(BMI≥30). The WHO further projects that by 2015, approximately 2.3 billion 
adults will be overweight and more than 700 million adults will be obese. 
Obesity has become to diabetes what tobacco is to lung cancer and roughly 
60% of all cases of diabetes can be directly attributed to weight gain (20). The 
total number of people with diabetes was estimated at 171 million in 2000 
(2.8%) and is projected to rise to 366 million (4.4%) in 2030 (21), with biggest 
increases expected in India and China (20). Notably, the majority of patients 
with type 2 diabetes fulfill the criteria of the metabolic syndrome. The other 
way around, many subjects with the metabolic syndrome do not have type 2 
diabetes although they often are insulin resistant. 
 
 
PATHOPHYSIOLOGY OF THE METABOLIC SYNDROME 
INSULIN RESISTANCE 
The pathophysiology of the metabolic syndrome is extremely complex. There 
is considerable controversy regarding the initiating factor, but the most ac-
cepted and unifying hypothesis to describe the pathophysiology of the meta-
bolic syndrome is insulin resistance. It is postulated that an overabundance of 
circulating non esterified fatty acids (NEFA), mainly derived from adipose 
tissue, is a very early and major contributor to the development of insulin 
resistance. Excessive caloric intake and sedentary life style are on the basis of 
excessive accumulation of body fat. Especially the increase of visceral adipose 
tissue is strongly associated with the development of insulin resistance (22) 
and the metabolic syndrome (23-30). A potential explanation is that lipolysis in 
visceral adipose tissue is less suppressed by insulin than peripheral fat depots, 
and because visceral fatty acids drain into the portal circulation directly to the 
liver. 
The hepatic uptake of fatty acids is not regulated and as a result, plasma fatty 
acid concentrations are directly related to the influx of fatty acids to the liver. 
This leads to hepatic insulin resistance, relative systemic hyperinsulinemia 
(due to reduced hepatic insulin clearance) and eventually Non Alcoholic Fatty 
Liver Disease (NAFLD), which is strongly related to hepatic insulin resistance. 
In the fasted state, adipose tissue contributes approximately 80% of fatty acid 
content to the plasma NEFA pool, and even in the fed state, this contribution 
remains at approximately 60% (31, 32). This plasma FFA pool in turn accounts 
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for approximately 65% of hepatic triglyceride content in subjects with NAFLD, 
illustrating the importance of free fatty acids in the pathogenesis of NAFLD 
and hepatic insulin resistance. Also increased de-novo synthesis of triglyce-
rides contributes to hepatic fat content in insulin resistance. This occurs be-
cause hyperinsulinemia and hyperglycemia induce the expression of sterol 
regulatory element binding protein 1c (SREBP1c), and carbohydrate respon-
sive element binding protein (ChREBP), respectively (33-35). Both transcrip-
tion factors activate genes involved in de-novo lipogenesis in liver. The contri-
bution of this pathway to hepatic triglyceride content is marginal in healthy 
subjects, but in hyperinsulinemia subjects with NAFLD, it accounts for 25% of 
liver triglycerides (31).  
Fat accumulation in muscle is also strongly correlated with insulin resistance. 
A proposed mechanism in muscle is that increased plasma FFA levels lead to 
increased intracellular long-chain fatty acyl-CoA (LCFA-CoA) concentration, 
which in turn results in diacylglycerol (DAG) and triglyceride formation. DAG 
is a known activator of protein kinase Cθ (PKCθ), which is linked to insulin 
resistance (36, 37). 
Insulin resistance may thus be viewed as a consequence of increased NEFA 
flux, mainly released from the visceral adipose tissue depot. Muscle insulin 
resistance results in hyperglycemia, whereas insulin resistance in the liver it 
underlies NAFLD, increased hepatic glucose output, dyslipidemia, and a pro-
coagulant and pro-inflammatory state.  
 
INFLAMMATION AND A PRO-THROMBOTIC STATE 
Obesity is associated with increased production of inflammatory cytokines, 
particularly from visceral adipose tissue. Despite the fact that considerable 
insight has been acquired in the many inflammatory factors that mediate insu-
lin resistance, and the intracellular pathways involved, it is unclear whether 
inflammation is a primary event which links obesity with insulin resistance, or 
rather secondary to hyperlipidemia or hyperglycemia. 
The first pro-inflammatory cytokine shown to be able to induce insulin resis-
tance was TNFα (38, 39). At present, adipose tissue has been shown to induce 
expression and secretion of many cytokines and bioactive compounds, includ-
ing monocyte chemoattractant protein-1 (MCP-1), plasminogen activator inhi-
bitor-1 (PAI-1), resistin, adiponectin, serum amyloid A (SAA), leptin, IL-1β, IL-
6, angiotensinogen, visfatin, retinol binding protein-4 (RBP4) and others (40, 
41). Adiponectin has anti-inflammatory properties, and its expression decreas-
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es with increased adiposity (42). Anti-inflammatory features of adiponectin 
include suppression of TNFα and induction of the anti-inflammatory cyto-
kines IL-10 and IL-1-receptor antagonist (43). Adiponectin and leptin appear to 
be true adipokines, exclusively produced by adipocytes, whereas the other 
molecules are also expressed in activated macrophages or other cell types (40). 
Inflammation of adipose tissue is characterized by macrophage infiltration (44, 
45). It has been suggested that secretion of MCP1 by adipocytes may play a 
role in the recruitment of macrophages to adipose tissue. Infiltrated macro-
phages may in turn secrete a variety of other cytokines and chemokines that 
further promote a local inflammatory response (46, 47).   
Also in liver, pro-inflammatory gene expression (PAI, CRP and others) in-
creases with increasing adiposity (48). This suggests either that hepatocyte 
lipid accumulation might induce an inflammatory response similar to that 
observed in lipid-laden adipose tissue, or alternatively, that pro-inflammatory 
substances, released from the abdominal fat depot in the portal circulation 
elicit an inflammatory response in liver (40). Whatever mechanism is applica-
ble, the final outcome is a further development of a pro-thrombotic and pro-
inflammatory state (40, 49).  
Many of the pro-inflammatory stimuli can provoke insulin resistance via acti-
vating IKKβ/NF-κB and JNK pathways (48, 50, 51). Activated JNK provokes 
insulin resistance through phosphorylation of serine residues in IRS-1. Unlike 
JNK, IKKβ does not phosphorylate IRS-1 to cause insulin resistance, but in-
stead liberates NF-κB for translocation to the nucleus where it promotes the 
transcription of target genes whose products induce insulin resistance. 
 
DYSLIPIDEMIA 
Lipid and lipoprotein abnormalities in the metabolic syndrome can be summa-
rized as follows 1) increased triglyceride levels, 2) increased small, dense LDL 
levels, 3) increased apolipoprotein B (apoB) levels, and 4) decreased HDL cho-
lesterol levels. It has been suggested that NAFLD plays a central and causal 
role in the atherogenic lipid profile seen in the metabolic syndrome (52-54). 
The hypertriglyceridemia which accompanies abdominal obesity, insulin resis-
tance and NAFLD is related to hepatic over secretion of apoB containing trig-
lyceride-rich VLDL particles. (55, 56) ApoB enhances assembly and secretion 
of VLDL particles. Furthermore, apoB is the structural protein of atherogenic 
lipoproteins including VLDL, intermediate density lipoproteins (IDL), and low 
density lipoproteins (LDL). Each of these lipoproteins contains one apoB mo-
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lecule, and the plasma apoB level reflects the total number of atherogenic par-
ticles in the blood (57).  Production of apoB is regulated at the post-
translational level. Insulin can degrade apoB via a phosphotidylinositol 3-
kinase dependent pathway (58). Hepatic insulin resistance, combined with the 
abundant availability of lipids in the liver dampen posttranslational degrada-
tion of apoB, and lead to increased secretion of VLDL and formation of larger 
VLDL particles (VLDL1) (53, 59). The result is hypertriglyceridemia. Under 
normal conditions, VLDL is hydrolyzed by lipoprotein lipase to IDL and LDL 
in the peripheral circulation, thereby generating FFA for energy use or storage. 
Lipoprotein lipase activity is also decreased in insulin resistance (60, 61). 
Hence, elevated VLDL (and thus hypertriglyceridemia), IDL and LDL particles 
in insulin resistance are due to a combination of increased VLDL production 
and decreased clearance. 
Low HDL-cholesterol and an increased number of small, dense LDL particles 
is an integral feature of dyslipidemia, and strongly linked to VLDL overpro-
duction (52). Increased levels of triglyceride rich lipoproteins, in combination 
with reduced lipoprotein lipase activity increase the residence time of these 
particles in the circulation.  Under conditions of hypertriglyceridemia, chole-
steryl esters in LDL and HDL particles are exchanged for triglycerides from 
VLDL particles, by action of cholesteryl ester transfer protein (CETP), which is 
increased in insulin resistance (52). The transfer of triglycerides into LDL and 
HDL particles makes them triglyceride-rich and hence a better substrate for 
hepatic lipase, which is also increased in insulin resistance (57). The result is a 
predominance of small, dense LDL particles and a reduction of HDL choles-
terol. This reduction is a consequence of changes in HDL metabolism (small 
HDL has an enhanced catabolic rate) and composition (especially HDL2, the 
large buoyant anti-atherogenic subspecies of total HDL is reduced) (53, 57).  
Small dense LDL particles can contribute to the risk conferred by LDL choles-
terol for increased cardiovascular disease (62-65). A potential mechanistic 
explanation for the association of small, dense LDL with an additionally in-
creased risk of cardiovascular disease is that it may enter the arterial wall more 
easily, binds better to proteoglycans, (66, 67), and is more susceptible to oxida-
tive modification, leading to macrophage uptake and eventually foam cell 
formation (68, 69).  
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DISTURBED GLUCOSE HOMEOSTASIS AND TYPE 2 DIABETES 
The conversion from normoglycemia to clinical type 2 diabetes can take a few 
years or even decades and requires two separate defects simultaneously: insu-
lin resistance and β-cell failure. Insulin resistance may be present many years 
before the diagnosis of type 2 diabetes, and it is believed that the pathological 
course towards developing type 2 diabetes starts with a gradual increase in 
insulin resistance, which results in compensatory hyperinsulinemia (70).  This 
state can be maintained as long as pancreatic β-cells are able secrete enough 
insulin to compensate for cellular insulin resistance by boosting their secretion 
capacity and increasing their β-cell mass (71-73). However at some point, 
modulated by the presence of genetic or acquired factors, β-cells become ex-
hausted. This results in impaired glucose tolerance and early type 2 diabetes. 
Hyperglycemia or glucotoxicity, once established promotes a series of events 
that contribute to severe β-cell failure and apoptosis, and ultimately overt type 
2 diabetes (74). Plasma free fatty acids do not only play a central role in insulin 
resistance (described above), but also contribute to pancreatic β-cell failure. 
Short term exposure of pancreatic islands to free fatty acids increases insulin 
secretion, but long term exposure inhibits insulin biosynthesis and secretion in 
response to glucose, and may eventually lead to β-cell death (75-78). The dele-
terious effect of excess free fatty acids on the β-cell is called lipotoxicity (79). 
 
HYPERTENSION 
The relation between insulin resistance and hypertension is less clear. Risk 
estimates from the Framingham Heart Study attributes excess weight as the 
cause of hypertension in 78% of men and 65% of women (80). A central feature 
of hypertension is increased sodium re-absorption in the kidney and extracel-
lular fluid volume expansion, which initiates hypertension. In insulin sensitive 
subjects insulin acts as a vasodilatator with secondary effects on sodium re-
absorption. In the setting of insulin resistance the vasodilatory effect of insulin 
can be lost (81), whereas the effect on sodium re-absorption by the kidney is 
preserved (82). Insulin also activates the sympathetic nervous system, even 
under conditions of insulin resistance (83). Fatty acids themselves can mediate 
vasoconstriction in humans (84) and infusion of fatty acids in the portal vein in 
rodents activates the sympathetic nervous system and increases blood pres-
sure (85). Elevated leptin levels may also increase blood pressure (86, 87).  
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GENETIC PREDISPOSITION TO THE METABOLIC  
SYNDROME 
Two subgroups of patients with the metabolic syndrome, those with type 2 
diabetes and Familial Combined Hyperlipidemia (FCHL), are at particularly 
high risk for premature CAD (57, 88). They share many of the phenotypic 
features of the metabolic syndrome including insulin resistance, abdominal 
obesity, hypertension and dyslipidemia. A recent report exemplified that near-
ly two-thirds of individuals with FCHL, and the vast majority of patients with 
type 2 diabetes, meet the diagnostic criteria of the metabolic syndrome (figure 
1) (89). 
 
 
 
 
 
 
 
Figure 1: The metabolic syndrome comprises a heterogeneous group of oligogenic disorders, 
such as familial combined hyperlipidemia and type 2 diabetes. 
Therefore, an improved understanding of the genetic background of FCHL 
and type 2 diabetes may benefit millions of people with the metabolic syn-
drome.  The marked presence of a genetic component in type 2 diabetes and 
FCHL, reflected by their familial clustering, provides us with two excellent 
models to study the genetic background of insulin resistance and the metabol-
ic syndrome. 
 
FAMILIAL COMBINED HYPERLIPIDEMIA 
FCHL is a combination of heterogeneous dyslipidemias, segregating in fami-
lies and predisposing affected individuals to early-onset cardiovascular dis-
ease. It is the most common familial dyslipidemia, and estimated to be respon-
sible for 10-20% of cardiovascular events before the age of 50 in Western socie-
ties (88). The metabolic features of subjects with FCHL are very similar to 
those of the metabolic syndrome, and most of the patients with FCHL, espe-
METABOLIC 
SYNDROME 
FCHL 
DM2 
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cially the hypertriglyceridemic subjects, meet the NCEP criteria for the meta-
bolic syndrome (57). In fact, FCHL patients develop multiple characteristics of 
the metabolic syndrome when waist circumference and body mass index are 
only slightly increased, reflecting their strong genetic predisposition to insulin 
resistance (90, 91). Purnell and colleagues showed that for any level of insulin 
sensitivity or abdominal obesity, apoB levels were higher in the FCHL subjects 
than in control subjects. They concluded that, although visceral obesity and 
insulin resistance are important determinants of increased apoB levels and the 
hyperlipidemic phenotype in FCHL, they cannot fully account for them, and 
that additive, genetic determinants are involved in the etiology of the lipid 
phenotype (92). Data from our own lab provided confirmatory evidence. For 
any level of abdominal obesity, apoB- and lipid levels were higher in FCHL-
patients than in their spouses (91). The strong genetic component in FCHL 
makes it an excellent model to study the genetic background of metabolic 
syndrome and insulin resistance. Conversely, FCHL-related research findings 
can be highly relevant for our understanding of the pathogenesis of the meta-
bolic syndrome and insulin resistance. Of note, although overt insulin resis-
tance is obvious, FCHL patients are not particularly prone to develop type 2 
diabetes. 
 
TYPE 2 DIABETES 
The vast majority (80-90%) of patients with type 2 diabetes meet the criteria of 
the metabolic syndrome. Several lines of evidence further support the view 
that genetic components also play an important role in the pathogenesis of 
type 2 diabetes. Data from the Framingham Offspring study showed that, 
when one parent was affected, the risk of type 2 diabetes in the offspring was 
3.5 fold increased compared to subjects in the general population, and even 6 
fold when both parents were affected (93). Furthermore, the high concordance 
rate in monozygotic twins, and the 50% fall in dizygotic twins further streng-
then the concept that DM2 has a strong genetic component of (94-98). Addi-
tional evidence comes from admixture studies. The prevalence of type 2 di-
abetes varies greatly in different ethnic groups, from 1% in rural Chinese areas 
to 50% in Nauruans and Pima Indians (99). Moreover, the prevalence of type 2 
diabetes in Pima Indians is inversely related to the extent of interbreeding with 
European Americans (100). Similar findings have been reported for Nauruans 
(101). The ultimate proof for inherited risk to type 2 diabetes and Familial 
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Combined Hyperlipidemia comes from the identification of susceptibility 
genes predisposing to these diseases. 
 
 
OUTLINE OF THIS THESIS 
The central aim of this thesis was to identify novel genes and pathways that 
underlie the pathophysiology of insulin resistance, using FCHL and type 2 
diabetes as a model. Since FCHL and type 2 diabetes are postulated to share 
substantial genetic overlap, our side by side research design also provides an 
unique opportunity to investigate whether established and novel susceptibility 
genes for FCHL confer also increased risk to type 2 diabetes and vice versa. In 
Chapter 2 we provide an update on the present understanding of genes that 
underlie FCHL and type 2 diabetes. The first experimental chapter (Chapter 3) 
is the basis of this thesis. It describes a gene expression study conducted on 
cultured pre-adipocytes from patients with FCHL and healthy control subjects. 
The use of cultured human cells instead of freshly isolated adipocytes allowed 
us to suppress adaptive gene expression differences and preserve the 
(epi)genetic effects. This approach revealed increased CD36-expression and 
CD36-functionality as a novel, potentially important feature of FCHL adipose 
tissue. Furthermore gene-expression data of chapter 3 and another expression 
array were integrated with results from linkage analyses and led to the identi-
fication of Activating Transcription Factor 6 (ATF6) as a new candidate gene 
for type 2 diabetes in Chapter 4. The potential significance of ATF6 is extended 
in Chapter 5 were we demonstrate association of an exonic variant in ATF6 
with FCHL in three independent samples from Dutch and Finnish origin. In 
vitro studies support the genetic data and unequivocally implicate the ATF6 
exon polymorphism as a causal variant. Together, results from chapter 4 and 5 
provide proof for the postulated shared genetic background in FCHL and type 
2 diabetes, and highlight the endoplasmic reticulum stress response, a novel 
pathway in the pathophysiology of insulin resistance and dyslipidemia. Chap-
ter 6 evaluates the well-established FCHL-susceptibility gene Upstream Stimu-
latory Factor 1 (USF1), for its potential role in type 2 diabetes in two large 
Dutch case control samples comprising more than 2000 individuals. In Chapter 
7 we put all data in perspective, discuss their potential relevance for diagnostic 
or screening purposes, and integrate them with emerging insights in the field 
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of insulin resistance, with emphasis on the endoplasmic reticulum stress re-
sponse. 
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Introduction 
In contrast to other approaches to the dissection of pathophysiological me-
chanisms, genetic studies have the advantage of establishing chains of causali-
ty, since physiological changes are the result of genomic variation, and never 
the reverse (1). 
The genetic dissection of non-mendelian, or so-called “complex diseases”, is 
extremely challenging. Familial combined hyperlipidemia and type 2 diabetes 
are typical examples of such complex diseases with substantial genetic hetero-
geneity. At the molecular level they cannot be looked upon as one disease, but 
in fact include different molecular disorders which are grouped together be-
cause they manifest with the same (combination of) phenotype(s). Obviously 
this leads to a dilution of effects and consequently loss of power in genetic 
studies. A major task of genetic research includes providing clarity in the dif-
ferent categories of diabetes and hyperlipidemia, and allowing more specific 
classification and possibly clinical treatment. For diabetes several subgroups 
with autosomal dominant inheritance (Maturity-onset Diabetes of the Young, 
reviewed in (2, 3)), or a specific pathway involved (Mitochondrial diabetes (4)) 
have been successfully identified.  
Two main approaches have been employed to unravel the genetic background 
of complex diseases such as DM2 and FCHL: a candidate gene approach and a 
positional cloning approach. Valuable complementary approaches to help 
directing the search for candidate genes include the use of gene expression 
experiments, and animal models. An overview of the candidate gene approach 
and positional cloning approach to susceptibility gene identification for DM2 
and FCHL, as well as their individual strengths and drawbacks, is described 
below. It should be noted that the skewed attention in favor of results from the 
diabetes field reflects the attention given to these disorders by the scientific 
community, and explain why several DM2 genes have not been tested for their 
potential role in FCHL, despite the fact that they are attractive biological can-
didates.  
 
 
 
 
 
 
Genetic Approaches to the Molecular Understanding of DM2 and FCHL 
29 
 
The candidate gene approach 
Candidate genes selected for their biologic plausibility 
Most association studies have been conducted on genes, identified through 
their known function in a relevant physiologic pathway. Given the present 
incomplete knowledge of the pathogenesis of DM2 and FCHL, the list of po-
tentially interesting genes is large. In fact, it includes –without being limited 
to– all genes whose proteins are involved in, adipocyte-, muscle-, hepatocyte- 
and beta cell-function, insulin signaling pathways and hypothalamic regula-
tion. It can be expected that only a small subset of these candidates will harbor 
genetic variants that substantially contribute to the population attributive risk. 
Several tens and hundreds of biological candidate genes have been genetically 
explored in relation to FCHL and DM2 respectively. Although many of them 
showed modest associations in single populations, replication studies often 
failed to confirm the initial results, preventing definitive statements on their 
involvement. Genes with abundant evidence for conferring genetic risk to 
DM2, FCHL or both are discussed below. 
 
Box 1. Diagnostic problems in FCHL 
In addition to the genetic complexity in itself, FCHL research is additionally complicated by diagnostic 
disagreements. Because no single pathognomonic marker is available for the diagnosis of FCHL in an 
individual, family studies are needed to establish the diagnosis. However in this family based diagnos-
tic process, different research groups applied different criteria to categorize members of FCHL families 
either as affected, or unaffected. Fixed cut-off values as well as age-and sex-specific 90-95th population 
percentiles have been used to distinguish normolipidemic relatives from affected family members (5, 6). 
Also the incorporation of apolipoprotein B in the diagnostic criteria has been advocated (7-11), but 
until now only applied in a limited fashion (12).  
The absence of uniform diagnostic criteria for FCHL, like we do have for DM2, impedes the direct 
comparison of genetic studies from different research groups, and likely contributes to the inconsisten-
cies encountered when aiming to replicate results from linkage and association studies. Obviously, the 
fact that many studies are actually underpowered, increasing the chance of type 1 and type 2 errors, is 
the main reason.  Some efforts have been made to work towards a uniform diagnostic consensus for 
FCHL (9), but in analogy to the attempts being made for a uniform diagnosis of the metabolic syn-
drome, this appears an extremely demanding and diplomatic process. 
 
Peroxisomal Proliferator-Activated Receptor gamma (PPARγ) 
PPARγ is a member of the nuclear hormone receptor superfamily of transcrip-
tion factors, and a target of thiazolidinediones, a widely used class of insulin 
sensitizers. PPARγ was initially selected as a candidate gene for DM2 because 
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of its key role in adipogenesis and adipocyte function (13). Multiple studies 
investigated the common Pro[12]Ala variant in the PPARγ2-isoform for asso-
ciation with type 2 diabetes, Familial Combined Hyperlipidemia, the metabol-
ic syndrome and related traits. An initial study reported that the alanine allele 
reduce DM2 risk with 75% (13). Subsequent smaller -often underpowered- 
studies provided inconclusive results (14-17), but as larger cohorts were ex-
amined and results combined, a consistent relative risk of 1.25 could be attri-
buted to carriers of the proline allele (18, 19). The potential contribution of 
Pro[12]Ala on FCHL has been investigated in the Finnish and Dutch popula-
tion (20, 21). In Finns, the [12]Ala allele was associated with less severe ma-
nifestations of both insulin resistance and unfavorable lipid- and lipoprotein 
phenotypes (20). In the Dutch study, significant associations with free fatty 
acid levels and glycerol were reported (21). Also associations of the 
Pro[12]Ala-variant and other metabolic syndrome-related traits have been 
described in populations not ascertained for DM2 or FCHL (22). Finally, other 
naturally occurring substitutions in the PPARγ-gene, Pro[467]Leu and 
Val[290]Met, cause insulin resistance, hypertension, hypertriglyceridemia, and 
early-onset diabetes (23). Together, these data have given PPARγ, as one of the 
first genes in this field of research, the status of generally accepted genetic risk 
factor for DM2 and the metabolic syndrome. PPARγ is an excellent example to 
illustrate the potential importance of “common alleles of weak effects”:  al-
though the Pro[12]Ala substitution has only a modest effect for individuals 
carrying the risk variant (odds ratio ≈ 1.25), it has dramatic impact at the popu-
lation level. As much as 85% of subjects carry the risk allele (proline), which 
translates in a population attributive risk of 25% (18). This means, that if the 
population were monomorphic for the protective alanine allele, the prevalence 
of type 2 diabetes would be 25% lower. PPARγ is also particularly appropriate 
to illustrate the limitations of linkage studies in common diseases. Despite the 
population impact of the risk allele, its contribution would have never been 
discovered by linkage analysis. Since the risk allele would typically be trans-
mitted from both parents, a genome scan of approximately 3 million sib pairs 
would be required to obtain a LOD peak of 3 (18). Admittedly, PPARγ-
Pro[12]Ala may represent an extreme example, but it illustrates one of the 
aspects why power to detect linkage for common diseases is generally consi-
derably lower than for rare mendelian diseases (24). 
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Peroxisome proliferator activated receptor-γ co-activator-1α (PGC1α) 
A promising candidate gene for DM2 is PGC1α. PGC1α is a transcriptional co 
activator of a series of nuclear receptors, including PPARγ. Modest downregu-
lation of PGC1α, was shown to affect the expression of a whole set of genes 
involved in oxidative phosphorylation, influencing total body aerobic capaci-
ty, which can be very important in muscle (25). The gly[482]ser variant was 
associated with type 2 diabetes and related traits in many (26-30), but not all 
studies (31). Also significant associations with metabolic syndrome related 
traits such as hypertension (32, 33) and obesity (34) have been reported.  
 
Peroxisomal Proliferator-Activated Receptor alpha (PPARα) 
PPARα is a member of the nuclear hormone receptor superfamily of ligand-
regulated transcription factors, and a master regulator of fatty acid metabol-
ism. Activation of PPARα causes a dramatic lowering of plasma, hepatic, and 
intramuscular triglycerides. The fibrate class of lipid-lowering drugs are li-
gands for PPARα (35). Although it represents an excellent candidate gene 
from a biologic point of view, evidence for conferring genetic risk to develop 
DM2 and FCHL is less abundant than for PPARγ. Variation in the PPARα 
gene, especially the Leu[162]Val substitution has been subject to genetic re-
search, and was found to influence plasma lipid levels (36, 37), and risk of 
coronary artery disease (38). An association study from our lab demonstrated 
that PPARα could act as a modifier gene for FCHL (39). Also PPARα gene 
variation may influence onset and progression of type 2 diabetes (40). None-
theless, results remain equivocal (41) and await meta-analysis for conclusive 
interpretation. 
 
The apolipoprotein A1/C3/A4/A5 gene cluster 
Apolipoproteins are lipid binding proteins that are involved in the transport of 
lipids in plasma. Defects in apolipoprotein structure or synthesis may affect 
lipid metabolism and result in increased susceptibility to cardiovascular dis-
ease. The chromosomal region 11q23-q24  harbors 4 tightly clustered apolipo-
protein genes, and is a well investigated locus for FCHL. 
Strong linkage between the apolipoprotein A1/C3/A4 and FCHL was first 
reported in 1991 by Wojciechowski and colleagues (42). Apolipoprotein A5, a 
new member of this gene cluster was only recently identified and shown to 
modulate plasma triglycerides in mice and humans (43). Meanwhile several 
research groups have investigated the contribution of the apolipoprotein 
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A1/C3/A4/A5 gene cluster in the pathogenesis of FCHL using linkage and/or 
association analyses. Most, but not all reports (44), confirmed a potential mod-
ulating effect of this locus on HDL cholesterol and triglyceride levels, especial-
ly for variants in aplolipoprotein C3 and apolipoprotein A5 (45-51). Due to the 
strong linkage disequilibrium between the genes in this cluster it has proven 
challenging to identify the true contribution of each separate gene. According 
to the current thinking, apolipoprotein C3 and apolipoprotein A5 harbor inde-
pendent risk alleles for HDL cholesterol and triglyceride levels (52). 
 
The β-cell potassium channel: KCNJ11 and ABCC8 
In pancreatic beta cells, ATP-potassium channels are crucial for the regulation 
of glucose-induced insulin secretion and are the target for the sulfonylureas, 
oral hypoglycemic agents widely used in the treatment of noninsulin-
dependent diabetes mellitus. The β-cell potassium channel comprises two 
subunits: the channel itself encoded by the KCNJ11-gene (alias kir6.2 or BIR) 
and a regulatory subunit, encoded by the neighboring gene ABCC8, which 
binds sulfonylureas and ATP. Most attention has focused on the Gly[23]Lys 
variant in KCNJ11, which in most studies is consistently associated with a 
modest odds ratio (approximately 1.2) for DM2 (53-56). Despite accumulating 
genetic evidence for this polymorphism, it remains to be established whether it 
is the sole or the best marker of DM2 susceptibility at this locus, as significant 
LD extends into the neighboring ABCC8 gene. In fact, the Gly[23]Lys variant is 
almost in complete LD with a serine to alanine change at position 1369 in 
ABCC8, and thus Gly[23]Lys and Ser[1369]Ala are genetically undistinguisha-
ble. Not surprisingly KCNJ11 and ABCC8 have not been explored in relation 
to FCHL, lipid metabolism or the metabolic syndrome, as they do not 
represent the most attractive candidates for modulating these traits. 
 
Candidate genes from monogenic diseases: Same gene, different muta-
tions in rare and common forms of disease 
 
The study of subjects with extreme phenotypes, or exceptional families segre-
gating a disease in a Mendelian fashion, provided significant insight in the 
molecular pathogenesis of common complex diseases. A recurrent observation 
is that different variations in the same gene cause rare (often severe) and 
common (often mild) forms of disease. Typical examples include PPARγ 
(Pro[115]Gln causes severe obesity, whereas Pro[12]Ala  increases susceptibili-
ty to DM2) (57), LMNA encoding Lamin A/C (mutations cause lipodystrophy 
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whereas common variants are potentially involved in DM2, the metabolic 
syndrome and dyslipidemia) (58, 59). Box 2 describes three additional exam-
ples of rare and common variants in the same gene 
 
Box 2 
Maturity-Onset Diabetes of the Young (MODY) is a rare autosomal dominant inherited form of 
common diabetes, accounting for 1-5% of diabetes mellitus in western societies (60). It is characterized 
by early onset, usually before 25 years of age, primary β-cell defect and lack of association with obesity 
(2). At present, six genes can functionally be linked to MODY: HNF4α, GCK, HNF1α, IPF1, HNF1β 
and NEUROD1. All these genes are expressed in pancreatic β-cells, and all except for GCK code for 
transcription factors with a role in β-cell development and function (reviewed in (2, 3). Since 15-20% 
of MODY families are not linked to polymorphisms in known genes, the genetic background of MODY 
has not yet been fully unraveled. The close clinical and physiological overlap of MODY and common 
DM2 triggered several research groups to investigate common variants in MODY genes for their 
contribution to inherited susceptibility to common type 2 diabetes. Preliminary evidence is now emerg-
ing that common variants in at least 5 of 6 MODY genes also predispose to common type 2 diabetes 
(61). However, strong and consistent evidence is currently limited to variants in HNF4α (62-70). 
Interestingly, variants and haplotypes in HNF4α were also associated with increased serum lipid 
levels and the metabolic syndrome in families with FCHL from Finland and Mexico (71). 
Autosomal Dominant Familial Hypercholesterolemia (FH) (prevalence 1:500) is characterized 
by increased levels of (LDL)-cholesterol levels and early coronary artery disease, typically before the 
age of 50. FH is associated with mutations in the low density lipoprotein-receptor, apolipoprotein B or 
proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9, which regulates the degradation rate 
of the LDL-receptor, was only recently identified as a third gene for FH (72). The two identified muta-
tions in PCSK9 causing FH are probably gain-of-function mutations, as over expression of PCSK9 in 
the liver of mice produces hypercholesterolemia by reducing LDL-receptor number (73). Interestingly, 
various common polymorphisms and haplotypes in PCSK9 do not cause FH, but modulate  
(LDL-)cholesterol levels in the general populations to a various degree (74-78). PCSK9 is a very attrac-
tive candidate gene for FCHL, but has not yet been tested for segregation with this disease. 
Tangier Disease patients have truncating mutations in both alleles (autosomal recessive) of the ATP-
binding cassette transporter A1-gene (ABCA1). The ABCA1 gene product regulates the rate-
controlling step in the efflux of cellular cholesterol and phospholipids to an apolipoprotein acceptor. 
The phenotypic characteristics Tangier Disease are an almost complete absence of HDL-cholesterol, 
severe deposition of cholesteryl esters in cells of the reticulo-endothelial system, and increased risk for 
coronary artery disease (79). Tangier disease is extremely rare, affecting approximately 100 patients 
worldwide. Interestingly, heterozygote family members also present with decreased HDL-cholesterol 
levels. This stimulated the hypothesis that variants of ABCA1 and other genes in the same pathway 
might be associated with plasma HDL-cholesterol levels in the general population. Common variants 
in ABCA1 were found associated with plasma lipid levels and severity of cardiovascular disease (80). 
In a sample of 9000 Danes from the general population, a common non-synonimous SNP in ABCA1 
was associated with extremes of the HDL-cholesterol distribution (81). These studies suggest that 
common variants of ABCA1 may indeed contribute to the HDL-cholesterol level in the general popula-
tion. 
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The positional cloning approach: 
linkage and linkage disequilibrium analyses 
 
Candidate gene studies have one obvious major drawback: they are con-
strained by our fragmentary knowledge of the pathophysiological mechan-
isms underlying the disease. To overcome this disadvantage of candidate gene 
studies, the genome wide linkage scan strategy has been applied. This hypo-
thesis-free, unbiased approach attempts to map susceptibility loci, purely on 
the basis of chromosomal location (82). The underlying expectation is that 
genes with similar chromosomal positions will only rarely be separated during 
meiotic recombination. Computational analyses of transmission patterns 
through successive generations allow localization of susceptibility variants by 
detecting chromosomal markers that show significant co-segregation with 
disease. Typically, families are genotyped using a dense set of highly poly-
morphic microsatellite markers (~400), covering the genome. 
Identification of genes responsible for mendelian or monogenic disorders such 
as MODY, using linkage analysis has proven very successful the last decade. 
Efforts have been made to extend this method to complex diseases, and at this 
moment about thirty whole genome scans for DM2 (reviewed in (83), and 5 for 
FCHL (12, 84-87), have been completed in a wide range of ethnic groups. The 
yield of these efforts is by far not as good as for monogenic diseases, and there 
is no single global linkage signal for DM2 or FCHL similar to that generated 
by HLA in type 1 diabetes. Apart from differences in study design, analytical 
approaches, family configuration, and ethnic heterogeneity there are two prin-
cipal reasons for these somewhat disappointing results. First, the power to 
detect linkage in complex diseases is considerably lower than in a monogenet-
ic setting. By definition, a multifactorial complex trait is determined by the 
concerted action of multiple genes, interacting with one another and with the 
environment. The consequence is that the magnitude of a genetic effect, attri-
butable to a single genetic factor is small, or modest at best, and generally 
large sample sizes are needed for reasonable power of detection. The second 
explanation is related to diagnostic problems. DM2 and FCHL are so-called 
late onset diseases with incomplete penetrance, complicating correct classifica-
tion of subjects. Some research groups have tried to overcome this problem (in 
part) by focusing on the intermediate quantitative traits, rather than on type 2 
diabetes itself (88, 89). A concomitant advantage of this approach is that the 
power available in the analysis of pedigrees is preserved, which would other-
wise be considerably reduced by the dichotomization process.  
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Despite the absence of one recurrent region in all populations, several chromo-
somal locations have been linked to disease at a higher frequency than one 
would expect by chance. It has been argued by prominent researchers in the 
field that each linkage region will in fact harbor multiple disease genes of 
small effect, and that no single variant will fully explain the linkage peak (90). 
The regions with strongest evidence of replication include 1q21-25, 2q, 3q, 
8p,10q, 11q, 12q, 18p, 20q for DM2, and 1q21-23, 11p, 16q24.1 and 20q13 for 
FCHL. All these regions are currently subject to positional cloning efforts to 
identify the etiological variants. For some of them an underlying susceptibility 
gene has been identified. 
 
1q21-25 
The 1q21-25 region is the most replicated chromosomal region for FCHL and 
DM2 (5, 91-100). It was first presented as a region that harbors one or more 
susceptibility genes for FCHL in 1998 (5). Later, its potential relevance was 
extended to DM2 through a sub analysis of genome scan data from young-
onset Pima Indian families (91). After these initial reports, linkage with FCHL 
was confirmed in families from Germany, China, the United States and Mexico 
(92-94) and linkage with DM2 was reported Utah Caucasians, Amish, United 
Kingdom, US Caucasians and two Chinese populations (95-100). Noteworthy, 
the 1q21-25 locus has also been linked to the metabolic syndrome and related 
quantitative traits in various populations (101-103). The 1q21-25 region is cha-
racterized by a high gene density including several attractive candidate genes 
for FCHL and/or DM2 such as C-reactive protein, apolipoprotein A II, LMNA 
(encoding lamin A/C) and IRR (coding for the insulin receptor-related recep-
tor). Probably multiple genes in this region underlie the linkage signal (104). 
The first convincing evidence for Linkage and association with a susceptibility 
gene in this region was again reported in families with Familial Combined 
Hyperlipidemia. Genetic variation in Upstream Stimulatory Factor 1 (USF1) 
was associated with FCHL and triglyceride levels in Finnish patients, with an 
impressive level of statistical significance (105). Association with FCHL and 
related lipid traits was subsequently confirmed in UK Caucasians, Utah Cau-
casians, Mexicans, and Dutch Caucasians (106-109). Also linkage and associa-
tion with the metabolic syndrome in Chinese subjects has been reported (110). 
No coding variants were identified in the USF1-gene, and the SNPs that 
yielded the strongest statistical evidence for association are located in an in-
tron and the 3’untranslated region. Nevertheless, a potential functional role 
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may be ascribed to the intronic SNPs as it resides in a 20 base-pair sequence 
that binds nuclear proteins, representing a potential transcriptional regulatory 
element (111). USF1 is a ubiquitously expressed transcription factor that be-
longs to the basic helix-loop-helix leucine zipper family, and regulates expres-
sion of about 40 genes involved in lipid and glucose metabolism. The convinc-
ing results for USF1 in relation to FCHL and lipid metabolism, with accompa-
nying p-values in the order of 10-7, generated enormous enthusiasm and expec-
tation in the DM2- genetics community, and triggered researchers to investi-
gate its potential contribution as a genetic risk factor for DM2. Initially, posi-
tive results were reported (106, 110), extending the role of USF1 as a risk factor 
for DM2. However, two more recent analysis using French Caucasian subjects 
and several populations with evidence of chromosome 1q linkage respectively, 
failed to pursue the initial positive line of evidence. Additional studies in 
large, well-characterized cohorts are required to investigate the contribution of 
USF1 risk alleles to DM2 in distinct populations, and provide robust assess-
ment of effect size. We evaluated the USF1 gene for its potential involvement 
in type 2 diabetes in two large Dutch case control samples, comprising more 
than 2000 individuals (Chapter 6 of this thesis). The 1q region is probably the 
most intensively studied region for DM2 and FCHL, and an international col-
laborative effort funded by the NIH has been established, “ The international 
1q consortium”, to map the susceptibility genes responsible for replicated 
linkage signal on chromosome 1q.  
 
2q 
The first chromosomal locus for DM2 was mapped to 2q33-37 (112). Four years 
later following dense linkage-disequilibrium mapping efforts, Calpain 10 
(CAPN10) was identified as the underlying susceptibility gene (113). The road 
to widespread acceptance of CAPN10 as risk gene for type 2 diabetes was 
impeded by several factors: 1) CAPN10 was a gene of unknown function with 
and the potential biological mechanism through which it could be influencing 
DM2 risk was at first unclear. 2) Associated SNPs were intronic and of un-
known functional significance. 3) The linkage signal was only found in Mex-
ican Americans and replication efforts were with varying success (114-121). 
However, recent functional studies support a biological role for CAPN10 in 
insulin secretion (122) and a recent meta-analysis comprising over 7000 sub-
jects calculated an odds ratio of 1.2, comparable to the risk allele of PPARγ and 
KCNJ11/ABCC8 (123). 
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10q 
Linkage to 10q has been reported in Icelandic subjects and Mexican Americans 
(124, 125). In a subsequent positional cloning effort, Grant and colleagues ge-
notyped 228 microsatellite markers in Icelandic individuals with type 2 di-
abetes and controls throughout a 10.5 Mb interval on 10q (126). Microsatellite 
marker DG10S478 in intron 3 of TCF7L2 was strongly associated with DM2 in 
Icelandic subjects, a Danish Cohort and a US cohort (p-value combined:  
4.7*10-18). A series of replication studies confirmed this finding shortly after the 
initial report (127-143). In a very short time span TCF7L2 acquired the status of 
well-accepted DM2 susceptibility gene, exceeding genome wide significance 
criteria, and with the largest odds ratio for a DM2 susceptibility gene reported 
thus far (odds ratio for one risk allele ≈1.4; for two risk alleles ≈ 2.0). The high 
prevalence of the risk allele again translates into a large effect in the context of 
the population, with calculated population attributive risks from 10-27%. The 
biological mechanism by which TCF7L2 variants modulate DM2-risk is un-
clear. The TCF7L2 gene encodes for a transcription factor with a role in the 
Wnt signaling pathway, involved in very fundamental processes of cell proli-
feration and differentiation. Evidence for effects on insulin secretion as well as 
insulin sensitivity has been reported (128). A potential speculative mechanism 
how TCF7L2 variants may influence type 2 diabetes susceptibility is through 
altered transcriptional regulation of the insulinotropic hormone glucagon-like 
peptide-1 (GLP1), a peptide encoded by GCG and expressed in the brain and 
gut (126). An alternative hypothesis is that variants in TCF7L2 disrupt adipo-
genesis and/or adipocyte function by altering transcriptional regulation of 
PPARγ, leading to deposition of triglycerides in peripheral tissues and result-
ing in insulin resistance (128). Functional studies towards unraveling the exact 
molecular mechanism are keenly awaited. 
 
20q12-13  
The chromosomal region 20q12-13 was one of the first loci with evidence for 
linkage to DM2, first reported approximately 10 years ago (144). This result 
has meanwhile been repeatedly replicated in families with DM2 and FCHL 
(85, 145-151). Two interesting candidate genes underlie this region: HNF4α 
and PTPN1. HNF4α is one of the MODY-genes and PTPN1 codes for protein 
tyrosine phosphatase 1B, which negatively regulates insulin signaling via 
dephosphorylating the phosphotyrosine residues of the insulin receptor kinase 
activation domain. Although the biological pathway is plausible, and results 
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from knockout studies highlight PTPN1 as an excellent candidate gene for 
DM2 (152), robust evidence from association studies remains missing. Al-
though significant (but modest) associations with common non coding SNPs 
and haplotypes in PTPN1 have been reported with DM2 and related traits 
(153-155), a large association study comprising more than 7000 Caucasian 
subjects failed to replicate these findings (156). 
 
 
Recent developments 
Most recently, thanks to technological and analytical advances a novel ap-
proach became available that combines the power of association studies and 
the unbiased approach of linkage studies. This technique, genome wide asso-
ciation (GWA) study, has until now been applied in a limited fashion. One of 
the first GWA-studies reported association between a variant in the insulin 
induced gene 2 (INSIG2) and obesity (157). This finding was confirmed in 
some studies, but not in most other replication attempts (158-163).  Other 
genes identified by GWA-studies ‒most of them in 2007‒ include the lympho-
toxin-alpha gene (164, 165) (susceptibility to myocardial infarction), SLC30A8 
(140, 141, 166, 167), IDE-KIF11-HHEX (140, 141, 166-168), EXT2-ALX4 (141), 
CDKAL1, CDKAL2(140, 166-169), CDKN2A, CDKN2B (140, 166-168, 170). 
IGF2BP2 (140, 166, 167) (susceptibility to type 2 diabetes), FTO (140, 168, 171, 
172) (susceptibility to obesity and type 2 diabetes), and GCKR (166) (serum 
triglycerides). The INSIG2 story illustrates that replication studies are of criti-
cal importance to validate the results from GWA-studies. Nevertheless,   
GWA-studies represent thé major breakthrough for studying complex genetic 
diseases. The ultimate goal of the genetics community however, is nothing less 
than fast, affordable “whole-genome-sequencing”. According to the Nature 
Genetics “Question of the Year 2007” website, reaching this goal is a matter of 
when, rather than if. 
 
 
Summary 
In this chapter we discussed the various approaches that can be used to dissect 
the genetic background of complex diseases, and the contribution of each me-
thod to our present understanding of the genetic background of FCHL and 
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type 2 diabetes . The approach employed in this thesis is a combination of 
various techniques and can be described as a candidate gene approach, guided 
by data from gene expression studies and genome wide linkage analyses. 
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Up-regulation of CD36/FAT in Pre‒adipocytes  
in Familial Combined Hyperlipidemia 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SUMMARY 
Familial combined hyperlipidemia (FCHL) shows many 
features of the metabolic syndrome. The strong genetic 
component makes it an excellent model to study the 
genetic background of metabolic syndrome and insulin 
resistance. Adipose tissue is believed to contribute to, or 
even underlie, the FCHL phenotype and is an interest-
ing target tissue for gene expression studies. However, 
interpretation of adipose tissue gene expression experi-
ments is complex since expression differences cannot 
only arise as a direct consequence of a genetic trait, but 
may also reflect an adaptation to metabolic influences 
at the cellular level. In the present study, we measured 
gene expression levels in cultured primary human 
preadipocytes from FCHL and control subjects. Since 
isolated preadipocytes were allowed to replicate for 
weeks under standardized conditions, the contribution 
of previous metabolic influences is rather small whereas 
genetic defects are preserved and expressed in vitro. 
The main finding was up-regulation of CD36/FAT in 
FCHL preadipocytes, confirmed in two independent 
groups of subjects, and a concomitant increase in 
CD36/FAT-mediated fatty acid uptake. CD36/FAT 
overexpression has previously been shown to be asso-
ciated with other insulin-resistant states. The present 
data suggest that CD36/FAT overexpression in FCHL 
occurs very early in adipocyte differentiation and may 
be of genetic origin. 
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Introduction 
Familial combined hyperlipidemia (FCHL), a familial form of dyslipidemia 
with typical features of the metabolic syndrome, was delineated three decades 
ago (1–3) and has been associated with a fivefold increased risk of myocardial 
infarction before the age of 60 (4). Although substantial insight has been ac-
quired in this common lipid disorder, the complex genetics are not yet fully 
understood. Genome-wide scans revealed a number of chromosomal loci, 
among others 1q21, 1p31, 11p, and 16q, which are expected to be involved in 
the pathogenesis of FCHL (5–8). Recently, association was found in a Finnish 
FCHL study population with upstream stimulatory factor 1 (USF1) on 1q21 
(9), a ubiquitous transcription factor directing a number of genes involved in 
lipid and glucose metabolism. Several organs, including liver, fat, muscle, and 
brain, are plausible targets in which genetic alterations may result in the typi-
cal FCHL phenotype of insulin resistance and dyslipidemia. 
Arrays for gene expression studies are promising tools to identify the underly-
ing genetic defects of complex disorders such as FCHL and diabetes mellitus 
type 2 (DM2) (10). A recent gene expression study from our laboratory in 
freshly isolated, subcutaneous adipocytes from matched FCHL and control 
subjects (11) revealed a number of consistently up- and down-regulated genes 
in FCHL, involved in lipid- and lipoprotein metabolism, cell growth, apopto-
sis, matrix remodeling, and fatty acid metabolism. However, an inherent limi-
tation of gene expression analyses in tissue samples, obtained in vivo, is the 
difficulty to discriminate between primary genetic modifications that cause 
FCHL, and secondary changes resulting from cellular adaptations to the 
hyperlipidemia. In the present study, we used a novel approach in an attempt 
to identify primary genetic alterations, or the direct cellular consequences 
thereof, in FCHL. We prepared pre-adipocyte cell cultures obtained from sub-
cutaneous fat biopsies from FCHL patients and matched healthy controls. Pre-
adipocytes were repeatedly cultured under the same experimental conditions 
and studied for differential gene expression by arrays and quantitative 
RT-PCR (qRT-PCR). As the contribution of previous metabolic influences is 
rather small, this approach avoided overwhelming noise of adaptational gene 
expression, whereas genetic defects are preserved and expressed in vitro, the-
reby increasing—at least in theory—the chance of discovering the genetic de-
fect. 
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Materials and methods 
Subjects 
FCHL probands and controls were recruited through the Lipid Clinic of the 
Maastricht University Hospital. FCHL families were ascertained as described 
previously (12). The affected FCHL subjects in this study had each been ascer-
tained as an affected relative of a FCHL family that contained at least one oth-
er first-degree relative with a total cholesterol (TC) ≥6.5 mmol/l and/or trigly-
ceride (TG) ≥2.3 mmol/l, combined with the presence of premature CAD with-
in the family. Control participants were recruited from the spouse group or by 
an advertisement, and matched for body mass index (BMI) and sex with the 
FCHL patients. All controls had fasting TC<5.5 mmol/l, and fasting TG <1.7 
mmol/l, and no family history of CAD. The clinical characteristics of the sub-
jects at the time of the fat biopsy are listed in Table 1. The Human Investiga-
tion Review Committee of the Academic Hospital Maastricht approved the 
study protocol, and all subjects gave written informed consent. 
 
Table 1. Clinical characteristics of FCHL-control pairs for macro-array analyses and qRT-PCR. 
Familial Combined 
Hyperlipidemia 
Control 
Pair Sex Age BMI TC TG FFA Sex Age BMI TC TG FFA 
Array 
1 
2 
3 
4 
5 
F 
F 
M 
M 
M 
45 
63 
55 
58 
39 
24.5 
24.3 
26.8 
26.3 
24.2 
6.4 
7.5 
7.2 
4.6 
6.6 
1.1 
2.3 
1.3 
3.6 
3.7 
0.05 
0.27 
0.05 
0.23 
0.26 
F 
F 
F 
M 
M 
44 
55 
45 
51 
57 
23.5 
25.7 
27.0 
26.2 
25.4 
3.9 
4.9 
4.7 
4.3 
5.1 
1.1 
0.9 
1.7 
1.0 
1.2 
0.33 
0.18 
0.29 
0.38 
0.28 
qRT-PCR 
6 
7 
8 
9 
10 
M 
F 
M 
F 
F 
51 
46 
53 
48 
54 
27.0 
22.0 
23.5 
25.3 
26.4 
5.9 
7.7 
7.2 
7.4 
6.7 
7.1 
1.8 
1.8 
2.8 
3.9 
0.59 
0.40 
0.49 
0.58 
0.47 
M 
F 
M 
F 
F 
48 
48 
61 
42 
41 
26.9 
22.2 
23.4 
24.5 
25.7 
5.5 
3.3 
4.3 
4.7 
3.9 
1.4 
0.7 
0.5 
0.8 
0.8 
0.05 
0.43 
0.50 
0.19 
0.41 
Mean 
SD 
51 
7 
25.0 
1.6 
6.7 
0.9 
2.9 
1.8 
0.32 
0.2 
 
49 
7 
25.1 
1.6 
4.5 
0.7 
1.0 
0.4 
0.30 
0.13 
BMI: Body mass index; TC: Total Cholesterol; TG: Triglycerides; FFA: Free fatty acids. 
 
Blood and adipose tissue sampling 
Plasma TC and TG concentrations were measured after an overnight fast as 
described previously (12). Subjects had refrained from smoking and did not 
drink coffee or tea in the morning. To obtain unbiased lipid values, partici-
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pants had abstained from alcohol for at least 72 h and any lipid-lowering me-
dication had been withdrawn 2 weeks before blood sampling. Blood and 
liposuction samples were taken as described previously (11). 
 
Sample preparation 
Within minutes after the biopsy, the collagenase-treated cell suspension (11) 
was filtered through 500 μm nylon mesh and spun at 220 × g for 1 min to sepa-
rate pre-adipocytes from mature adipocytes. Pre-adipocytes were suspended 
in 5 ml DMEM medium containing 10% fetal calf serum (FCS) and 1% gluta-
mine/streptomycine/peniciline (GSP) and cultured. At passage 4, RNA was 
isolated using the TRIzol reagent (GibcoBRL, Grand Island, NY) according to 
the manufacturer’s protocol. The Rneasy kit (Qiagen, Hilden, Germany) was 
used for total RNA clean up, and quality was assessed following the manufac-
turer’s instructions. Plastic disposables were purchased from Greiner Bio-One 
(Alphen aan den Rijn, The Netherlands). 
 
Suppression subtractive hybridization 
Human subcutaneous adipose tissue samples obtained from a single 
FCHL/control pair were used for suppression subtractive hybridization (SSH) 
(Figure 1). The SMART PCR cDNA Synthesis Kit (Clontech, Palo Alto, CA) 
was used for preparation and amplification of double stranded cDNA, and 
subtractive hybridization was carried out using the PCR-Select cDNA Subtrac-
tion Kit (Clontech), both according to the manufacturer’s instructions. The 
amplified differentially expressed cDNAs were gel-purified using the QIAEX 
gel subtraction kit (Qiagen), and cloned into the pGEMT-easy vector before 
transformation into highly competent Escherichia coli JM109 cells (Promega, 
Leiden, The Netherlands). 
 
Sequence identification 
All SSH clones were sequenced using the T7 and SP6 primers and the Dye 
Terminator Sequencing Kit (Applied Biosystems, Nieuwekerk a/d IJssel, The 
Netherlands) on an ABI310 genetic analyzer (Applied Biosystems).The cleaned 
sequence reads, that is, SSH clone sequences without adaptor and vector se-
quences, were assembled into contigs, thus lowering the number of sequences 
to be evaluated and increasing the average length of the sequences. In this 
way, the original number of 547 sequences, representing 369 different clones,  
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Figure 1. The design of the gene expression experiments is schematically depicted in this 
flow chart. Subcutaneous fat biopsies were taken from 11 familial combined hyperlipidemia 
(FCHL) subjects and 11 healthy controls, pair-matched for sex and body mass index (BMI). 
Suppression subtractive hybridization (SSH) was applied using one FCHL-control pair to 
generate a library of differentially expressed genes in adipose tissue, leaving 10 pairs for 
study. A selection of differentially expressed genes generated by SSH combined with concep-
tual candidate genes were spotted on macro-arrays. Gene expression levels in pre-adipocytes 
from 5 FCHL-control pairs, cultured and harvested under the same conditions, were meas-
ured by macro-array. A three-step validation procedure was applied. First, reliability of the 
array was tested by measuring gene expression levels in a selection of genes by qRT-PCR 
with the same RNA as used for the macro-array. Second, a selection of differentially ex-
pressed genes was validated by qRT-PCR using RNA from regrown cell lines of the same 
subjects. Third, genes with consistent differential expression were validated in pre-adipocytes 
of 5 additional, genetically independent, FCHL-control pairs 
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was reduced to 264 contigs. Megablast searches with these 264 contigs against 
the Unigene database showed that 167 contigs obtained a significant blast hit 
(E<10−3; sequence identity >95%), which represented 73 unique genes and 65 
unique ESTs. For 97 contigs, no significant blast hits were obtained. As a quali-
ty control check, 32 of the 271 commercially obtained clones were sequenced, 
using M13 primers, to verify their cDNA content. In all, 15% of the clones did 
not contain the insert guaranteed by the supplier. Therefore, all commercial 
clones discussed in the current study were sequence verified. 
 
Macroarray procedure 
Clones derived by SSH, representing genes differentially expressed between 
FCHL and control adipocytes, and commercially obtained clones with concep-
tual candidate genes for FCHL, were used in macroarray analyses. Inserts 
were amplified by PCR using the T7/Sp6 primer set or the M13 primer set. 
PCR products were purified using a 96-well PCR filtration system (Milli-
pore,Bedford, MA). Subsequently, the PCR products were spotted in duplicate 
on nylon filters using a BioRobotics gridder (Eurogentec, Seraing, Belgium), 
and denatured in 0.66 M NaCl and 0.5 M NaOH, neutralized in 40 mM phos-
phate buffer pH 7.3, and subsequently UV cross-linked to the membrane. The 
macro-arrays were hybridized with an α-32P[dATP]-labeled cDNA probe gen-
erated from 10 μg of total RNA from either a FCHL or control subject using an 
oligo(dT)12-18 primer according to standard procedures. Probe purification was 
done using ProbeQuant G-50 microcolumns (Amersham, Piscataway, NJ). The 
arrays were pre incubated for 30 min in 5 ml ExpressHyb hybridization solu-
tion (Clontech) with denatured salmon sperm DNA (100 μg/ml,Invitrogen, 
Merelbeke, Belgium) at 55°C. Subsequently, denatured probes, and 25 μg of 
CoT-1 DNA (Invitrogen), were hybridized to the arrays for 16 h at 55°C. The 
arrays were washed once with 2× SSC/1% SDS and twice with 0.1× SSC/0.5% 
SDS and exposed to an imaging screen (Bio-Rad, Hercules, CA). 
 
Macroarray data analysis 
The array consisted of 369 clones from our cDNA library generated by SSH, 
271 commercially acquired conceptual candidates for cardiovascular disease, 4 
housekeeping genes in triplicate and 100 blanco spots. All were represented in 
duplicate on the array. The software package Imagene (Biodiscovery, El Se-
gundo, CA) was used to construct and superimpose a series of grids over the 
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blot. Radiation intensities of the spots were quantified, and the numerical out-
put was exported to Microsoft Excel for further analyses. All spots were vi-
sually inspected, and only visible spots with a homogeneous round shape 
were taken into account. Expression in at least 4 of 5 pairs was required for a 
gene to be included for analyses. As a reference for background correction, the 
intensities of a number of empty spots in the blot and a complete row of empty 
spots at the top and the bottom of the blots were averaged. Intensities of the 
spots were corrected for background and mean intensities of 3 housekeeping 
genes (23 kD highly basic protein, hypoxanthine phosphoribosyltransferase 1, 
and β-actine) present in sixfold on each array. Akaike information criterion 
(AIC) (13, 14), the likeliness of a model based on the observed data penalized 
by the complexity of this model, was used to identify differentially expressed 
genes. The AIC complexity penalization was chosen to be more stringent than 
usual in order to match a two-sided test with a 95% significance level. A gene 
was therefore found to be differentially expressed when the AIC indicated the 
model, including a group effect, that is, being an FCHL patient or a control 
subject, was describing better the observed radiation intensities. Differences 
were expressed as a ratio of normalized spot intensities on the FCHL array 
and the control array. 
 
qRT-PCR validation procedure 
The accuracy and reproducibility of the macro-array data were verified in a 
three-stage validation procedure using qRT-PCR (Figure 1). In the first stage of 
the validation procedure, the reliability of the array itself was tested. To this 
purpose, expression patterns of a selection of genes were determined in one 
FCHL/control pair by qRT-PCR, using the same RNA sample as used for the 
array. Fold expression differences were calculated and correlated with the 
array results of the same couple. In the second validation stage, the reproduci-
bility of the results was tested. The same cell cultures as used for the macro-
array were recultured and qRT-PCR was performed on a selection of genes, 
using newly extracted RNA. In the third validation phase, we tested whether 
observed differences in gene expression levels were also present in pre-
adipocyte RNA of another group of five unrelated FCHL/control pairs. 
qRT-PCR was carried out using the qPCR for SYBR Green core kit (Eurogen-
tec, Seraing, Belgium) on an ABI PRISM 7700 sequence detection system (Ap-
plied Biosystems). The selected genes and primers used are listed in Table 2. 
Target gene mRNA levels were normalized to 18S rRNA and analyzed using a 
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standard curve, or the 2-ΔΔct method when appropriate. Absence of primer 
dimers and presence of a single amplification product were verified by a melt-
ing curve analysis at the end of each assay. 
 
Table 2. Primers used for qRT-PCR validation 
Gene name Primers (5’-3’) 
Adipophilin (ADRP) 
Forward: ACCAGTGCTCTGCCCATCA 
Reverse: CCCCTTACAGGCATAGGTATTGG 
CD36 antigen (CD36/FAT) 
Forward: AGTCACTGCGACATGATTAATGGT 
Reverse: CTGCAATACCTGGCTTTTCTCA 
Surfeit 1 (SURF1) 
Forward: CCTATGTGGTCACTCCCTTCCA 
Reverse: TGGGAACGAACCCTCTATTTACC 
HSP70 interacting protein (ST13) 
Forward: AGAAGTTCAACCTAGGGCACAGA 
Reverse: TTGATCTCTCGCTCTTCACGTTT 
Tumor rejection antigen gp96 (TRA1) 
Forward: AAAAAGAGCGATTACATTAAGCTCTATG 
Reverse: CCACACCCTTGACAAAATTGAG 
Collagen, type 1, alpha 2 (Col1a2) 
Forward: TGAAAACATCCCAGCCAAGAA 
Reverse: CAAACTGGCTGCCAGCATT 
Matrix metalloproteinase 2 (MMP2) 
Forward: CATCTTTGCTGGAGACAAATTCTG 
Reverse: CTGCGATGAGCTTGGGAAA 
Tissue inhibitor of metalloproteinase 3 
(TIMP3) 
Forward: CTGACAGGTCGCGTCTATGATG 
Reverse: TTACAACCCAGGTGATACCGATAGT 
18S ribosomal RNA (18S rRNA) 
Forward: TGCATGGCCGTTCTTTAGTTG 
Reverse: AGTTAGCATGCCAGAGTCTCGTT 
 
 
Fatty acid uptake and esterification 
CD36/FAT-specific fatty acid uptake and subsequent esterification was studied 
using sulfo-N-succinimidyl esters (SSO). SSO specifically binds CD36 and 
arrests the LCFA transport function of this protein (15). 
Pre-adipocytes were pre incubated for 45 min at 37°C in the presence of SSO 
(concentration 0.2mM) or DMSO (concentration 0.4%). Palmitate uptake was 
measured by addition of [14C]palmitate (0.3 μCi, final concentration, 0.6 mM) 
in a 2% BSA/MKR solution. The reaction was carried out at 37°C for 30 min. 
Cells were rinsed three times with 1 ml stop solution (MKR 0.2% BSA+0.2 mM 
phloretin) to terminate palmitate uptake. Cells were lysed in 1 ml isopropa-
nolheptane (2:3). Samples were applied to HP-TLC plates to separate triglyce-
rides and phospholipids. Radioactivity was measured after exposure to an 
imaging screen with the Personal Molecular Imager FX (Bio-Rad). 
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RESULTS 
Subjects 
Initial macro-array experiments were done with 5 FCHL/control pairs, which 
were also used in the first and second stage of validation by qRT-PCR (Figure 
1). In the third stage of validation with qRT-PCR, 5 additional FCHL/control 
pairs were studied, all unrelated and independent subjects not used in earlier 
experiments. The clinical characteristics of all subjects are listed in Table 1. 
FCHL patients showed higher plasma levels of total cholesterol (TC), TG, FFA, 
glycerol, and apolipoprotein B, and lower levels of HDL cholesterol, as ex-
pected. Age was not different between patients and controls.  
 
Differentially expressed genes  
Subcutaneous fat from a female/female FCHL/control pair was used to create a 
differential mature adipocyte SSH library. The FCHL subject was 47 years old, 
BMI 26.8 kg/m2, with a plasma TC of 7.77 mmol/l, TG 2.26 mmol/l, and HDL 
cholesterol 1.08 mmol/l. The control subject was 39 years old, BMI 25.0 kg/m2, 
and a plasma TC of 5.59 mmol/l, TG 0.69 mmol/l, and HDL cholesterol 1.41 
mmol/l. SSH procedures resulted in a forward and a reverse library containing 
up-regulated and down-regulated FCHL clones, respectively. In total, 369 
clones were selected from both libraries and combined with 271 commercially 
obtained conceptual cardiovascular candidate gene clones on macro-arrays 
(Figure 1). Housekeeping genes were used to normalize macro-array expres-
sion data. Relative intensities of housekeeping genes were similar on the 
FCHL and control arrays (Table 3). This low variability in relative expression 
of housekeeping genes in FCHL and control pre-adipocytes illustrated the 
suitability of these genes for normalization. 
 
Table 3. Relative housekeeping gene intensities (%) on FCHL and control macro-arrays 
Housekeeping gene FCHL (%) Control (%) 
23-kDa basic protein 5.1 ± 3.3 4.9 ± 2.0 
HPRT 1.1 ± 1.1 0.9 ± 0.6 
ACTB 93.8 ± 4.1 94.3 ± 2.4 
Data represent mean ± SD 
 
Macro-array analyses showed that 256 of 640 (40%) genes reported on the 
array were expressed in at least 4 of 5 FCHL/control pairs (Figure 1). Twenty-
seven (11%) of these genes exhibited statistically significant altered expression  
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Table 4. FCHL/Control ratios + 95% confidence intervals of 27 genes found statistically sig-
nificant (P<0.05) differentially expressed in pre-adipocyte cellines 
 
Gene Name Chromosome 
Ratio 
fchl/cont 
95% C.I. 
Receptors 
CD36 antigen (CD36/FAT)1+2 7q11.2 1.71 1.21-2.21 
Platelet-derived growth factor receptor alpha 
polypeptide (PDGFRA)2 
4q12 0.63 0.43-0.82 
Adenosine A2a receptor (ADORA2A)1 22q11.2 0.47 0.18-0.76 
Mitochondrion 
Surfeit 1 (SURF1)1 9q34 0.42 0.24-0.60 
Succinate dehydrogenase complex, subunit C, 
integral membrane protein, 15kD (SDHC)1 
1q21 0.58 0.31-0.85 
ATP synthase, H+ transporting, mitochondrial 
F0 complex, subunit F6 (ATP5J)1 
19p13.2 0.56 0.32-0.80 
Translocase of inner mitochondrial membrane 
17 homolog A yeast (TIMM17A)2 
1q32 0.46 0.32-0.60 
Matrix turnover 
Collagen, type VI, alpha 3 (COL6A3)1 2q37 1.73 1.02-2.45 
Collagen, type XVIII, alpha 1 (COL18A1)1 21q22.3 0.60 0.43-0.76 
Collagen, type I, alpha 2 (COL1A2)1 7q22.1 0.55 0.09-0.38 
Matrix metalloproteinase 2 (MMP2)1 16q13 0.37 0.22-0.52 
Matrix metalloproteinase 9 (MMP9)1 20q11.2q13.1 0.50 0.28-0.73 
Tissue inhibitor of metalloproteinase 3 
(TIMP3)1 
22q12.1q13.2 0.41 0.10-0.73 
Metabolism and others 
Methylene tetrahydrofolate dehydrogenase 
(NAD+ dependent) (MTHFD1)1 
14q24 0.45 0.21-0.69 
LIM domain-containing preferred translocation 
partner in lipoma (LPP)1 
3q28 0.64 0.42-0.86 
Suppression of tumorigenicity 13 colon carci-
noma (ST13) (Hsp70 interacting protein)1 
22q13 0.41 0.16-0.65 
3-hydroxymethyl-3-methylglutaryl-Coenzyme 
A lyase (HMGCL)1 
1pter-p33 0.61 0.35-0.88 
Glutamyl-prolyl-tRNA synthetase (EPRS)2 1q41-q42 0.64 0.44-0.84 
Vimentin (VIM)2 10p13 1.51 1.05-1.97 
Tumor rejection antigen gp96 (TRA1)2 12q24.2q24.3 0.54 0.31-0.78 
ATPase, H+ transporting, lysosomal 42kDa, V1 
subunit C isoform 2 (ATP6V1C2)2 
2p25.1 0.63 0.40-0.87 
ESTs 
Est (BE621121)2  1.53 1.04-2.02 
Est 4c.12 (AI570255)2  1.66 1.05-2.27 
Est/hypothetical protein DC42 (AK025746)2  0.37 0.06-0.69 
Est weakly similar to hypothetical protein 
FLJ20234 (AI090487)2 
 0.51 0.26-0.77 
Est (NM_002085)2  0.32 0.14-0.49 
Est/hypothetical protein My014 
(NT_032962.5)2 
 0.66 0.44-0.88 
1Genes from the candidate gene library 
2Genes from the SSH library 
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in FCHL. Five genes were up-regulated in FCHL and 22 were down-regulated. 
These genes, with their chromosomal location, are listed in Table 4 and di-
vided into 4 main groups: receptors (3 genes), mitochondrial function (4 
genes), matrix turnover (6 genes), and metabolism and others (8 genes). Six 
clones were ESTs. 
 
Multistep validation procedure 
Six genes (CD36/FAT, MMP 2, TIMP 3, TRA1, ST13 [mentioned in Table 4], 
and ADRP [not in Table 4]) were selected for the first stage of validation. 
Quantitative expression differences were measured by qRT-PCR in the same 
RNA samples as used for the array (Figure 1). A highly significant correlation 
coefficient of 0.78 (P<0.001) was found between the logarithm of the fold dif-
ferences obtained by macro-array and qRT-PCR (Figure 2), which demonstrat-
ed the accuracy and validity of the array data obtained. 
 
 
 
Figure 2. Fold changes of mRNA levels measured by macro-array and qRT-PCR (r2=0.78, 
P<0.01). 
 
 
The second stage of the validation procedure tested whether the expression 
data of a selection of 8 genes was confirmed by qRT-PCR in newly isolated  
RNA from regrown cell cultures of the same 5 pairs of subjects (Figure 1). The 
8 genes were CD36/FAT, COL1A2, MMP2, ST13, SURF1, TIMP3, and TRA1 
(mentioned in Table 4), as well as ADRP (not in Table 4). Very similar expres-
sion patterns to those observed on the arrays were found with CD36/FAT (5 of 
5 pairs, shown in Fig. 3A) as well as TRA1 (4/5 pairs), COL1A2 (4/5 pairs), and 
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to a lesser extent with MMP2, TIMP3, ST13, and ADRP (3 of 5 pairs). SURF1, 
which has low expression levels in pre-adipocytes, showed a similar expres-
sion difference as observed on arrays in only 2 of 5 couples. Combined, this 
second stage of the validation confirmed a true expression difference in 
CD36/FAT, TRA1, and COL1A2 genes in pre-adipocyte cell lines from the first 
5 FCHL patients vs. paired controls. 
In the third validation step, we evaluated which gene(s) remained differential-
ly expressed in a new, independent set of 5 pairs of BMI- and sex-matched 
 
 
Figure 3. White bars represent expression data of the macro-array. Black bars represent 
qRT-PCR expression data. Left panel: CD36/FAT was up-regulated in 4 out of 5 FCHL patients 
on the macro-array. CD36/FAT expression levels measuredby qRT-PCR in re-cultured pre-
adipocytes closely followed expression levels of the macro-array, indicating the reproducibil-
ity of the data. Right panel: Up-regulation of CD36/FAT was confirmed by qRT-PCR in a 
second group of 5 independent FCHL-control pairs. 
 
 
FCHL and control subjects (pairs 6–10 in Table 1 and Fig. 3), aiming to answer 
the question of which genes can be regarded as consistently FCHL-specific. 
Up-regulation of CD36/FAT was confirmed in 4 of 5 new FCHL/control pairs 
(Fig. 3B). Down-regulation of TRA1 and COL1A2 could not be confirmed in 
the new pairs. All combined, CD36/FAT showed up-regulation in 8 out of 10 
FCHL pre-adipocyte cell cultures compared with pre-adipocytes derived from 
sex- and BMI-matched controls. 
 
CD36/FAT up-regulation is functional 
To investigate whether CD36/FAT up-regulation was functional, we recul-
tured FCHL and control pre-adipocytes, and measured total and CD36/FAT-
specific LCFA uptake and incorporation in phospholipids and triglycerides. In 
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the combined group (FCHL + control subjects) a significant correlation was 
found between CD36/FAT expression measured by quantitative PCR and the 
fraction of fatty acids taken up via CD36/FAT and incorporated into phospho-
lipids and triglycerides (Figure 4). 
 
 
 
Figure 4. CD36/FAT RNA levels are positively correlated with the CD36/FAT mediated fatty 
acid esterification fraction (spearman’s rho = 0.65, P=0.01). CD36/FAT expression is de-
picted as the CD36/FAT Ct value measured by qRT PCR, corrected for housekeeping gene 
(18srRNA) expression. 
 
 
Discussion 
In the present study, we investigated gene expression profiles in human pre-
adipocyte cell cultures from human subjects with FCHL and pair-wise-
matched normolipidemic controls. The main finding was up-regulation of 
CD36/FAT in FCHL pre-adipocytes, confirmed in two independent groups, 
and a concomitant increase in CD36/FAT-mediated incorporation of fatty acids 
into triglycerides and phospholipids. Since gene expression differences in 
cultured pre-adipocytes reflect the direct expression of a genetic trait, and 
adaptive expression differences are suppressed, these results indicate that 
CD36/FAT overexpression in FCHL impacts very early in adipocyte differen-
tiation state and may be of genetic origin. 
The application of the SSH library combined with a candidate gene approach 
offered some substantial advantages. Because a selection was made of genes 
that are differentially expressed, a limited number of genes needed statistical 
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testing, thereby reducing the multiple-testing problem and the number of 
false-positive results. Given these relative advantages and its known limita-
tions, in combination with a stringent statistical analysis and a rigorous valida-
tion procedure, the present results offer an intriguing insight into an FCHL 
preadipocyte and perhaps general fat tissue functioning in FCHL. 
Adipose tissue is an interesting target tissue for gene expression studies in 
FCHL, since impaired function of adipose tissue is believed to contribute to, or 
even underlie, the expression of the FCHL phenotype. Previously, the expres-
sion profile of mature adipocytes, freshly isolated from fat tissue of FCHL 
adipose tissue, was investigated by our lab (11). However, an inherent draw-
back of gene expression studies on in vivo samples is the inability to distin-
guish between primary genetic defects, or direct cellular consequences thereof, 
and adaptive responses to, for example, hyperlipidemia. In the present study, 
we cultured pre-adipocytes of FCHL subjects and BMI- and sex-matched con-
trols. This design is based on the assumption that gene expression differences 
due to previous metabolic influences are rather small, as isolated pre-
adipocytes were allowed to replicate for weeks in a standardized environment, 
equal for FCHL and control pre-adipocytes. A similar approach was used by 
Gaster et al. (16), using cultured myotubes to study genetic effects of reduced 
lipid oxidation in muscle from type 2 diabetes subjects. This approach ruled 
out expression differences due to environmental factors, and allowed us to 
attribute the increased CD36/FAT expression to the underlying genetic back-
ground in FCHL (Figure 5). 
CD36/FAT is a multiligand class B scavenger receptor that has been implicated 
in multiple biological processes. Apart from its function as a scavenger recep-
tor, CD36/FAT has been identified as a regulator of angiogenesis and as a fatty 
acid translocase (FAT) facilitating the transmembrane transport of long-chain 
fatty acids (LCFAs) (17). CD36/FAT has atherogenic and anti-atherogenic as-
pects (18). Ligands for CD36/FAT are, among others, oxidized LDL, LCFAs, 
collagen, thrombospondin-1, and apoptotic cells. CD36/FAT expression is 
broad but especially abundant in tissues with high LCFA storage capacity, 
such as adipocytes, or oxidative capacity, such as heart and muscle (18). 
The consistent up-regulation of CD36/FAT is remarkable given the metabolic 
(Fredrickson type IIa, Iib, or IV) and genetic heterogeneity of FCHL (1, 19). In 
pre-adipocytes, CD36/FAT was upregulated in 8 of 10 FCHL patients, equally 
expressed in one pair, and down-regulated in another FCHL patient. Further-
more, in mature, freshly isolated adipocytes, CD36/FAT expression was also  
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Figure 5. Gene expression experiments in mature freshly isolated adipocytes do not allow to 
distinguish between adaptations to metabolic influences or expression differences that are a 
direct result of a genetic trait. In cultured pre-adipocytes, the contribution of previous meta-
bolic traits on gene expression is suppressed, whereas genetic defects, and direct conse-
quences thereof, are preserved and expressed in vitro. CD36/FAT expression was increased 
in FCHL pre-adipocytes. Up-regulation was confirmed at the functional level, as FCHL pre-
adipocytes demonstrated increased CD36/FAT-mediated uptake and esterification of fatty 
acids. 
 
 
50% increased in FCHL (unpublished data). Nevertheless, in contrast to the 
spontaneous hypertensive rat (SHR) in which CD36/FAT has been identified 
as the causal insulin-resistance gene (20), CD36/FAT is probably not the mu-
tated gene in FCHL. CD36/FAT is located on chromosome 7q11.2, and to our 
knowledge, no genome-wide scan showed linkage in this region with FCHL or 
any related trait. Obviously, this may change when more data become availa-
ble and phenotypes are refined. Furthermore, from a biological point of view, 
overexpression of CD36/FAT is expected to result in a more favorable plasma 
lipid spectrum than presently seen in FCHL, due to increased CD36/FAT-
mediated FA uptake. This is supported by observations in transgenic mice 
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overexpressing CD36/FAT in muscle. These animals typically exhibit reduced 
plasma triglycerides and fatty acids but increased plasma glucose and insulin 
(21). In line with this mechanism, CD36/FAT knockout mice have increased 
levels of fatty acids, triglycerides, and cholesterol (22). In our opinion, 
CD36/FAT up-regulation is therefore more likely a manifestation for a genetic 
alteration in FCHL, rather than the defect itself, in analogy to overexpression 
of the 3-HMG-CoA-reductase enzyme in fibroblasts from patients with an LDL 
receptor defect (23). 
CD36/FAT overexpression may well reflect insulin resistance (24) or defective 
insulin signaling in FCHL. Previously, CD36/FAT was found to be increased in 
other insulin-resistant states. Cardiac myocytes from obese Zucker rats, a 
commonly used rodent model for obesity and insulin resistance, have in-
creased sarcolemmal CD36/FAT and enhanced extracellular fatty acid uptake 
(25). Similarly, in skeletal muscle from human subjects with type 2 diabetes, 
sarcolemmal CD36/FAT was increased and associated with increased LCFA 
transport (26). CD36/FAT protein was also increased in diabetic macrophages 
as a response to defective insulin signaling (27). Finally, Griffin et al. (28) 
showed increased CD36/FAT translation efficiency in diabetic macrophages. 
These data and ours show that CD36/FAT is increased in insulin resistance. 
In the present study, increased CD36 RNA and functional CD36/FAT protein 
in cultured pre-adipocytes suggests that CD36/FAT up-regulation is the direct 
consequence of a genetic defect, rather than a metabolic adaptation to, for 
example, hyperlipidemia, and that the actual defect in FCHL is already meta-
bolically apparent in a very early adipocyte differentiation state. This defect 
may be increased genetic susceptibility to insulin resistance of FCHL adipose 
tissue.  
In conclusion, CD36/FAT is the first gene found with consistent increased 
expression in pre-adipocytes of two independent groups of unrelated FCHL 
subjects. The use of cultured pre-adipocytes suppressed expression differences 
due to adaptive compensations at the cellular level and allowed us to specifi-
cally select for gene expression differences that are a direct consequence of a 
genetic trait. Increased CD36/FAT RNA and functional CD36/FAT protein in 
cultured pre-adipocytes implies that a genetic defect in FCHL affects fatty acid 
metabolism in a very early adipocyte differentiation stage and that FCHL adi-
pocyte dysfunction may be of genetic origin. Future gene expression studies in 
other candidate tissues such as liver and muscle will further advance our un-
derstanding of insulin resistance and altered lipid metabolism in FCHL. 
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Activating Transcription Factor 6 Polymorphisms and Haplotypes 
Are Associated with Impaired Glucose Homeostasis  
and Type 2 Diabetes in Dutch Caucasians. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SUMMARY 
An association between genetic variation in ATF6 and type 2 
diabetes was recently reported in Pima Indians. To investigate the 
broader significance of this association for type 2 diabetes, replica-
tion studies in distinct ethic populations are required. We investi-
gated ATF6 for its association with type 2 diabetes in Dutch 
Caucasians.Two independent Dutch cohorts, comprising a total of 
952 subjects, were used to investigate the genetic association 
between polymorphisms in the ATF6 gene and disturbed glucose 
homeostasis / type 2 diabetes. Cohort 1 (N=154) was used to eva-
luate genetic variation in the ATF6-gene in relation to glucose 
homeostasis in the general population. Cohort 2 (N=798) consisted 
of patients with type 2 diabetes, impaired glucose tolerance, im-
paired fasting glucose, and normoglycaemic control subjects and 
was used to investigate ATF6 polymorphisms for their contribu-
tion to disturbed glucose homeostasis and type 2 diabetes. Sixteen 
tag-SNPs, including three nonsynonymous coding variants, 
captured all common allelic variants of ATF6, and were genotyped 
in all subjects of both cohorts. Our data show that common ATF6 
variants are associated with elevated glucose levels in the general 
population (Cohort 1, P = 0.009-0.04). Furthermore, the majority 
of these variants, and haplotypes thereof, were significantly asso-
ciated with impaired fasting glucose, impaired glucose tolerance 
and type 2 diabetes. (Cohort 2, p=0.006-0.05). Associated variants 
differ from those identified in Pima Indians.This study extensively 
investigated the ATF6-gene in Dutch Caucasians. Our results 
strengthen the evidence that one or more variants in ATF6 are 
associated with dissturbed glucose homeostasis and type 2 diabetes. 
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Introduction 
Evidence is emerging in literature that the endoplasmic reticulum (ER) may 
represent a major link between obesity, insulin resistance, beta cell function 
and type 2 diabetes (DM2) (1-5). Obesity generates stress conditions that in-
crease the demand on the ER. To cope with this stress, cells initiate a signal 
transduction pathway called the ER-stress response, or unfolded protein re-
sponse (UPR). Activation of the UPR is regulated by three ER stress sensors: 
PERK (PKR-like endoplasmic reticulum kinase), IRE1 (inositol requiring 1) 
and ATF6 (activating transcription factor 6) (6). Activation of PERK, IRE1 and 
ATF6 is under control of a master UPR regulator, the ER chaperone protein 
BiP/Grp78. The PERK and IRE1 initiated pathways of the unfolded protein 
response play an important role in DM2 through effects on beta cell function 
and peripheral insulin signaling respectively (1, 3).  
Within the framework of a previous gene expression study (7) we found a 
positive significant correlation between in vitro mRNA levels of BiP/Grp78 in 
cultured EBV-transformed lymphoblasts, and the fasting plasma glucose levels 
that had been measured in the corresponding subjects, in vivo. Therefore, we 
hypothesized that the intrinsic cellular UPR capacity may partially determine 
a subject’s plasma glucose level, and moreover that genetic variation in UPR 
genes may contribute to DM2. An excellent candidate gene to link UPR capaci-
ty to DM2 is ATF6.  First, ATF6 is essential for full activation of the UPR and 
considered as a critical UPR-initiator in mammalian cells (8). Second, ATF6 
induces expression of BiP/Grp78 both directly and indirectly via activation of 
XBP1. Third, ATF6 maps to chromosome 1q23.3, the most replicated chromo-
somal locus for DM2 (9). While preparing this manuscript, Thameem et al 
reported an association of ATF6 with DM2 in Pima Indians (10). To investigate 
the broader significance of this association for DM2, replication studies in 
additional populations are required. In the present study, we investigated 
ATF6 as a positional and functional candidate gene for disturbed glucose ho-
meostasis and DM2. 
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Materials and Methods 
Study populations 
Two independent Dutch cohorts, comprising a total of 952 Caucasian subjects, 
were used to investigate the genetic association between polymorphisms in 
the ATF6 gene, disturbed glucose homeostasis, and DM2. The first cohort 
(N=154) was recruited as spouses of hyperlipidemic patients, collected within 
the framework of a family study on the genetics of Familial Combined Hyper-
lipidemia. These subjects, not selected in any way, represent the general popu-
lation and exhibited the following clinical characteristics: 42% males, age 51 ± 
11 years, body mass index 25.4 ± 3.9 kg/m2, fasting blood glucose 4.9 ± 0.7 
mmol/L, fasting plasma insulin 6.1 ± 5.4 μU/mL and HOMA IR 1.4 ± 1.5. In this 
cohort, 137 subjects (89%) had normal fasting glucose levels, 16 subjects 
(10.5%) had impaired fasting glucose levels, and one subject (<1%) had DM2. 
No DNA was available for three subjects, leaving 151 subjects available for 
analyses. This cohort was used to explore the genetic variation in the ATF6 
gene in relation to glucose homeostasis in the general population. 
A second independent Dutch cohort (N=798) that consisted of 211 DM2 pa-
tients, 208 IFG/IGT subjects and 379 normoglycemic controls was used to in-
vestigate ATF6 polymorphisms for their contribution to disturbed glucose 
homeostasis and type 2 diabetes. This case control cohort was collected as 
described previously (11, 12). Briefly, more than 2700 subjects with one or 
more cardiovascular risk factors, including hypertension, BMI>25 kg/m2, a 
positive family history for DM2, or a history of gestational diabetes, were 
screened for DM2. Exclusion criteria were the use of medication that affects 
glucose metabolism and non-Caucasian ethnicity. All newly diagnosed sub-
jects with impaired fasting glucose, impaired glucose tolerance or type 2 di-
abetes, and a random selection of 379 normoglycemic control subjects were 
included in the present study. Characteristics of this cohort are provided in 
table 1. The Human Investigation Review Committee of the Academic Hospit-
al Maastricht approved the study protocol, and all subjects gave written in-
formed consent. 
 
SNP selection and genotyping 
SNP selection was designed to achieve a 100% coverage of the common genet-
ic variation (Minor allele frequency MAF >10%) of the ATF6-gene including 
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3kb upstream and downstream this locus. Using the HAPMAP database, 13 
tag-SNPs were selected for genotyping. One tag-SNP (SNP 4) was located in 
an exon and caused an amino acid substitution. In addition to the selection of 
13 SNPs by the tagging process, 3 additional SNPs were selected for their po-
tential direct functional effect: SNP3 and SNP5 for their location in exons, 
causing an amino acid substitution, and SNP15 for its location in the 3’ UTR. 
In total, 16 SNPs were genotyped in 952 subjects. Genotyping was done using 
the TaqMan 7900HT (Applied Biosystems). 
 
Table 1. Characteristics of sample 2. 
Trait NGT IFG/IGT DM2 
N (male/female) 379 (222/157) 208 (125/83) 211 (144/67) 
Age (years) 58 ± 7 58 ± 7 60 ± 7 
BMI (kg/m2) 27.4 ± 3.8 29.3 ± 4.2 30.7 ± 4.4 
Data are mean ± SD, unless otherwise indicated. NGT normal glucose tolerance, IFG im-
paired fasting glucose, IGT impaired glucose e tolerance, DM2 type 2 diabetes. 
 
Statistical Analyses 
Power calculations were performed using the genetic power calculator of Pur-
cell et al (13) (available at  http://pngu.mgh.harvard.edu/~purcell/gpc/). As-
suming a disease prevalence of 0.1, a genotype relative risk of 1.1 and 2.3 (the 
calculated relative risks of Aa and AA respectively in a previous study (10)), 
and an allele frequency of 0.2 (the frequency of the ATF6 risk allele, previously 
associated with DM2 (10)), the case control sample afforded an estimated 
power of 71% at p<0.05.  Linkage disequilibrium statistics were analyzed by 
Haploview software (14). Haplotypes were constructed using the program 
SNPHAP. Analyses of variance and Student’s t-tests were used to test poly-
morphisms in the ATF6 gene for association with plasma glucose levels. Odds 
ratios and P-values for case control analyses were calculated using logistic 
regression analyses in which “allele” was parameterized in the model as a 
dichotomous variable. Adjustments for age, gender and body mass index were 
done by including these variables in the logistic regression model. 
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Results 
The intrinsic capacity of the unfolded protein response may influence 
fasting plasma glucose levels  
 
In a previous gene expression experiment, designed to study the genetic back-
ground of combined hyperlipidemia, we cultured EBV-transformed lympho-
blast cells from 12 hyperlipidemic patients and 12 normolipidemic controls (7). 
To further explore this dataset in relation to glucose homeostasis, we meas-
ured plasma glucose levels in these subjects and re-analyzed transcript levels 
in relation to this previously unstudied trait. One subject with a fasting plasma 
glucose > 3 standard-deviations of the mean was excluded, leaving 23 subjects 
for analyses. Subjects exhibited the following characteristics: age 50 ± 9 years, 
11 males / 12 females, and fasting plasma glucose levels: 5.3 ± 0.8 mmol/L. A 
complete clinical characterization of these subjects has been provided in an 
article by Morello et al (7). We observed a strong positive correlation (r = 0.57, 
p=0.004) between in vitro mRNA levels of BiP/Grp78 and the fasting plasma 
glucose levels in the corresponding subjects, in vivo (Figure 1).  
 
 
Figure 1 Grp78 gene expression levels in immortalized cultured lymphoblasts versus corres-
ponding fasting plasma glucose levels in each of the 23 subjects studied. Mean fasting plas-
ma glucose level at the time of B-cell isolation was 5.3 ± 0.76 mmol/L. Other clinical and 
anthropometric characteristics of the subjects are described in (7) 
This correlation is very unlikely the result of the well-known response of 
Bip/Grp78 expression to glucose (15), since all cells had been cultured for sev-
eral weeks under isoglycaemic and standardized conditions. This observation 
led to the hypothesis that the intrinsic UPR capacity may partially determine 
fasting plasma glucose levels, and that UPR genes may be involved in glucose 
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homeostasis. We therefore performed a genetic association study with ATF6, a 
key gene of the unfolded protein response, and transcriptional regulator of 
Bip/Grp78. 
 
Genetic variation in the ATF6 gene 
The ATF6 gene consists of 16 exons that span approximately 193kb of genomic 
DNA. The gene structure of ATF6, the frequencies of the minor alleles for each 
SNP, and the pairwise correlation of alleles between various SNPs are de-
picted in Figure 2 (data for cohort 2, N=798). Genotype success rate was >97% 
for all 16 genotyped SNPs. All SNPs were in Hardy Weinberg equilibrium. 
 
Figure 2. Genetic structure of the ATF6 gene, including the 16 genotyped SNPs and minor 
allele frequencies (MAF). Dashed boxes represent the promoter region and the 3’untranslated 
region. Exons are represented by vertical lines. Minor allele frequencies of the genotyped 
SNPs are shown in the gray horizontal bar. The shade of the diamonds represents the pair-
wise r2 between the two SNPs defined by the top left and the top right sides of the diamond. 
Shading represents the magnitude of pairwise r2, with at the extremes white reflecting very 
low r2 (<0.20) and black reflecting very high r2 (>0.80) 
ATF6 
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ATF6 polymorphisms are associated with fasting plasma glucose levels 
in the general population (Cohort 1) 
 
First, we investigated whether genetic variation in the ATF6-gene was asso-
ciated with fasting glucose levels in the first cohort from the general popula-
tion (Table 2). Analyses of variance revealed a significant association of SNP 9, 
SNP 12, SNP 13 and SNP 15 with fasting glucose levels in this cohort (p=0.018-
0.053). Further analyses under a dominant genetic model strengthened the 
evidence for association with these SNPs (p=0.005-0.015). In addition, SNP3 
and SNP6 were borderline significant under a dominant genetic model. These 
data suggest that ATF6 polymorphisms modulate plasma glucose levels in the 
general population.  
 
ATF6 polymorphisms are associated with disturbed glucose homeostasis 
and type 2 diabetes (Cohort 2) 
 
Next, to test the hypothesis that variation in ATF6 contributes to disturbed 
glucose metabolism and DM2, we genotyped all selected SNPs in the second 
cohort (n=798), comprising 211 patients with type 2 diabetes, 208 subjects with 
IFG/IGT, and 379 normoglycemic controls (Table 3). In line with results from 
the first cohort, prevalence of the minor allele of SNP 12, SNP 13 and SNP 15 
was significantly increased in cases compared to control subjects (p=0.033-
0.051). Furthermore SNP 6, which showed a trend for association in cohort 1, 
was significantly different in cases and controls of cohort 2 (unadjusted 
p=0.027). For SNP 3 and SNP 9 we were not able to confirm the significant 
association of cohort 1. Statistical analyses using alternative genetic models 
(genotype, dominant, recessive) support these findings (p=0.01-0.05; Table 4) 
 
Haplotype analysis 
Haplotype analysis provided similar results. Statistical reconstruction of hap-
lotypes comprising the four significantly associated SNPs (SNP 6, 12, 13 and 
15), identified three common haplotypes which together account for 99% of 
observed haplotypes in cases and controls (Table 5). We identified an “at risk” 
haplotype (GGAG), with higher prevalence in subjects with type 2 diabetes, 
impaired glucose tolerance and impaired fasting glucose compared to controls 
(14.4% versus 9.9%, odds ratio=1.54; 95% C.I.  1.13-2.09; p=0.006). The opposite 
AAGA-haplotype showed a trend for  higher prevalence in  control subjects 
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Table 2. Associations (genotype effects) of ATF6 polymorphisms with fasting plasma glucose 
levels in the general population. (Sample 1) 
 
SNP 
(rs) 
Genotype N Glucose ± sd 
(mmol/L) 
p-value 
gen. 
p-value 
rec. 
p-value 
dom. 
SNP 1 
rs4657101 
A/A 
A/C 
C/C 
94 
34 
12 
4.85 ± 0.54 
5.00 ± 0.89 
4.90 ± 0.51 
0.501 0.938 0.276 
SNP 2 
rs7553368 
T/T 
T/C 
C/C 
70 
56 
16 
4.95 ± 0.68 
4.90 ± 0.73 
4.82 ± 0.61 
0.789 0.559 0.584 
SNP 3 
rs1058405 
A/A 
A/G 
G/G 
78 
53 
13 
5.00 ± 0.79 
4.78 ± 0.57 
4.72 ± 0.45 
0.123 0.331 0.043 
SNP 4 
rs2070150 
G/G 
G/C 
C/C 
125 
17 
1 
4.88 ± 0.65 
5.05 ± 0.81 
5.60 
0.357 0.297 0.232 
SNP 5 
rs16846208 
C/C 
C/T 
T/T 
124 
16 
1 
4.89 ± 0.67 
5.08 ± 0.83 
5.6 
0.356 0.323 0.214 
SNP 6 
rs4579731 
A/A 
A/G 
G/G 
102 
38 
1 
4.84 ± 0.58 
5.10 ± 0.91 
4.60 
0.127 0.657 0.057 
SNP 7 
rs2134697 
T/T 
T/C 
C/C 
76 
63 
6 
4.81 ± 0.58 
4.99 ± 0.83 
5.03 ± 0.45 
0.306 0.625 0.125 
SNP 8 
rs1503815 
C/C 
C/T 
T/T 
115 
31 
1 
4.89 ± 0.72 
4.89 ± 0.50 
5.3 
0.838 0.552 0.912 
SNP 9 
rs2340721 
AA 
C/A 
C/C 
61 
73 
14 
4.73 ±  0.51 
5.03 ± 0.77 
5.01 ± 0.75 
0.033 0.567 0.009 
SNP 10 
rs11581364 
G/G 
G/T 
T/T 
53 
66 
22 
4.93 ± 0.59 
4.89 ± 0.69 
4.84 ± 0.54 
0.857 0.664 0.636 
SNP 11 
rs7554023 
A/A 
A/G 
G/G 
107 
28 
8 
4.94 ± 0.65 
4.87 ± 0.88 
4.71 ± 0.29 
0.630 0.397 0.441 
SNP 12 
rs10918215 
A/A 
A/G 
G/G 
80 
56 
10 
4.77 ± 0.53 
5.08 ± 0.81 
5.09 ± 0.83 
0.025 0.390 0.006 
SNP 13 
rs7514053 
G/G 
G/A 
A/A 
78 
56 
10 
4.76 ± 0.53 
5.08 ± 0.81 
5.09 ± 0.83 
0.018 0.376 0.005 
SNP 14 
rs10918243 
T/T 
T/C 
C/C 
64 
61 
18 
4.98 ± 0.76 
4.91 ± 0.65 
4.68 ± 0.48 
0.260 0.120 0.304 
SNP 15 
rs13401 
A/A 
A/G 
G/G 
82 
57 
12 
4.77 ± 0.53 
5.05 ± 0.82 
5.00 ± 0.79 
0.053 0.577 0.015 
SNP 16 
rs3795649 
C/C 
C/T 
T/T 
57 
62 
26 
4.94 ± 0.73 
4.91 ± 0.66 
4.85 ± 0.67 
0.849 0.616 0.657 
gen: genotype; rec: recessive; dom: dominant. 
p-values in bold reflect statistical significance. 
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Table 3. ATF6 SNP allele frequencies in cases (DM2. IFG, and IGT) and normoglycemic con-
trol subjects. (Sample 2) 
 
SNP 
rs no 
No. of 
alleles 
Affected 
status 
No. of 
allele 1 
(%) 
No. of 
allele 2 
(%) 
p-value p-value 
adjusted* 
SNP 1 
rs4657101 
1570 
Controls 
Cases 
551 (0.74) 
613 (0.75) 
197 (0.26) 
209 (0.25) 
0.680 0.805 
SNP 2 
rs7553368 
1570 
Controls 
Cases 
506 (0.68) 
576 (0.70) 
244 (0.32) 
244 (0.30) 
0.235 0.237 
SNP 3 
rs1058405 
1582 
Controls 
Cases 
527 (0.70) 
576 (0.70) 
227 (0.30) 
252 (0.30) 
0.887 0.855 
SNP 4 
rs2070150 
1578 
Controls 
Cases 
693 (0.92) 
760 (0.92) 
61 (0.08) 
64 (0.08) 
0.812 0.974 
SNP 5 
rs16846208 
1584 
Controls 
Cases 
693 (0.92) 
766 (0.92) 
61 (0.08) 
64 (0.08) 
0.780 0.992 
SNP 6 
rs4579731 
1564 
Controls 
Cases 
656 (0.89) 
703 (0.85) 
82 (0.11) 
123 (0.15) 
0.027 0.037 
SNP 7 
rs2134697 
1576 
Controls 
Cases 
590 (0.79) 
615 (0.75) 
162 (0.21) 
209 (0.25) 
0.074 0.082 
SNP 8 
rs1503815 
1566 
Controls 
Cases 
672 (0.90) 
736 (0.90) 
76 (0.10) 
82 (0.10) 
0.929 0.985 
SNP 9 
rs2340721 
1584 
Controls 
Cases 
519 (0.69) 
545 (0.66) 
235 (0.31) 
285 (0.34) 
0.180 0.136 
SNP 10 
rs11581364 
1574 
Controls 
Cases 
458 (0.61) 
536 (0.65) 
290 (0.39) 
290 (0.35) 
0.133 0.165 
SNP 11 
rs7554023 
1574 
Controls 
Cases 
608 (0.81) 
677 (0.82) 
140 (0.19) 
149 (0.18) 
0.729 0.730 
SNP 12 
rs10918215 
1578 
Controls 
Cases 
580 (0.77) 
603 (0.73) 
170 (0.23) 
225 (0.27) 
0.039 0.043 
SNP 13 
rs7514053 
1592 
Controls 
Cases 
575 (0.77) 
606 (0.73) 
169 (0.23) 
242 (0.27) 
0.051 0.058 
SNP 14 
rs10918243 
1576 
Controls 
Cases 
481 (0.64) 
526 (0.64) 
273 (0.36) 
296 (0.36) 
0.935 0.758 
SNP 15 
rs13401 
1596 
Controls 
Cases 
586 (0.77) 
609 (0.73) 
172 (0.23) 
229 (0.27) 
0.033 0.042 
SNP 16 
rs3795649 
1570 
Controls 
Cases 
439 (0.59) 
520 (0.63) 
307 (0.41) 
304 (0.37) 
0.084 0.143 
*adjusted for age, gender, and body mass index. 
p-values in bold reflect statistical significance.  
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Table 4. ATF6 genotype frequencies in cases (DM2, IFG and IGT) and normoglycemic control 
subjects. (Sample 2) 
 
SNP 
(rs) 
Genotype Controls 
N (%) 
Cases 
N (%) 
p-value 
gen. 
p-value 
rec. 
p-value 
dom. 
SNP 2 
rs4657101 
A/A 
A/C 
C/C 
206 (55) 
139 (37) 
29 (8) 
222 (54) 
169 (41) 
20 (5) 
0.179 0.095 0.765 
SNP 2 
rs7553368 
T/T 
T/C 
C/C 
167 (44) 
172 (46) 
36 (10) 
195 (48) 
186 (45) 
29 (7) 
0.385 0.199 0.395 
SNP 3 
rs1058405 
A/A 
A/G 
G/G 
179 (47) 
169 (45) 
29 (8) 
200 (48) 
176 (43) 
38 (9) 
0.675 0.453 0.816 
SNP 4 
rs2070150 
G/G 
G/C 
C/C 
319 (85) 
55 (14) 
3 (1) 
351 (85) 
58 (14) 
3 (1) 
0.973 0.913 0.820 
SNP 5 
rs16846208 
C/C 
C/T 
T/T 
319 (85) 
55 (14) 
3 (1) 
354 (85) 
58 (14) 
3 (1) 
0.962 0.906 0.787 
SNP 6 
rs4579731 
A/A 
A/G 
G/G 
293 (79) 
70 (19) 
6 (2) 
295 (71) 
113 (28) 
5 (1) 
0.021 0.622 0.010 
SNP 7 
rs2134697 
T/T 
T/C 
C/C 
233 (62) 
124 (33) 
19 (5) 
228 (55) 
159 (39) 
25 (6) 
0.168 0.535 0.059 
SNP 8 
rs1503815 
C/C 
C/T 
T/T 
305 (81) 
62 (17) 
7 (2) 
333 (81) 
70 (17) 
6 (2) 
0.893 0.658 0.962 
SNP 9 
rs2340721 
AA 
C/A 
C/C 
179 (47) 
161 (43) 
37 (9) 
174 (42) 
197 (47) 
44 (11) 
0.290 0.715 0.116 
SNP 10 
rs11581364 
G/G 
G/T 
T/T 
139 (37) 
180 (48) 
55 (15) 
173 (42) 
190 (46) 
50 (12) 
0.319 0.284 0.176 
SNP 11 
rs7554023 
A/A 
A/G 
G/G 
246 (66) 
116 (31) 
12 (3) 
270 (65) 
137 (33) 
6 (2) 
0.231 0.100 0.906 
SNP 12 
rs10918215 
A/A 
A/G 
G/G 
227 (60) 
126 (34) 
22 (6) 
214 (52) 
175 (42) 
25 (6) 
0.036 0.919 0.012 
SNP 13 
rs7514053 
G/G 
G/A 
A/A 
225 (60) 
125 (34) 
22 (6) 
216 (52) 
174 (42) 
25 (6) 
0.048 0.948 0.017 
SNP 14 
rs10918243 
T/T 
T/C 
C/C 
149 (39) 
183 (49) 
45 (12) 
167 (40) 
192 (47) 
52 (13) 
0.869 0.760 0.751 
SNP 15 
rs13401 
A/A 
A/G 
G/G 
228 (60) 
130 (34) 
21 (6) 
215 (51) 
179 (43) 
25 (6) 
0.039 0.797 0.012 
SNP 16 
rs3795649 
C/C 
C/T 
T/T 
129 (35) 
181 (48) 
63 (17) 
152 (37) 
216 (52) 
44 (11) 
0.040 0.011 0.500 
gen: genotype; rec: recessive; dom: dominant. 
p-values in bold reflect statistical significance.  
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Table 5. ATF6 haplotype distribution in cases (DM2+IFG+IGT) and normoglycemic controls 
 
Haplotype Controls (%) Cases (%) p-value 
AAGA 76.4 72.2 0.056 
AGAG 12.5 12.6 0.944 
GGAG 9.9 14.4 0.006 
Rare 1.2 0.7 0.330 
Total 100 100  
Haplotype frequencies for the four significantly associated SNPs in Table 3 were estimated 
with SNPHAP. Of haplotypes, 97% were estimated with a probability > 97%. p-values in 
bold reflect statistical significance. 
 
compared to subjects with disturbed glucose homeostasis (76.4% versus 72.2%, 
odds ratio 0.80; 95% C.I. 0.64-1.01; p=0.056).  Noteworthy, stratified analyses 
showed that the prevalence of the GGAG-risk haplotype was significantly 
increased in both subjects with impaired fasting glucose or impaired glucose 
tolerance (odds ratio= 1.59, p=0.011) as well as in patients with fully developed 
type 2 diabetes (odds ratio= 1.48, p=0.036). 
 
 
Discussion 
ATF6 is essential for full activation of the UPR and considered a critical UPR 
initiator in mammalian cells (8). In the present study we show that ATF6 po-
lymorphisms and haplotypes are associated with disturbed glucose homeosta-
sis and DM2 in Dutch Caucasians. While this work was in progress, a genetic 
association between amino acid variants in ATF6 and type 2 diabetes was 
reported in Pima Indians (10). Additional replication studies are strongly re-
quired to validate these findings, and evaluate their broader significance for 
predisposition to type 2 diabetes in different ethnic populations.  
In the present study, we identified polymorphisms in the ATF6 gene, signifi-
cantly associated with fasting glucose levels in a cohort representative for the 
general population, and with disturbed glucose homeostasis/DM2 in a second 
cohort, ascertained for IFG, IGT and DM2. Allele frequencies from associated 
SNPs 12, 13 and 15 were slightly higher in subjects from the general popula-
tion in cohort 1 (~26%) than in normoglycemic control subjects in cohort 2 
(23%). Different recruitment criteria and statistical variance may account for 
this difference: control subjects in cohort 2 are non-diabetic, verified by an oral 
glucose tolerance test, whereas subjects from the general population in cohort 
1 may include some undetected type 2 diabetes patients. 
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The associated SNPs in this study were all located in non-coding regions of the 
ATF6 gene. SNP6, SNP12 and SNP 13 map to introns, whereas SNP15 locates 
to the 3’ untranslated region. Noteworthy, SNP15 is in the direct vicinity (11 
basepairs in 5’ direction) of an AATAAA-poly-adenylation sequence in the 
3’UTR. This recognition site is involved in polyadenosine (poly-A) tail forma-
tion, which protects the mRNA molecule from exonucleases, and is important 
for transcription termination, for export of the mRNA from the nucleus, and 
for translation.  
Three known exonic variants have been described in ATF6: Pro[145]Ala, 
Ser[157]Pro, and Met[67]Val.  In Pima Indians, the amino acid variants 
Pro[145]Ala and Ser[157]Pro polymorphism showed an association (p=0.05) 
with DM2 (10). These amino acid substitutions (SNP-4 and SNP-5 respectively 
in our study) were not significantly associated with fasting glucose levels in 
our first cohort, or with disturbed glucose homeostasis and DM2 in the second 
cohort. The negative result is very unlikely to be due to a lack of statistical 
power, since allele frequencies were identical in cases and controls, not even 
revealing a trend towards significance (SNP 4 adjusted p=0.97, SNP 5 adjusted 
p=0.99). The third known ATF6 amino acid variant, Met[67]Val (SNP-3), which 
was not previously found associated with type 2 diabetes in Pima Indians (10),  
was associated with fasting plasma glucose levels in cohort 1, but again allele 
frequencies were not significantly different between cases and controls in co-
hort 2. Further genetic research and functional studies are needed to establish 
which SNP(s) in the ATF6-gene are functionally responsible for the observed 
associations in both populations. Although we do not provide a formal repli-
cation of the genetic association in Pima Indians – in which replication is de-
fined by same allele, same genetic model and same phenotype– our data do 
however confirm and extend the nature of their observations, and emphasize 
that the ATF6-gene is also relevant for susceptibility to disturbed glucose ho-
meostasis and DM2 in Dutch Caucasians. 
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The ATF6-Met[67]Val Substitution is Associated  
with Increased Apolipoprotein B Levels 
 and Plasma Cholesterol 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SUMMARY 
Activating Transcription Factor 6 (ATF6) is a proximal 
sensor of the endoplasmic reticulum (ER) stress response. 
Besides playing a critical role by inducing ER stress 
response genes involved in the unfolded protein response, 
ATF6 has also been shown to regulate expression of 
several key genes involved in lipogenesis. Using a tag-
ging SNP approach we identified an amino acid substitu-
tion (methionine[67]valine) in ATF6, associated with 
elevated apolipoprotein B (apoB) levels and hypercholes-
terolemia. The association was initially identified in two 
independent Dutch samples with increased cardiovascu-
lar risk and Familial Combined Hyperlipidemia (FCHL), 
respectively (Apolipoprotein B p=0.00004,Total Choles-
terol p=0.001, LDL cholesterol p=0.001). The association 
was replicated in 715 individuals from 61 extended 
Finnish FCHL families (apoB p=0.01, LDL-cholesterol 
p=0.04,). We functionally characterized the amino acid 
substitution, and found that a valine at position 67 
augments ATF6 protein levels, as well as its downstream 
transcriptional targets Grp78 and Grp94. In parallel, 
potency to induce luciferase expression through the 
Grp78 promoter was increased. This study provides the 
first evidence that the methionine[67]valine substitution 
in ATF6 can modulate apoB and cholesterol levels in 
humans, and highlights ATF6 as a new susceptibility 
gene for hypercholesterolemia. 
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Introduction 
The concept that elevated plasma levels of (LDL-) cholesterol are a primary 
causal factor in the pathogenesis of coronary heart disease is well established 
(1-3). Cholesterol synthesis and uptake are tightly regulated through a feed-
back pathway from the endoplasmic reticulum (ER) to the nucleus (4). Sterol 
regulatory element binding protein 2 (SREBP2), an ER resident transcription 
factor, has a central role in the cellular cholesterol homeostasis (5). When cellu-
lar cholesterol levels are normal, SREBP2 is anchored to the ER membrane. In 
response to cellular demand for cholesterol SREBP is escorted to the Golgi 
compartment where it undergoes sequential cleavage by site 1 protease (S1P) 
and site 2 protease (S2P) (8). The transcriptionally active amino terminal do-
main of SREBP2 is released in the cytoplasm and migrates to the nucleus 
where it binds sterol response element (SRE) sequences in the promoter region 
of target genes, including cholesterogenic enzymes and the LDL receptor (9). 
Recent studies have identified an Activating Transcription Factor 6 (ATF6) 
dependent mechanism for the subtle regulation of these processes (10). 
ATF6 is also an ER membrane-bound transcription factor and a major regula-
tor of the unfolded protein response (UPR) (11). The UPR is an evolutionary 
conserved stress-signaling pathway from the endoplasmic reticulum to the 
nucleus. Various stressful conditions, e.g. nutrient deprivation, oxidative 
stress, viral infections, obesity, and increased synthesis of secretory proteins, 
lead to documented accumulation of unfolded proteins in the ER lumen and 
trigger the UPR (12, 13). Activation of the UPR is regulated by ATF6 and two 
other proximal stress sensors in the ER membrane: inositol requiring 1(IRE1) 
and PKR-like endoplasmic reticulum kinase (PERK). Together, these three 
branches coordinate a complex network of physiological responses oriented 
towards relieve of ER stress. Besides a critical role for ATF6 in initiation and 
full activation of the UPR (11), lipogenic properties have been ascribed to 
ATF6, and cross talk with the SREBP2 pathway has been demonstrated (10). 
Although ATF6 and SREBP2 in the ER membrane are activated by distinct 
cellular triggers ‒ endoplasmic reticulum stress and sterol deprivation respec-
tively‒ an intriguing convergence exists in their mechanistic activation. In 
analogy to SREPB2, ATF6 is transported from the ER to the Golgi where it 
undergoes sequential cleavage by S1P and S2P. Subsequent release of its tran-
scriptionally active amino terminal domain in the cytoplasm and migration to 
the nucleus allow binding to Endoplasmic Reticulum Stress Element (ERSE) 
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sequences in the promoter region of target genes, including the molecular 
chaperones Grp78 (BiP) and Grp94. Thus, ATF6 activation by ER stress, and 
SREBP activation by sterol deprivation may have evolved from a common 
ancestral pathway, and there is growing evidence that ATF6 mediated attenu-
ation of SREBP2 fine tunes the cholesterol biosynthetic pathway in cells under 
conditions of ER stress (10). Parallel pathways may exist through which ATF6 
could modulate cholesterol homeostasis, suggested by the presence of ATF6-
binding elements in the promoter of the apoB gene (14).   
In the present study, we investigated the hypothesis that genetic variation in 
the ATF6 gene is associated with increased plasma (LDL-)cholesterol levels, 
and that it contributes to the complex genetic background of hypercholestero-
lemia. Our data indicate that a common metionine[67]valine amino acid subs-
titution in ATF6 is associated with (LDL-)cholesterol and apoB in Dutch and 
Finnish individuals. Moreover, we show that this variant is functional, which 
augments ATF6 protein levels and its downstream transcriptional targets. 
 
 
Methods 
Genetic association studies 
Subjects 
The genetic association between common polymorphisms in the ATF6-gene 
and cholesterol levels was first investigated in two Dutch independent sam-
ples and the implicated SNP was further tested in a Finnish sample, compris-
ing a total of 1,310 subjects. All subjects were either at increased risk to devel-
op cardiovascular disease (CVD) (sample 1), or identified as member of fami-
lies ascertained for Familial Combined Hyperlipidemia (FCHL) (sample 2+3). 
The study design was approved by the ethics committees of the participating 
centers and all subjects gave written informed consent.  
Sample 1, Dutch CVR (cardiovascular risk). The first Dutch sample consisted of 
393 unrelated subjects at increased risk for CVD, i.e. with at least one of the 
following risk factors: hypertension, body mass index >25 kg/m2, or a family 
history of type 2 diabetes. Subjects were member of The Cohort study of Di-
abetes and Atherosclerosis Maastricht (CoDAM). Collection of this cohort has 
been extensively described previously (15). To exclude a possible interaction of 
polymorphisms in the ATF6 gene with type 2 diabetes (16), all individuals 
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were subjected to an oral glucose tolerance test, and those with a positive di-
agnosis for type 2 diabetes were excluded in the present study. Lipid lowering 
drug treatments were withheld for 2 weeks prior to phenotypic data mea-
surements. Clinical characteristics of subjects from sample 1 are listed in Table 
1.  
Sample 2, Dutch FCHL. The second sample consisted of 202 Dutch unrelated 
members from families with an established diagnosis of FCHL. Clinical cha-
racteristics of Dutch probands and spouses are presented in Table 1. Dutch 
FCHL families were recruited through the Lipid Clinic of the Utrecht Universi-
ty Hospital (until 1997) and Maastricht University Hospital (1997-2004). The 
criteria to establish the diagnosis of FCHL in a Dutch family were extensively 
described previously (17). To obtain unbiased lipid values, participants had 
abstained from alcohol for at least 72 h and any lipid-lowering medication had 
been withdrawn 2 weeks before blood sampling. Also subjects had refrained 
from smoking and did not drink coffee or tea on the morning of their visit to 
the lipid clinic. 
Sample 3 (Finnish FCHL, replication sample). A total of 61 Finnish FCHL families 
(715 individuals genotyped) were recruited in the Helsinki and Turku Univer-
sity Central Hospital, as described in detail previously (18). The inclusion cri-
teria for probands were premature CVD and abnormal lipid profile with total-
cholesterol (TC) and/or triglyceride levels (TG) ≥ the age-sex-specific 90th Fin-
nish population percentiles. Exclusion criteria were type 1 diabetes, hypo-
thyreosis or renal disease. Lipid phenotypes were measured as described pre-
viously (18). Lipid lowering drug treatments were withheld for 4 weeks prior 
to phenotypic data measurements. Clinical characteristics of Finnish FCHL 
families are provided in Table 1. 
 
SNP selection and genotyping 
SNP selection was designed to cover 100% of the common genetic variation of 
the ATF6-gene including the region 3kb upstream and downstream this locus 
using a minor allele frequency (MAF) >10%. We selected 13 tag-SNPs for geno-
typing using the HAPMAP database. One tag-SNP (SNP4, rs2070150) was 
located in an exon and caused a Pro[145]Ala amino acid substitution. In addi-
tion to the selection of 13 SNPs by the tagging process, 3 additional SNPs were 
selected for their potential direct functional effect: SNP3 (rs1058405) and SNP5 
(rs16846208) for their location in exons, inducing amino acid substitution 
Met[67]Val and Pro[157]Ser respectively, and SNP13 (rs13401) for its location 
ATF6 Gene and Familial Combined Hyperlipidemia 
89 
 
in the 3’ untranslated region. According to the NCBI SNP database rs1058405 
is possibly tri-allelic (Met-Val- Leu), but no leucine variant was detected in a 
subset of 200 subjects, using an allele-specific primer for this variant. In total, 
16 SNPs were genotyped in all subjects of the 2 Dutch samples (sample 1 and 
2), using the TaqMan 7900HT (Applied Biosystems). Two SNPs (rs10918215 
and rs7514053) were in complete LD with rs13401, and therefore not separately 
presented in Tables 2 and 3. The implicated exonic variant (SNP3, rs1058405) 
was further genotyped in a replication sample of 61 Finnish FCHL families 
(Sample 3), with 715 genotyped individuals. Genotyping in the Finnish sample 
was done using the pyrosequencing technique on the PSQ HS96A platform. 
The genotype call rate was >97% for all SNPs in the Dutch samples and 98% in 
the Finnish FCHL families. For quality control, we replicated 7% of genotyped 
samples. The percentage agreement between samples was over 98%. The geno-
types of the individuals with Mendelian errors were called as zeroes in the 
analyses of the Finnish families. All SNPs were in Hardy-Weinberg equili-
brium in the total study sample 1, as well as in the Dutch and Finnish FCHL 
spouses.  
 
Statistical Analyses 
All selected SNPs were first tested in two independent Dutch samples using 
the SPSS software (version 11.0, SPSS, Inc.). Two factor ANOVA was used to 
assess the effects on plasma (LDL)-cholesterol levels. The rs1058405 SNP im-
plicated in both samples was further analyzed in the 2 Dutch samples sepa-
rately and combined using the PLINK package  
(v0.99r, http://pngu.mgh.harvard.edu/purcell/plink/) (19) and was also tested 
for association in a replication sample of 61 Finnish FCHL families. A recessive 
model of inheritance was used, as the cholesterol traits distribution in the three 
genotype groups clearly suggests a recessive mode of action. In the two Dutch 
samples, multivariate linear regression was used to assess the effects of 
rs1058405 on continuous traits (TC, LDL-C and apoB) including age and sex as 
covariates, as well as “center” in the combined analyses of both samples. Since 
the Dutch FCHL sample is relatively small and was selected in part on the 
basis of elevated TC, we also tested rs1058405 for association with qualitative 
TC using a Fisher exact test to avoid false positive results due to violation of 
normality assumptions of continuous phenotypes. The Lipid Clinic Research 
age-sex specific 90th percentile of TC was used to classify the Dutch FCHL 
sample (20). Subjects with TC levels greater than the age-sex specific 90th per-
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centiles were classified as TC affected. Accordingly, 58 of the probands were 
classified as affected. Classification according to the age-sex specific 90th Fin-
nish population percentiles (18) was also applied to illustrate that the obtained 
association is robust under different classification procedures. In the Finnish 
families, the quantitative association analyses of age and sex adjusted residual 
values of TC, LDL-C, apoB and TG were performed using the empirical va-
riance option –e of the family based association test (FBAT). The FBAT –e op-
tion is a test of association given linkage and the test statistics takes thus the 
linkage information into account in extended families. Log transformations 
were performed for traits with non-normal distributions. To control for possi-
ble substructure, violation of normality assumptions of continuous traits and 
small sample size, an empirical p-value was calculated by a permutation pro-
cedure using 10000 permutations. Linkage disequilibrium statistics were ana-
lyzed by the Haploview software (21). The PedCheck program (22) was used 
to detect Mendelian errors in the Finnish FCHL families. 
 
Cell studies and functional experiments 
Isolation and culture of pre-adipocytes  
Adipose tissue was collected as described previously (23). Following the fat 
biopsy and collagenase treatment, the cell suspension was filtered through 500 
μm nylon mesh and spun at 220×g for 1 min to separate pre-adipocytes from 
mature adipocytes. Pre-adipocytes were suspended in 5 ml DMEM medium 
containing 10% fetal calf serum (FCS) and 1% glutamine / streptomycine / 
peniciline (GSP) and cultured during 4 passages under standardized condi-
tions. ATF6 protein levels were measured by western blot in lysates of cul-
tured primary pre-adipocytes, derived from 11 subjects. Clinical characteristics 
of these subjects at the time of the fat biopsy were as follows: 6 women/5 men, 
age 50±12 years, BMI 26.8±2.2 kg/m2, TC 5.7±1.5 mmol/L, LDL-C 4.1±1.7 
mmol/L, apoB 1.12±0.33 g/L, TG 2.1±1.8 mmol/L. 
 
HeLa cell culture and transfection 
HeLa cells were maintained in DMEM containing 10% fetal calf serum. HeLa 
cells were resuspended at 2.5*106 cells per 400μl of cold Dulbecco’s phosphate-
buffered saline and electroporated in a 0.4-cm gap electroporation cuvette at 
250V and 950 microfarads using a GenePulser II Electroporator (Bio-Rad). 
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Cells were then plated at a density of 0.5*106 per 24-mm well for luciferase and 
galactosidase assays, or 1.5*106 per 35-mm well for Western blot experiments. 
 
Plasmids 
- Cytomegalovirus-Galactosidase 
Cytomegalovirus-galactosidase, which codes for a galactosidase reporter dri-
ven by the cytomegalovirus promoter, was used to normalize for transfection 
efficiency. 
 
- Flag-ATF6-(1373[67]-Methionine); Flag-ATF6-(1373[67]-Valine) and Flag-
ATF6-(1373[67]-Leucine). 
These constructs encode amino acid 1-373 of the ATF6 protein and confer 
strong constitutive transcriptional activity, mimicking all aspects of cleaved 
endogenous ATF6. All three constructs contain a 3xFLAG-epitope and only 
differ by their amino acid at position 67. Construction of Flag-ATF6-
(1373[67]-Leucine) has been described previously (24). This parent vector 
was used as a template to create Flag-ATF6-(1373[67]-Methionine) and Flag-
ATF6-(1373[67]-Valine) by site-directed mutagenesis (QuickChange kit, 
Stratagene, Inc.). The following primers were used:  
[67]-Methionine-sense GATTTGGATTTGATGCCTTGGGAGTCAGAC;  
[67]-Methionine-antisense GTCTGACTCCCAAGGCATCAAATCCAAATC;  
[67]-Valine-sense GATTTGGATTTGGTGCCTTGGGAGTCAGAC;  
[67]-Valine-antisense GTCTGACTCCCAAGGCACCAAATCCAAATC.  
Nucleotides in bold were responsible for the desired amino acid substitutions. 
 
-Grp78 promoter(-284+221)-Luciferase 
This construct encodes the GRP78 promoter from -284 to +221 driving lucife-
rase. It was created by PCR using HeLa genomic DNA as a template and a 
sense primer that begins at base -284 and includes a Kpn1 restriction site and 
an antisense primer at +221 and includes an Xho1 restriction site. The resulting 
PCR product was digested with Kpn1 and Xho1, creating the GRP78-promoter 
(-284 to +221), which was ligated into the vector pGL2 (Promega). 
 
- pGL2p 
pGL2 promoter (catalog number E1631; Promega) is a vector containing an 
SV40 promoter inserted into the pGL2-Basic vector upstream of a luciferase 
reporter gene. 
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Reporter assays 
-β-galactosidase 
48 hours after transfection, cells were lysed in 500 μl of ice-cold lysis buffer (25 
mM Gly-Gly, pH 7.8, 15 mM MgSO4, 4 mM EDTA, 0.25% Triton X-100, and 1 
mM dithiothreitol). After centrifugation of the cell lysate, 100 μl of supernatant 
was combined with 500 μl of galactosidase buffer (60 mM Na2HPO4, 40 mM 
NaH2PO4, 10 mM KCl, 1mM MgSO4, 1 mg/ml chlorophenol red-D-
galactopyranoside, and 50 mM 2-mercaptoethanol). After incubation for 1 h, 
the absorbance was measured at 570 nm. 
 
-Luciferase 
Following cell lysis and centrifugation as described above, 100μl cell lysate 
was combined with 100 μl of luciferase buffer (the above described lysis buffer 
containing 45 mM MgSO4, 0.3 mM D-luciferin, and 3 mM ATP). An Opto-
compt II luminometer (MGM Instruments, Inc) was used to measure light 
emission of each sample for 10 seconds. Relative luciferase activities were 
determined by dividing luciferase values by β-galactosidase values.  
 
Western Blotting 
Cell cultures were extracted in lysis buffer composed of 20 mM Tris-HCl, pH 
7.5, 150 mM NaCl, 1% Triton X-100, 0.1% SDS, 1 mM phenylmethylsulfonyl 
fluoride, 10 mg/ml leupeptin, and 10 mg/ml aprotinin. After clearing by centri-
fugation, the protein concentration of the lysate was determined, and after 
dilution with the appropriate amount of 2x Laemmli buffer, equal amounts of 
protein from each sample were fractionated by 10% SDS-PAGE and then trans-
ferred to a polyvinylidene difluoride membrane. Membranes were then 
probed with ATF6-alpha antiserum (Santa Cruz Biotechnology, California), 
beta-actin antiserum (Biolegend, San Diego), FLAG antiserum (F-3165, Sigma), 
KDEL antiserum (SPA-827,Stessgen Biotechnologies Inc, San Diego, CA), or 
GAPDH (RDI-TRK 5G4-65C; Research Diagnostics Inc, Flanders, NJ). 
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Results 
ATF6 protein levels in cultured pre
(LDL-)cholesterol levels and apolipoprotein B.
 
To obtain additional support for our rationale to study the ATF6
tion to hypercholesterolemia, we first evaluated the relation betwe
ATF6 levels and plasma (LDL) cholesterol. ATF6 protein was measured in 
extracts prepared from cultured human primary pre
relation between ATF6 levels in vitro, and plasma (LDL
the corresponding subjects in vivo was observed (Figure 
tween ATF6 and apoB levels was identical, and equally significant, to that 
observed with total cholesterol (figure not shown). The advantage of cultured 
pre-adipocytes instead of freshly isolated mature ad
sumption that cellular effects due to previous metabolic influences are largely 
repressed by standardized cell-culture, and that remaining variation in the 
expression of proteins can be ascribed to (epi)genetic factors.
To study whether we could find evidence of a genetic variant within the 
ATF6-gene associated with cholesterol traits, 16 single nucleotide polymo
phisms (SNPs), selected to capture the common genetic variation in the ATF6
 
 
Figure 1. ATF6 protein levels in cultured hu
were positively correlated with plasma total cholesterol and LDL
(Pearson correlations 0.645 and 0.724, p=0.032 and 0.018 respectively).  Plasma LDL
cholesterol levels were determined accord
for one subject with a plasma triglyceride concentration >4.5 mmol/L.
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gene, were first tested for association in two independent samples: 393 Dutch 
individuals with increased cardiovascular risk (CVR) (Sample 1), and 202 un-
related probands and their spouses from Dutch FCHL families (Sample 2). The 
variant implicated in both of the Dutch samples was further tested for associa-
tion in a replication sample of 61 Finnish FCHL families with 715 genotyped 
individuals (Sample 3). Clinical characteristics of the three study samples are 
shown in Table 1 
 
Table 1. Clinical characteristics of study samples 1-2-3 
 
Trait 
Sample 1 
(Dutch) 
Sample 2 
(Dutch) 
Sample 3 
(Finnish) 
CVR Spouses 
FCHL 
probands 
Non FCHL FCHL 
Male/Female (N) 236/157 50/75 45/32 224/224 144/176 
Age (years) 59±7 51±11 51±11 38±18 44±16 
BMI (kg/m2) 28±4 25±4 27±3 24±4 27±4 
TC (mmol/L) 5.2±0.9 5.57±1.02 6.96±1.46 5.34±0.98 7.26±1.26 
LDL-C (mmol/L) 3.4±0.8 3.8±0.9 4.5±1.5 3.4±0.9 4.7±1.2 
apoB (g/L) 1.12±0.24 1.00±0.25 1.42±0.34 0.91±0.24 1.41±0.35 
TG (mmol/L) 1.44±0.68 1.33±0.58 3.30±2.51 1.28±0.68 3.18±2.27 
Gluc (mmol/L) 5.2±0.9 4.9±0.7 5.4±0.8 4.8±1.0 5.4±1.9 
Data represent mean ± standard deviation, unless otherwise indicated. 
“BMI” Body Mass Index, “TC” Total Cholesterol, “LDL-C” LDL Cholesterol, 
“HDL-C” HDL Cholesterol, “apoB” apolipoprotein B, “TG” Triglycerides, “Gluc” Glucose. 
 
 
Association analyses in Dutch subjects at increased cardiovascular risk 
(Sample 1) 
 
First, genotypic associations for all 16 SNPs in the ATF6-gene with cholesterol 
and LDL-cholesterol levels were explored in sample 1. All SNPs were in Har-
dy-Weinberg equilibrium in this sample. We found evidence of association for 
SNP3 (rs1058405) with apoB (0.011) and LDL-cholesterol (p=0.026) (Table 2). 
SNP3 is a coding variant that translates into the methionine[67]valine amino 
acid substitution. Total cholesterol and LDL-cholesterol and apoB distributions 
in the three genotype groups suggest a recessive mode of action with highest 
levels in homozygous carriers of the rare G-allele. Table 4 shows age and sex 
adjusted p-values, which are statistically significant for apoB, total cholesterol, 
and LDL-cholesterol under a recessive genetic model. 
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Table 2. Analyses per genotype of ATF6 polymorphisms: total cholesterol levels, LDL-
cholesterol levels and apolipoprotein B (Sample 1) 
 
SNP 
(rs) 
Gen. MAF N 
TC 
mmol⁄L 
P 
LDL‒C 
mmol⁄L 
P 
apoB 
g⁄L 
P 
SNP1 
4657101 
C/C 
A/C 
A/A 
0.26 
27 
146 
205 
5.2±0.6 
5.3±0.9 
5.2±0.9 
0.833 
3.4±0.6 
3.4±0.8 
3.3±0.9 
0.894 
1.15±0.2 
1.12±0.2 
1.15±0.2 
0.833 
SNP2 
7553368 
C/C 
T/C 
T/T 
0.31 
32 
165 
178 
5.1±0.9 
5.3±0.9 
5.2±0.9 
0.636 
3.3±0.7 
3.4±0.9 
3.3±0.8 
0.948 
1.10±0.2 
1.13±0.2 
1.11±0.2 
0.654 
SNP3 
1058405 
G/G 
A/G 
A/A 
0.30 
33 
168 
183 
5.5±0.8 
5.2±0.9 
5.2±0.9 
0.140 
3.7±0.8 
3.3±0.8 
3.3±0.9 
0.026 
1.23±0.2 
1.10±0.2 
1.12±0.2 
0.011 
SNP4 
2070150 
C/C 
G/C 
G/G 
0.08 
4 
54 
322 
5.1±0.6 
5.2±0.8 
5.3±0.9 
0.706 
3.2±0.4 
3.3±0.8 
3.4±0.8 
0.567 
1.09±0.2 
1.08±0.2 
1.13±0.2 
0.410 
SNP5 
16846208 
T/T 
C/T 
C/C 
0.08 
4 
53 
324 
5.1±0.6 
5.2±0.8 
5.3±0.9 
0.724 
3.2±0.4 
3.3±0.8 
3.4±0.9 
0.634 
1.09±0.2 
1.09±0.2 
1.13±0.2 
0.456 
SNP6 
4579731 
G/G 
A/G 
A/A 
0.14 
8 
86 
280 
5.2±0.7 
5.3±0.8 
5.3±0.9 
0.994 
3.5±0.9 
3.3±0.8 
3.4±0.8 
0.790 
1.08±0.2 
1.12±0.2 
1.13±0.2 
0.826 
SNP7 
2134697 
C/C 
T/C 
T/T 
0.25 
24 
139 
216 
5.0±1.0 
5.2±0.8 
5.3±0.9 
0.374 
3.2±0.9 
3.3±0.8 
3.4±0.9 
0.418 
1.05±0.2 
1.11±0.2 
1.14±0.2 
0.206 
SNP8 
1503815 
T/T 
C/T 
C/C 
0.11 
6 
70 
302 
4.4±1.2 
5.3±0.8 
5.3±0.9 
0.057 
2.7±1.1 
3.4±0.7 
3.4±0.8 
0.145 
0.95±0.3 
1.12±0.2 
1.13±0.2 
0.184 
SNP9 
2340721 
C/C 
C/A 
A/A 
0.34 
44 
171 
167 
5.0±0.9 
5.2±0.9 
5.3±0.9 
0.159 
3.1±0.8 
3.4±0.8 
3.4±0.9 
0.104 
1.04±0.2 
1.12±0.2 
1.14±0.2 
0.036 
SNP10 
11581364 
T/T 
G/T 
G/G 
0.37 
53 
171 
155 
5.2±1.0 
5.2±0.9 
5.2±0.9 
0.952 
3.4±0.9 
3.3±0.8 
3.3±0.8 
0.851 
1.13±0.2 
1.12±0.2 
1.11±0.2 
0.765 
SNP11 
7554023 
G/G 
A/G 
A/A 
0.19 
10 
120 
246 
5.0±0.6 
5.3±0.9 
5.2±0.9 
0.378 
3.2±0.4 
3.5±0.8 
3.3±0.9 
0.167 
1.12±0.1 
1.15±0.2 
1.11±0.2 
0.310 
SNP14 
10918243 
C/C 
T/C 
T/T 
0.35 
42 
183 
153 
5.4±0.8 
5.3±0.9 
5.2±0.9 
0.199 
3.6±0.8 
3.4±0.8 
3.3±0.8 
0.154 
1.20±0.2 
1.12±0.2 
1.10±0.2 
0.045 
SNP15 
13401 
G/G 
A/G 
A/A 
0.25 
21 
144 
210 
5.1±0.8 
5.2±0.9 
5.3±0.9 
0.417 
3.2±0.9 
3.3±0.8 
3.4±0.8 
0.177 
1.07±0.2 
1.10±0.2 
1.14±0.2 
0.106 
SNP16 
3795649 
T/T 
C/T 
C/C 
0.40 
57 
186 
134 
5.2±0.9 
5.2±0.9 
5.3±0.9 
0.922 
3.4±0.8 
3.3±0.9 
3.4±0.8 
0.680 
1.13±0.2 
1.12±0.2 
1.12±0.2 
0.881 
“Gen” genotype,.”MAF” Minor Allele Frequency, “N” number of subjects, “TC” Total Choles-
terol, “LDL-C” LDL Cholesterol, “apoB” apolipoprotein B, “P” p-value. 
p-values in bold reflect statistical significance. 
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Table 3. Analyses per genotype of ATF6 polymorphisms: total cholesterol levels, LDL-
cholesterol levels and apolipoprotein B (Sample 2) 
 
SNP 
(rs) 
Gen. MAF N 
TC 
mmol⁄L 
P 
LDL‒C 
mmol⁄L 
P 
apoB 
g⁄L 
P 
SNP1 
4657101 
C/C 
A/C 
A/A 
0.23 
12 
57 
106 
6.0±1.4 
6.3±1.5 
5.9±1.3 
0.333 
4.2±1.2 
4.1±1.4 
3.9±1.1 
0.655 
1.2±0.3 
1.2±0.4 
1.1±0.3 
0.680 
SNP2 
7553368 
C/C 
T/C 
T/T 
0.30 
19 
72 
87 
6.2±1.4 
6.0±1.3 
6.1±1.4 
0.838 
4.0±0.9 
4.0±1.2 
4.0±1.2 
0.952 
1.2±0.3 
1.1±0.3 
1.1±0.4 
0.903 
SNP3 
1058405 
G/G 
A/G 
A/A 
0.27 
20 
58 
103 
6.7±1.6 
5.9±1.3 
6.0±1.2 
0.040 
4.4±1.6 
3.9±1.2 
3.9±1.0 
0.182 
1.3±0.4 
1.1±0.4 
1.1±0.3 
0.052 
SNP4 
2070150 
C/C 
G/C 
G/G 
0.08 
1 
25 
152 
6.8 
6.3±1.8 
6.0±1.3 
0.583 
5.0 
4.0±1.6 
4.0±1.1 
0.695 
1.4 
1.1±0.4 
1.1±0.3 
0.757 
SNP5 
16846208 
T/T 
C/T 
C/C 
0.07 
1 
23 
155 
6.8 
6.2±1.7 
6.0±1.3 
0.674 
5.0 
3.9±1.5 
4.0±1.1 
0.646 
1.4 
1.1±0.3 
1.1±0.3 
0.715 
SNP6 
4579731 
G/G 
A/G 
A/A 
0.12 
2 
39 
135 
6.2±1.3 
5.9±1.3 
6.1±1.3 
0.866 
4.3±1.2 
3.8±1.1 
4.0±1.2 
0.583 
1.4±0.4 
1.1±0.3 
1.1±0.4 
0.522 
SNP7 
2134697 
C/C 
T/C 
T/T 
0.25 
8 
75 
100 
6.1±0.8 
5.8±1.2 
6.3±1.5 
0.087 
4.1±0.6 
3.8±1.0 
4.2±1.4 
0.205 
1.1±0.3 
1.1±0.3 
1.2±0.4 
0.758 
SNP8 
1503815 
T/T 
C/T 
C/C 
0.13 
3 
40 
139 
6.4±0.7 
5.7±1.0 
6.1±1.4 
0.239 
4.0±0.4 
3.9±0.8 
4.0±1.3 
0.823 
1.2±0.1 
1.1±0.4 
1.1±0.3 
0.956 
SNP9 
2340721 
C/C 
C/A 
A/A 
0.34 
19 
86 
80 
5.8±1.0 
6.0±1.4 
6.2±1.4 
0.360 
3.9±1.0 
3.9±1.1 
4.1±1.3 
0.629 
1.1±0.3 
1.1±0.3 
1.2±0.4 
0.563 
SNP10 
11581364 
T/T 
G/T 
G/G 
0.39 
32 
75 
70 
6.1±1.1 
6.0±1.4 
6.1±1.4 
0.738 
4.0±0.8 
3.9±1.3 
4.1±1.3 
0.692 
1.1±0.3 
1.1±0.3 
1.2±0.4 
0.168 
SNP11 
7554023 
G/G 
A/G 
A/A 
0.17 
7 
47 
123 
6.1±1.9 
6.1±1.3 
6.0±1.3 
0.861 
4.5±1.8 
4.0±1.1 
3.9±1.2 
0.472 
1.2±0.4 
1.2±0.3 
1.1±0.3 
0.827 
SNP14 
10918243 
C/C 
T/C 
T/T 
0.35 
24 
75 
80 
6.6±1.5 
5.9±1.3 
6.0±1.3 
0.127 
4.3±1.5 
3.9±1.1 
4.0±1.2 
0.304 
1.2±0.4 
1.1±0.4 
1.1±0.3 
0.402 
SNP15 
13401 
G/G 
A/G 
A/A 
0.25 
14 
65 
110 
5.8±1.1 
6.0±1.5 
6.1±1.3 
0.641 
3.9±1.1 
3.9±1.3 
4.1±1.2 
0.695 
1.1±0.3 
1.1±0.4 
1.1±0.3 
0.737 
SNP16 
3795649 
T/T 
C/T 
C/C 
0.40 
33 
81 
65 
6.1±1.3 
5.9±1.3 
6.1±1.5 
0.578 
4.1±1.1 
4.0±1.1 
4.0±1.3 
0.949 
1.2±0.3 
1.1±0.3 
1.2±0.4 
0.589 
“Gen” genotype,.”MAF” Minor Allele Frequency, “N” number of subjects, “TC” Total Choles-
terol, “LDL-C” LDL Cholesterol, “apoB” apolipoprotein B, “P” p-value. 
p-values in bold reflect statistical significance. 
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Association analyses in Dutch FCHL relatives (Sample 2) 
Next, we tested the same set of 16 ATF6-SNPs for association with apoB and 
plasma cholesterol levels in a second Dutch sample, comprising unrelated 
members from families with an established diagnosis of FCHL. All SNPs were 
in Hardy-Weinberg equilibrium in spouses. Again, SNP3 was associated with 
increased apoB and total plasma cholesterol levels (Table 3), and, identical to 
sample 1, the highest signals were obtained under a recessive genetic model 
(Table 4, Total Cholesterol, LDL-cholesterol and apoB). A combined analysis of 
sample 1 and 2 strengthened the evidence for association with these traits 
(Table 4, p=0.00004-0.001).  
We also investigated the direct effect of SNP3 on hypercholesterolemia in a 
case control setting. Irrespective of whether hypercholesterolemia was defined 
by the Lipid Clinic Research age-sex specific 90th percentile (p=0.002, OR=2.11, 
95% C.I. 1.31-3.39) or by the age-sex specific 90th Finnish population percentile 
(p=0.001, OR=2.45, 95% C.I. 1.44-4.19), the qualitative analyses strongly sup-
ported the results of the quantitative analyses. 
 
Table 4. Genetic association analyses of SNP3 (rs1058405, Met[67]Val): recessive model of 
inheritance, all study samples 
 
Sample 
TC LDL-C apoB 
p E-p p E-p p E-p 
Sample 1 
Dutch CVR 
0.034 0.033 0.007 0.007 0.003 0.003 
Sample 2 
Dutch FCHL 
0.011 0.012 0.061 0.06 0.007 0.007 
Sample 1+2 
Dutch CVR+FCHL 
0.001 0.001 0.001 0.001 0.00004 0.0002 
Sample 3 
Finnish FCHL 
0.068 0.065 0.045 0.041 0.013 0.025 
Quantitative analyses of TC, LDL-C and apoB under a recessive genetic model. P-values 
represent the results of multivariate linear regression analyses in the Dutch cohorts, and 
the FBAT-e test in the Finnish FCHL families. 
“E-p” Empirical p-values using 10.000 permutations 
 
Association analyses in Finnish FCHL families (Sample 3) 
To validate and generalize the associations observed in the two Dutch sam-
ples, we examined SNP3 in 715 individuals from 61 Finnish FCHL families. 
For this purpose we used the FBAT –e option, which is a test of association 
given linkage, and the test statistics takes thus the linkage information into 
account in extended families. SNP3 was in Hardy-Weinberg equilibrium in 
spouses. Consistent with the results obtained in the two Dutch samples, the 
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highest signal was obtained under a recessive genetic model. Family based 
association tests under a recessive genetic model showed that the minor allele 
of SNP3 was significantly associated with LDL-C, (p=0.04) and apoB (p=0.01) 
in Finnish FCHL families (Table 4). The signal for total cholesterol did not 
exceed the threshold for statistical significance in this sample (p=0.07). 
 
Secondary association analyses of triglyceride levels and FCHL.  
The lipid core of apoB containing lipoproteins consists of both cholesterol and 
triglycerides, and elevated plasma triglyceride levels represent the second core 
phenotypic component of the FCHL definition. We therefore performed sec-
ondary analyses and explored the possibility that SNP3 is also associated with 
triglyceride levels and the binary FCHL-trait itself. No evidence for a signifi-
cant effect on triglyceride levels was found in sample 1. In the Dutch and Fin-
nish FCHL family members (Sample 2 and 3), association analyses with trigly-
cerides showed a non-significant trend (p=0.08), and a borderline significant 
association (p=0.05) respectively. The trend with triglycerides in FCHL family 
members only, may thus be driven mainly by the high correlation between 
cholesterol and triglyceride levels in these subjects. Associations with the bi-
nary FCHL trait were not significant in the Dutch and Finnish FCHL samples 
separately. A combined analysis of Dutch and Finnish FCHL probands and 
spouses resulted in a p-value of 0.04 for FCHL. It is plausible that the pro-
found effect of SNP3 on (LDL-)cholesterol levels and apoB explains the modest 
association with FCHL. Taken together our results show a consistent genetic 
association of SNP3 with (LDL-) cholesterol and apoB levels in the indepen-
dent samples under a recessive mode of action, whereas evidence for an effect 
of on plasma triglyceride levels and the complex FCHL trait is modest at best. 
 
Genetic association data from a publicly available genome wide study 
To obtain independent support for the genetic associations above, we also 
mined the publicly available database from a recent genome wide association 
study comprising Scandinavian subjects with type 2 diabetes and unrelated 
population controls. (www.broad.mit.edu/diabetes) (25). In this previous 
study, subjects were neither genotyped for SNP3, nor for markers that exhibit 
high LD with SNP3. Also, data on possible associations with total cholesterol 
were not available. However, five polymorphisms within the ATF6-locus were 
significantly associated with apoB levels (strongest signals p=0.003-0.004; 
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rs10918029 and rs1875762), but not LDL-cholesterol. This unexpected disparity 
could be due to the combined presence of healthy subjects and patients with 
type 2 diabetes. In the diabetic state, VLDL is preferably catabolized to small 
dense LDL, rather than LDL (26), which could have disrupted the linear rela-
tionship between apoB and LDL-cholesterol in this study sample. For com-
pleteness, two other SNPs in the ATF6-gene (rs1027700 and rs3767635) showed 
a marginal association with triglyceride levels in this sample (p=0.04). 
 
Functional characterization of the methionine-67-valine variant. 
The implicated SNP3 is a coding SNP that translates to the met[67]val substitu-
tion in the ATF6 protein. This amino acid locates to the transcription activation 
domain (TAD) of ATF6, more specifically the VN8-like region (amino acid 61-
68) (Figure 2).  
 
Figure 2. A. Schematic representation of full-length and cleaved (activated) ATF6. B. Detailed 
representation of the VN8-like region (amino acid 61-68) in ATF6. The methionine to valine 
substitution at position 67 (grey box), is associated with increased (LDL-) cholesterol levels 
and apolipoprotein B. Three ATF6 (1-373) constructs were created that only varied by their 
amino acid at position 67 (methionine (wildtype), valine (variant) and leucine (not detected 
in Dutch and Finnish subjects), and tested for their transcriptional potency. Site directed 
mutagenesis of amino-acids 62 and 64, was previously shown to cause a dramatically de-
creased ATF6-mediated transcription (27). 
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The VN8 sequence was previously found of critical importance for transcrip-
tional activity and degradation of ATF6 (27). To explore the possibility that the 
associated Met[67]Val polymorphism is a functional variant, we assessed the 
effect of amino-acid variations at position 67 on ATF6 levels and transcription-
al activity of ATF6 in vitro. Notably, according to the NCBI SNP-database 
rs1058405 is in fact tri-allelic (A-G-T → Met-Val-Leu). Although the leucine-
variant was not detected in our study sample, it may exist in other populations 
and we therefore tested it for potential functionality as well. Accordingly, 
three FLAG-tagged ATF6(1-373) constructs were prepared, which mimic the 
transcriptional active N-terminal part of ATF6 generated by ER-stress. These 
three constructs varied only by their amino acid at residue 67 (methionine, 
valine or leucine) (Figure 2B), and were tested in HeLa cells for their potency 
to induce luciferase expression through the GRP78 promoter. FLAG-ATF6(1-
373)-[67]-valine and FLAG-ATF6(1-373)-[67]-leucine activated the reporter to a 
greater extent (140% and 250% respectively), compared to the construct with 
the wildtype methionine amino acid at residue 67 (Figure 3). 
 
 
Figure 3. Potency of FLAG-ATF6(1-373)-[67]-methionine, FLAG-ATF6(1-373)-[67]-valine, 
and FLAG-ATF6(1-373)-[67]-leucine to induce luciferase expression in Hela cells through the 
GRP78 promoter. * p<0.05, # p<0.001 
 
 
As a complementary experiment, we also examined the potency of the various 
ATF6-constructs to induce expression of the endogenous ER-chaperone genes 
Grp78 and Grp94, which are direct transcriptional targets of ATF6. In agree-
ment with results from the luciferase assay, the levels of Grp78 and Grp94 
were significantly greater in cells transfected with FLAG-ATF6(1-373)-[67]-
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valine and FLAG-ATF6(1-373)-[67]-leucine, than those transfected with the 
wildtype construct (Figure 4A and 4B). Higher levels of Grp78 and Grp94 were 
observed in parallel with increased amounts of ATF6 protein. Together these 
data provide evidence that the Met[67]Val substitution in ATF6 is a functional 
variant, with a direct effect on ATF6 protein levels and its downstream targets. 
 
 
 
Figure 4. Potency of FLAG-ATF6(1-373)-[67]-methionine, FLAG-ATF6(1-373)-[67]-valine, 
and FLAG-ATF6(1-373)-[67]-leucine to induce endogenous GRP94 and GRP78 levels (panel 
A: visualization by western blot, panel B: quantification). * p<0.05, # p<0.01 
 
 
 
Discussion 
The principal finding of this study is the association of the Met[67]Val amino 
acid substitution in ATF6 with increased apoB and plasma (LDL-)cholesterol 
levels. This finding was replicated in three independent samples, originating 
from two distinct populations, Dutch and Finnish. Despite a relatively modest 
number of individuals (N combined = 1310, the observed association with 
ATF6 was replicated in these various study samples consistently with a reces-
sive mode of inheritance. In a recent publicly available genome wide associa-
tion study with approximately 3000 subjects, five SNPs in the ATF6 gene were 
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also significantly associated with apoB (www.broad.mit.edu/diabetes) (25), 
but, the use of an additive model and lack of genotyping information on the 
implicated SNP rs1058405 -or SNPs in strong LD- precludes the statement of 
replication in a strict statistical sense. Importantly, the genetic association with 
ATF6 is supported by biological data indicating a strong positive relationship 
between ATF6 protein levels in cultured human pre-adipocytes and plasma 
(LDL-)cholesterol concentrations in the corresponding patients. Moreover, we 
showed that the implicated polymorphism is a potentially functional variant, 
which augments ATF6 levels and its downstream transcriptional targets. 
The Met[67]Val substitution in ATF6 (rs1058405) is a common variation. Minor 
allele frequencies range from 7% in African American to 23% and 29% in Asian 
and European populations respectively (http://www.ncbi.nlm.nih.gov/SNP/). 
The genetic model of Met[67]Val variant is close to recessive for the valine 
disease allele. Heterozygous subjects (Met/Val) have identical (LDL-) choles-
terol levels as homozygous Met/Met subjects, while only homozygous Val//Val 
subjects present with significantly higher plasma (LDL-) cholesterol and apoB 
concentrations. Transfection experiments with mutated ATF6 constructs re-
vealed that the [67]-valine variant increases ATF6 transcriptional activity in 
cultured cells, suggesting that it constitutes a gain-of-function polymorphism. 
According to the NCBI SNP-database rs1058405 is possibly tri-allelic (A-G-T → 
Met-Val-Leu). Remarkably, mutating amino acid 67 to leucine increased ATF6 
levels even more, as well as its downstream transcriptional targets, Grp78 and 
Grp94. However, the [67]-leucine variant was not detected in our study sam-
ple, which precluded examination of the potential phenotypic consequences of 
this variation in vivo. The Met[67]Val substitution represents a priori an excel-
lent candidate polymorphism that could functionally affect ATF6: it resides 
within a VN8-like domain of ATF6 (Figure 3), and a previous study showed 
that mutating residue 62 and 64 in VN8 dramatically affected degradation and 
transcriptional activity of ATF6 (27). Of special interest, a VN8 domain was 
first identified in the virion protein 16 (VP16) transcription factor (75% homol-
ogy with ATF6) from herpes simples virus type I (28). Also in VP16 the VN8 
domain was found to be required for transcriptional activation and rapid pro-
teosomal degradation (29). Together these data illustrate the critical impor-
tance of this domain and specifically amino acid 67 for ATF6 activity. 
Zeng and colleagues recently elucidated a potential molecular mechanism 
through which ATF6 can modulate cholesterol homeostasis (10). Activated 
ATF6 can interact with SREBP2 and bind as a heterodimer to sterol response 
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elements (SREs) in the promoters of cholesterogenic genes. Bound to SRE, the 
ATF6-SREBP2 heterodimer recruits HDAC1, and together they exert a major 
inhibitory effect on SREBP2-regulated transcription (10). The inhibitory effect 
of an enhanced ATF6 response due to the Met[67]Val gain-of-function-
polymorphism on SREBP2 activity, might further reduce the number LDL 
receptors that bind and internalize LDL and VLDL particles, and increases 
plasma cholesterol levels. In parallel with this mechanism, ATF6 may also 
modulate cholesterol- and lipoprotein metabolism more directly, since the 
promoter region of the apoB gene contains ATF6-binding elements (14). Other 
proteins of the unfolded protein response have also been implicated in human 
lipid- and cholesterol metabolism through activation and deregulation of 
SREBPs.(30-34) The fact that even in yeast and plants a coordinated regulation 
of ER stress related proteins and lipid metabolic enzymes has been reported, 
suggests a conserved common ancestral pathway (35, 36). 
ER stress and activation of the UPR is linked with various components of the 
metabolic syndrome, including insulin resistance, beta-cell failure, inflamma-
tion and atherosclerosis (13, 14, 37, 38). We and others recently reported the 
replicated genetic association between variants in the ATF6-gene and type 2 
diabetes(16, 39, 40). This is especially interesting in light of the overlapping 
genetic and metabolic background between type 2 diabetes and FCHL. How-
ever, The Met[67]Val substitution was not reproducibly associated in our pre-
vious diabetes study (40), nor was it associated in Pima Indians (16). Thus, 
distinct genetic lesions in ATF6 may account for the disturbances in glucose 
and cholesterol metabolism. Association of the Met[67]Val substitution with 
plasma triglyceride levels was modest at best. The shared metabolic pathway 
and statistical correlation of triglycerides and cholesterol is a plausible expla-
nation for this observation. Similarly, the modest association with the complex 
FCHL trait in the combined Dutch and Finnish FCHL samples is probably 
almost entirely accounted for by a profound effect on apoB and (LDL-) choles-
terol levels. 
In conclusion, we showed that Met[67]Val substitution in the ATF6-gene is 
associated in a threefold replication with (LDL-)cholesterol and apoB levels in 
samples of Dutch and Finnish ethnicity, implicating ATF6 as a novel gene 
contributing to variation in plasma cholesterol levels and hypercholesterole-
mia. Evidence from functional experiments indicates that the Met[67]Val subs-
titution is a gain-of-function polymorphism that increases ATF6 transcription-
al activity. The exact mechanism however, through which the Met[67]Val 
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substitution in ATF6 affects cholesterol metabolism is a major challenge to be 
addressed in future studies. Also, the possibility that this variant may predis-
pose homozygous carriers to develop cardiovascular disease, is an interesting 
hypothesis to be tested in prospective cohort studies. 
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Upstream Transcription Factor 1 (USF1) in Risk of  
Type 2 Diabetes: Association Study in 
2000 Dutch Caucasians 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SUMMARY 
Type 2 diabetes (DM2) shares substantial genetic 
and phenotypic overlap with Familial Combined 
Hyperlipidemia (FCHL). Upstream stimulatory 
factor 1 (USF1), a well-established susceptibility 
gene for FCHL, is postulated to be such a shared 
genetic determinant. We evaluated two established 
FCHL-variants (rs2073658 and rs3737787) for 
association with DM2 in two Dutch case-control 
samples (N=2011). The first case-control sample 
comprised 501 subjects with DM2 from the Breda 
cohort and 920 healthy blood bank donors of Dutch 
Caucasian origin. The second case-control sample 
included 211 subjects with DM2, and 379 normog-
lycemic controls. SNP rs2073658 and SNP 
rs3737787 were in perfect linkage disequilibrium. In 
the first case-control sample, prevalence of the major 
allele was higher in patients than in controls (75% 
versus 71%, OR=1.25, p=0.018). A similar effect-
size and -direction was observed in the second case-
control sample (76% versus 72%, OR=1.22, 
p=0.16). A combined analysis strengthened the 
evidence for association (OR=1.23, p=0.006). Nota-
bly, the increased risk for DM2  could be ascribed to 
the major allele, and its high frequency translated to 
a substantial population attributive risk of 14.5%. 
In conclusion, the major allele of rs2073658 in the 
USF1 gene is associated with a modestly increased 
risk to develop DM2 in Dutch Caucasians, with 
considerable impact at the population level.  
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Introduction 
The first chromosomal locus for Familial Combined Hyperlipidemia (FCHL) 
on 1q21-23 in Finnish pedigrees led to the identification of Upstream Tran-
scription Factor 1 (USF1), a transcriptional regulator critically involved in lipid 
and glucose homeostasis (1, 2). Since this original report, association of USF1 
with FCHL was replicated in Mexican Americans and Utah Caucasians (3, 4) 
and subsequent studies in distinct ethnic population samples also linked va-
riants in the USF1 gene to inherited susceptibility for hyperlipidemia, the me-
tabolic syndrome and its component traits (5-7). Importantly, in a recent pros-
pective study, specific alleles of the USF1 gene proved to modify CVD risk and 
contribute both to CVD and all-cause mortality at the population level (8).  
Considerable genetic and phenotypic overlap exists between FCHL and Type 
2 diabetes, and dyslipidemia is a very commonly observed phenomenon in 
patients with type 2 diabetes. FCHL and type 2 diabetes both develop against 
a background of insulin resistance and predispose to early cardiovascular 
disease. The USF1 chromosomal region 1q21-23 has not only been repeatedly 
attributed to FCHL (1, 9-11), but also represents the most consistently repli-
cated locus in genome wide scans for linkage to type 2 diabetes (12-21). USF1 
is therefore an attractive biological and positional candidate gene for type 2 
diabetes. Yet, the direct contribution of the USF1 gene on type 2 diabetes sus-
ceptibility has been addressed in a more limited fashion and results are less 
unequivocal than for FCHL and lipid traits. Two studies thus far reported a 
significant genetic association with type 2 diabetes or its component traits with 
the same single nucleotide polymorphisms (SNPs) -or SNPs in tight LD- as 
identified for FCHL and lipid traits (5, 6). Data from the two most recent stu-
dies did not provide additional support for a statistically significant effect (22, 
23). In order to adequately evaluate the contribution of USF1 risk alleles to 
type 2 diabetes in distinct populations, and provide robust assessment of effect 
size, replication studies in large, well-defined cohorts are required. 
In the present study we investigated whether variants in the USF1 gene con-
tribute to the inherited susceptibility for developing type 2 diabetes in 2011 
subjects of the Dutch population, using two independent case-control samples 
comprising 712 patients with type 2 diabetes and 1299 healthy controls. 
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Methods 
Subjects 
The first case-control sample comprised 501 subjects with type 2 diabetes from 
the Breda cohort (24) and 920 healthy blood bank donors of Dutch Caucasian 
origin (25). Patients were diagnosed according to the WHO criteria (random 
plasma glucose level >11.1 mmol/l or a fasting plasma glucose level >7.0 
mmol/l). The clinical characteristics of the patients (HbA1c, total cholesterol, 
HDL cholesterol and triglycerides) were available, as well as the level of obesi-
ty (body mass index) in each individual. Clinical characteristics of the first 
case-control sample are provided in Table 1.  
 
Table 1. Clinical characteristics of case-control sample 1. 
Trait Patient Group Control group 
N (male/female) 501 (270a/230) 920 (354/557b) 
Age at study (years) 70.7±9.9 47.8±12.7 
Age at diagnosis (years) 57.6±14.4 - 
BMI (kg/m2) 27.6±4.9 NA 
HbA1c (%) 6.6±2.4 NA 
HDL-cholesterol (mmol/L) 1.1±0.5 NA 
Total Cholesterol (mmol/L) 4.9±1.8 NA 
Triglycerides (mmol/L) 1.7±1.1 NA 
Data are mean ± SD. 
aNot available for 1 subject; bNot available for 9 subjects 
“HbA1c” Hemoglobin A1c (glucose bound to hemoglobin), “NA” not available 
 
The second case-control sample was collected as described previously (26, 27). 
Briefly, more than 2700 subjects with one or more cardiovascular risk factors, 
including hypertension, BMI>25 kg/m2, a positive family history for type 2 
diabetes mellitus, or a history of gestational diabetes, were screened for type 2 
diabetes. Exclusion criteria were the use of medication that affects glucose 
metabolism and non-Caucasian ethnicity. The case-control sample comprised 
all newly diagnosed subjects with type 2 diabetes (N=211), and a random se-
lection of 379 normoglycemic control subjects. Clinical characteristics of the 
second case-control sample are provided in Table 2. The Human Investigation 
Review Committee of the Academic Hospital Maastricht and the Medical Eth-
ics Committee of the University Medical Center Utrecht approved the study 
protocol and all subjects gave written informed consent. 
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Table 2. Clinical characteristics of case-control sample 2 
Trait Patient Group Control group 
N (male/female) 211 (67/144) 379 (157/222) 
Age 59.7±6.5 57.8±7.3 
BMI (kg/m2) 30.7±4.4 27.4±3.8b 
Fasting glucose 7.9±1.8 5.3±0.4 
HDL-cholesterol (mmol/L) 1.0a±0.3 1.3c±0.4 
Total Cholesterol (mmol/L) 5.1a±1.0 5.2c±0.9 
Triglycerides (mmol/L) 2.0a±1.1 1.3c±0.6 
Data are mean ± SD. 
aNot available for 88 subject; bNot available for 1 subjects, cNot available for 94 subjects 
 
Genotyping.  
Previous studies that investigated the genetic contribution of USF1 to FCHL 
and type 2 diabetes identified two specific SNPs -or variants in tight LD with 
these SNPs- that were consistently most strongly associated with disease. 
These variants, rs2073658 and rs3737787 are 1239 bp apart and located in in-
tron 7 and the 3’ untranslated region of the USF1 gene respectively. In pre-
vious reports both variants were in (almost) complete linkage disequilibrium.  
SNPs rs2073658 and rs3737787 were genotyped using Taqman assays (Applied 
Biosystems). Assays were performed according to the manufacturer’s instruc-
tions. The DNA samples were processed in 384-well plates. Each plate con-
tained eight negative controls and 16 genotyping controls. Genotypes were 
analyzed using a TaqMan 7900 HT (Applied Biosystems, Nieuwerkerk a/d 
IJssel, The Netherlands). 
 
Statistical Analyses 
Power calculations were performed using the genetic power calculator of Pur-
cell et al (28) (available at  http://pngu.mgh.harvard.edu/~purcell/gpc/). 
Assuming a disease prevalence of 0.1, a genotype relative risk of 1.25 and 1.50, 
and an allele frequency of 0.75, the combined case-control sample afforded an 
estimated power of 0.77 at p<0.05. Odds ratios and p-values for case-control 
analyses were calculated using χ2 tests. D’ and r2 between the USF1 SNPs were 
calculated using Haploview. 
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Results 
We genotyped rs2073658 in all subjects from both cohorts. Genotype success 
rate was >98%, and the SNP was in Hardy Weinberg equilibrium. In addition, 
we genotyped SNP rs3737787 in a subset of 590 subjects. In accordance with 
previous studies both SNPs were in complete linkage disequilibrium (D’=1, 
r2=1). The results of SNP rs2073658, which has the best credentials as a poten-
tial causal variant in USF1 (29), are presented in Table 3. 
 
Table 3. Genotype and allele frequencies in patients with type 2 diabetes and control subjects 
Genotype 
rs2073658 
DM2 (%) Control (%) 
Odds 
Ratio 
95% C.I. p-value 
Case-control sample 1 (N=1421)  
AA 
AG 
GG 
35 (7.2) 
174 (35.6) 
280 (57.3) 
87 (9.6) 
355 (39.1) 
465 (51.3) 
1 
1.22 
1.50 
 
0.79-1.88 
0.98-2.28 
 
0.370 
0.058 
A-allele 
G-allele 
244 (24.9) 
734 (75.1) 
529 (29.2) 
1285 (70.8) 
1 
1.25 
 
1.04-1.48 
 
0.018 
Case-control sample 2 (N=590)  
AA 
AG 
GG 
13 (6.3) 
74 (35.6) 
121 (58.2) 
28 (7.5) 
152 (40.8) 
193 (51.7) 
1 
1.05 
1.35 
 
0.51-2.14 
0.67-2.71 
 
0.896 
0.396 
A-allele 
G-allele 
100 (24.0) 
316 (76.0) 
208 (27.9) 
538 (72.1) 
1 
1.22 
 
0.93-1.61 
 
0.155 
Case-control sample 1+2 combined (N=2011)  
AA 
AG 
GG 
48 (6.9) 
248 (35.6) 
401 (57.5) 
115 (9.0) 
507 (39.6) 
658 (51.4) 
1 
1.17 
1.46 
 
0.81-1.70 
1.02-2.09 
 
0.400 
0.038 
A-allele 
G-allele 
344 (24.7) 
1050 (75.3) 
737 (28.8) 
1823 (71.2) 
1 
1.23 
 
1.06-1.43 
 
0.006 
1396 subjects (98.2%) were genotyped successfully in case-control sample 1 
581 subjects (98.5%) were genotyped successfully in case-control sample 2 
 
In the first case-control sample, prevalence of the major allele was higher in 
patients than in controls (75% versus 71%, odds ratio 1.25, p= 0.018). In the 
second case-control sample, a similar frequency difference and concomitant 
odds ratio were observed: 76% in patients versus 72% in control subjects, odds 
ratio 1.22. Although insufficient power of the second case-control sample pre-
vented this frequency difference to meet the threshold for statistical signific-
ance (p=0.16), the effect-size and -direction were identical to the first case-
control sample and a combined analysis of both samples further strengthened 
the evidence for association (odds ratio 1.23, p=0.006). Importantly, the in-
creased risk for type 2 diabetes susceptibility can be ascribed to the major al-
lele, and its high frequency translates to a considerable population attributive 
Chapter 6 
114 
 
risk of 14.5%. Together, these data indicate that the major allele of rs2073658 is 
associated with a modest but consistent increased risk for developing type 2 
diabetes in Dutch Caucasians, with substantial impact at the population level. 
 
 
Discussion 
USF1 is a positional and functional candidate gene for type 2 diabetes. The 
main finding of this study is that a polymorphism within the USF1-gene with 
strongest prior odds for association, and best credentials for functional in-
volvement (rs2073658) is associated with type 2 diabetes in an analysis with 
2011 Dutch Caucasian subjects. The observed effect size of the USF1 risk allele 
is modest (OR≈1.25), but consistent in the two independent Dutch case-control 
samples.  
USF1 is a ubiquitously expressed transcription factor of the basic helix-loop-
helix leucine zipper family and regulates the expression of some 40 genes, 
several of them involved in lipid and glucose metabolism. USF1 mediates its 
transcriptional regulation through binding to E-box motifs in the promoter 
region of target genes with the consensus sequence CACGTG, either as homo-
dimer but in most cases as a heterodimer with the related transcription factor 
USF2 (30). 
USF1 was originally identified as a major susceptibility gene for FCHL, under-
lying the linkage signal on 1q21-23 in Finnish families with the disease (2). 
Two polymorphisms in USF1, rs2073658 and rs3737787, in strong LD with 
each other, were the most strongly associated variants. Subsequent replication 
studies in various FCHL samples of distinct ethnicities implicated the same 
polymorphisms (or variants in tight LD) in the genetic background of FCHL 
(3, 4, 31). Furthermore, differential expression of USF1-regulated genes in adi-
pose tissue from subjects with different allelic variants has been reported (29). 
Complementary to these findings, significant associations with lipid traits, 
parameters of adipose tissue metabolism, and the metabolic syndrome in pop-
ulations not specifically ascertained for FCHL, further extended the potential 
significance of USF1 as a cardiovascular risk determinant (6, 7, 32-34). Recent 
important data from a prospective follow up study demonstrate that USF1 risk 
alleles confer an approximately two fold increased risk to cardiovascular dis-
ease and all-cause mortality in women from two independent Finnish cohorts 
representative of the general population (8). These latter data provide impor-
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tant decisive evidence and illustrate how a gene originally identified in high-
risk families proves to be important also at the population level.  
No amino acid changes have been detected in the USF1 gene that could func-
tionally account for the observed associations. However, rs2073658 resides in a 
20-basepair DNA sequence that binds nuclear proteins and possibly represents 
a transcriptional regulatory element (29). In all studies to date rs2073658 and 
rs3737787 were among the strongest associated variants, suggesting that 
‒irrespective of whether one of these SNP is a true etiological variant‒ they 
represent reliable markers for FCHL across populations of different ethnicity.  
Triggered by the convincing results of USF1 variants in relation to FCHL and 
lipid traits, some research groups scrutinized the USF1 gene for its potential 
contribution to inherited DM2 susceptibility. Four studies thus far investigated 
the potential association of USF1 SNPs with type 2 diabetes or related traits (5, 
6, 22, 23). Putt et al were the first to report haplotypic associations (comprising 
SNPs in tight LD with rs3737787 and rs2073658) with glucose levels during an 
oral glucose tolerance test (5). In Hong Kong Chinese subjects rs3737787 was 
associated with type 2 diabetes in family cases with 1q-linkage but no associa-
tion was found in a second case-control cohort (6). Recent analyses in French 
Caucasian subjects and in several populations with evidence of chromosome 
1q linkage found no significant associations (22, 23).  
Although the USF1 risk allele in the present study confers only a modest risk 
to individuals carrying the risk variant, it may have a substantial impact at the 
population level. As much as ~75% of subjects carry the risk allele, which 
translates to a population attributive risk (PAR) of 14%. This means, that if the 
population were monomorphic for the protective allele, the prevalence of type 
2 diabetes would be 14% lower. This resembles the established type 2 diabetes 
variant Pro12Ala in PPARγ, which confers modest risk for the individual 
(OR=1.25), but high risk at the population level (PAR=25%) (35).  
From our present study and the available data thus far, we conclude that the 
diabetogenic properties of USF1 polymorphisms are likely modest at the level 
of the individual, but may be considerable at the population level. 
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General Discussion 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Years of intensive research in the field of insulin resis-
tance, hyperlipidemia and type 2 diabetes have substan-
tially improved our knowledge of their pathophysiologi-
cal mechanisms. However, the present level of know-
ledge does not yet allow individualized treatment 
according to differences in genetic make-up. In light of 
the emerging shift in medicine towards “personalized 
medicine” and the coinciding search for novel biomark-
ers, contributions in this area of research are keenly 
awaited. Studies, designed to understand the genetic 
background of disease, can also draw our attention to 
molecular pathways that would otherwise remain 
unconsidered, especially when they are led by unbiased, 
hypothesis free approaches such as gene expression 
studies or genetic linkage- and positional cloning 
analyses. In this thesis we aimed to identify new genes 
and molecular pathways underlying insulin resistance. 
In particular we used type 2 diabetes and Familial 
Combined Hyperlipidemia (FCHL) as two complemen-
tary genetic models for insulin resistance. 
This chapter is divided in 2 main sections. In the first 
part, we offer a perspective on an emerging novel 
pathway in the pathophysiology of the metabolic syn-
drome, which is strongly related to one of the major 
findings of this thesis: The endoplasmic reticulum (ER) 
stress response or unfolded protein response (UPR). In 
the second part of this chapter, our study approach, its 
strengths and limitations, as well as the potential 
impact and implications of our results are discussed. 
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Part 1 
 
In this thesis the proximal ER stress sensor ATF6, was identified as a novel 
susceptibility gene for type 2 diabetes and FCHL (Chapter 4 and 5). The value 
of genetic research beyond an improved understanding of the complex genetic 
background that underlies these diseases, is that it can expose previously un-
explored pathways. The implication of ATF6 in the pathophysiology of type 2 
diabetes and FCHL coincides with preliminary insights in literature that link 
ER stress to multiple components of the metabolic syndrome. In the following 
section we discuss these scientific developments, preceded by a short intro-
ductory paragraph that describes the basic physiological role of the unfolded 
protein response, deployed by the joint action of its three main branches. At 
the appropriate passages we integrate our ATF6 related findings in type 2 
diabetes and FCHL in the broader research area of ER stress and the metabolic 
syndrome. 
 
 
ER stress and activation of the unfolded protein      
response: an emerging pathway linked with multiple 
components of the metabolic syndrome 
ER stress and activation of the UPR is implicated in diverse cellular and physi-
ological processes (secretory apparatus, plasma cell differentiation, apoptosis) 
(1-10), as well as in various pathologies including genetic misfolding diseases 
(osteogenesis imperfecta, Wolcott-Rallison syndrome), cancer (11-14), and 
neurodegenerative disorders such as Alzheimer disease (15-17) and Parkinson 
disease. (18-20) Very recently, several independent discoveries implicated ER 
stress and activation of the unfolded protein response in various pathologies 
associated with the metabolic syndrome, including type 2 diabetes (both insu-
lin resistance and beta cell failure) (21-23), dyslipidemia (24, 25), hepatic stea-
tosis (26, 27), inflammation (28) and atherosclerosis (29).  
The ER is a membranous network that functions in the maturation and folding 
of most secretory and membrane proteins. The flux of proteins that enter the 
ER  as  unfolded  polypeptide  chains  can  change  rapidly  in  response  to  
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Figure 1.The ER chaperone protein BiP/Grp78 serves as a master UPR regulator and plays an 
essential role in activation of the transmembrane proteins IRE1, PERK and ATF6 (31). In the 
absence of ER stress, BiP is associated with IRE1, PERK and ATF6. When unfolded proteins 
accumulate in the ER lumen, BiP dissociates from the ER transmembrane proteins and binds 
the unfolded proteins. This is followed by activation of IRE, PERK and ATF6. BiP release 
permits IRE1 and PERK to undergo spontaneous homodimerization mediated by their luminal 
domains and subsequently trans-autophosphorylation by their endogenous kinase activities 
(32). Activated PERK phosphorylates eukaryotic translation initiation factor 2 (eiF2) on the α 
subunit, thereby reducing the general rate of translation initiation and preventing the entry of 
new proteins in the already saturated ER. Activation of IRE is characterized by induction of its 
endoribonuclease activity. This activity catalyzes the removal of a small (26-nucleotide) 
intron from the unspliced XBP1 mRNA, which changes the translational reading frame of 
XBP1 and yields a potent active and stable transcription factor for UPR responsive genes. In 
addition, upon release of BiP, ATF6 translocates to the Golgi compartment where it subse-
quently undergoes cleavage by S1P and S2P (33). Cleaved ATF6 is a potent transcription 
factor for UPR responsive genes, including X-Box-Binding-protein 1 (XBP1), BiP, and Grp94. 
Noteworthy, two different ATF6 genes exist: ATF6-alpha and ATF6 beta. ATF6-alpha, located 
on chromosome 1 is responsible for actual UPR activation, whereas ATF6-beta - a different 
gene on chromosome 6- is opposing to ATF6-alpha and may serve as a transcriptional rep-
ressor, functioning in part to regulate the strength and duration of ATF6 alpha-mediated 
transcription in the UPR (34). The isoform studied in this thesis is ATF6-alpha. 
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mental conditions. Cells can handle this dynamic situation because protein 
folding capacity in the ER can be adapted according to the load of unfolded 
proteins in the ER lumen. The signaling pathway that mediates this adaptation 
is called the ER stress response or unfolded protein response (30, 31). “ER 
stress” refers to the cellular state in which the ER machinery fails to cope with 
the load imposed by newly synthesized proteins, resulting in progressive ac-
cumulation of unfolded proteins in the ER lumen. Subsequent activation of the 
unfolded protein response is initiated by three proximal ER stress sensors: 
inositol requiring 1 (IRE1), PKR-like endoplasmic reticulum kinase (PERK), 
and activating transcription factor 6 (ATF6) (Figure 1). Restoration of ER ho-
meostasis is achieved by the combined effect of these three signaling path-
ways. First, general protein translation is strongly inhibited, preventing the 
entry of novel polypeptides in the already saturated ER (reviewed in (35)). 
Second, unfolded or misfolded proteins in the ER lumen are retrotranslocated 
through the translocon to the cytoplasm, where they are ubiquitinated and 
degraded by the proteasome, a process called ER stress associated protein 
degradation (ERAD) (36, 37). Third, a transcriptional program is induced in-
cluding genes that aid in the folding process of proteins (molecular chape-
rones) and boost the capacity of the ER (reviewed in (35) and (38)). Finally, if 
ER-homeostasis cannot be re-established by means of these adaptive res-
ponses, the UPR activates pro-apoptotic pathways (9, 39, 40). 
 
 
The UPR in relation to type 2 diabetes 
Animal studies have shown that the IRE1 and PERK initiated pathways of the 
UPR, play an important role in the development of type 2 diabetes through 
effects on peripheral insulin resistance and beta cell function respectively. (2, 
21) 
 
The UPR and peripheral insulin resistance 
Classical ER stress triggers include glucose or nutrient deprivation, oxidative 
stress, viral infections and increased synthesis of secretory proteins. Recently it 
was shown that obesity poses a chronic strain on the ER machinery, and in-
itiates the UPR in genetic and diet induced mouse models of obesity (21). This 
is particularly the case for adipose tissue, which undergoes severe changes in 
tissue architecture, increases in protein and lipid synthesis, and perturbations 
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in intracellular nutrient and energy fluxes. Obesity induced activation of the 
UPR slows protein synthesis and boosts the capacity of the ER, but does so at 
the expense of glucose homeostasis. Ozcan et al showed that the IRE1 initiated 
pathway of the UPR confers this negative side effect (Figure 2). Activated 
IRE1, apart from having endoribonuclease activity (Ire1 splices XBP1, figure 1), 
is a kinase that activates c-jun N-terminal kinase (JNK). The serine kinase JNK 
subsequently serine-phosphorylates insulin receptor substrate-1 (IRS1), there-
by reducing insulin receptor signaling (Figure 2) (21). Thus, obesity induced 
ER stress can directly affect insulin signaling and induce cellular insulin 
resistance. 
 
 
Figure 2. The Ire branch of the UPR contributes to cellular insulin resistance 
 
Another observation published by Nakatani and colleagues supports these 
findings. They reported improved insulin resistance and ameliorated glucose 
tolerance upon overexpression of oxygen related protein (ORP150) a molecu-
lar chaperone in the ER (23). This chaperone reduces ER stress, and corres-
pondingly restores insulin signaling. The mechanistic link between ER stress 
and insulin resistance holds promises as a novel therapeutic target: oral ad-
ministration of chemical chaperones alleviated ER stress in cells and whole 
animals. Moreover, treatment of obese and diabetic mice with these chape-
rones resulted in normalization of hyperglycemia, restoration of systemic insu-
lin sensitivity, resolution of fatty liver disease, and enhancement of insulin 
action in liver, muscle, and adipose tissue (22). 
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The UPR and beta cell function 
In addition to the link between ER stress and peripheral insulin resistance, 
evidence emerged for a role of the UPR in beta cell function. PERK activation 
and subsequent phosphorylation of eiF2α is of critical importance for transla-
tional regulation of insulin secretion by the beta cell. A 50% decrease of eiF2α 
phosphorylation at serine 51, induces obesity and type 2 diabetes in mice on a 
high fat diet (2). Of note, two mutations in PERK have been shown to cause 
Wolcott-Rallison syndrome, a rare autosomal disorder characterized by islet 
beta cell dystrophy and infantile diabetes mellitus (18). 
It can be seen that the impact of UPR signaling to the development of type 2 
diabetes is not straightforward. At the level of the pancreas, the UPR protects 
the beta cell by maintaining the balance between pro-insulin synthesis and ER 
folding capacity (2). Conversely, in liver and adipose tissue, obesity induced 
ER stress and activation of the unfolded protein response causes peripheral 
insulin resistance (21). Although provocative, it seems not impossible that 
genetic variation in genes regulating the UPR, for instance ATF6, could have 
opposite effects in terms of insulin sensitivity and beta cell function. Such ef-
fect would partly explain how genetic variation accounts for differences be-
tween individuals regarding their natural propensity to initially develop 
hyperlipidemia or hyperglycemia in the presence of insulin resistance. 
 
 
ER stress and lipid metabolism 
The mechanistic activation of Sterol Regulatory Element Binding Proteins 
(SREBPs) and ATF6 in response to sterol deprivation and ER stress respective-
ly, may have evolved from a common ancestral pathway. Sterol Regulatory 
Element Binding Protein 2 (SREBP2) is an ER resident transcription factor with 
a central role in cholesterol homeostasis. When cellular cholesterol levels are 
normal, SREBP2 is anchored to the ER membrane (41, 42). In response to cellu-
lar demand for cholesterol, SREBP undergoes a proteolytic activation process, 
identical to that of ATF6, known as regulated intramembrane proteolysis 
(RIP). The transcriptionally active amino terminal domain of SREBP2 is re-
leased in the cytoplasm and migrates to the nucleus where it binds sterol re-
sponse element (SRE) sequences in the promoter region of target genes, in-
cluding cholesterogenic enzymes and the LDL receptor (43). Importantly, 
ATF6 can serve as an inhibitor of this process (24). Activated ATF6 can interact 
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with SREBP2 and bind as a heterodimer to sterol response elements (SREs) in 
the promoters of cholesterogenic genes. Bound to SRE, the ATF6-SREBP2 hete-
rodimer recruits HDAC1, and together they exert an inhibitory effect on 
SREBP2-regulated transcription. This represents one of the hypothetic me-
chanisms through which the methionine[67]valine gain of function polymor-
phism in ATF6 could increase plasma cholesterol levels. Other possibilities 
exist, illustrated by the presence of ATF6 binding elements in the promoter 
region of the apoB gene (28).  
Antagonistic effects between activation of the UPR and sterol metabolism have 
also been demonstrated for the PERK-initiated arm of the UPR, centered on 
eIF2α serine 51 phosphorylation and also known as “the integrated stress re-
sponse” (ISR). Phosphorylation of this unit adapts mammalian cells to a varie-
ty of stressful conditions, but simultaneously reduces the level of active SREBP 
and sterol regulated mRNA’s. On the other hand, a mutation in eIF2α that 
prevented phosphorylation of this residue enhanced activation of sterol-
regulated genes (25). Together, these findings suggest that ATF6- and ISR-
mediated inhibition of SREBP activation fine-tunes cholesterol biosynthesis to 
the circumstances of ER-stressed cells. 
 
 
ER stress and hyperhomocysteinemia 
Hyperhomocysteinemia triggers the ER stress response. Epidemiological sur-
veys have suggested a relationship between serum homocysteine levels and 
the development of cardiovascular disease. A mechanistic link for these cor-
relative observations was provided by Werstuck et al, reporting a direct effect 
of homocysteine induced ER stress on triglyceride and cholesterol biosynthetic 
pathways (27). In line with these observations, a pharmaceutical intervention 
with valproate, a small molecule drug that protects cells from ER stress in-
duced dysfunction, increased the resistance of cells to ER stress-induced lipid 
accumulation (26). This mechanism may explain in part the development and 
progression of hepatic steatosis, and the authors suggested that a similar me-
chanism could also contribute to atherosclerotic lesion formation observed in 
hyperhomocysteinemia. 
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ER stress and inflammation 
The metabolic syndrome is characterized by a state of low-grade inflammation 
and production of multiple pro-inflammatory cytokines by liver and adipose 
tissue (44). The first evidence for a link between ER stress and inflammation 
came from a genetic association study. Curran and colleagues identified a 
promoter polymorphism in the selenoprotein S gene (SEPS1, SELS), which is 
implicated in the ER stress response. (45) In their study, a direct mechanistic 
link between the SELS -105 G/A variant and altered production of inflammato-
ry cytokines IL-6, IL-1β and TNFα was demonstrated. In 2006, researches from 
the Kaufman-laboratory discovered a novel ER stress-response pathway in-
itiating an acute inflammatory response (28). CREBH was identified as liver 
specific transcription factor that is cleaved upon ER stress and required to 
induce expression of acute phase response genes. Identical to ATF6 and 
SREBPs, CREBH is anchored to the ER membrane and activated by regulated 
intramembrane proteolysis (RIP). Pro-inflammatory cytokines (IL6 and IL1β), 
and LPS can induce cleavage of CREBH and activate the acute phase response 
and the UPR in the liver in vivo. Importantly, Activated CREBH and ATF6 can 
interact and synergistically induce transcription of target genes in hepatocytes 
upon ER stress (28). These data extend the physiological role of ATF6, suggest-
ing that ATF6 could be a general ER stress-activated dimerization partner for 
RIP regulated transcription factors such as SREBPs and CREBH, hence mod-
ulating their transcriptional effects on genes involved in lipid metabolism and 
inflammation. The possibility that genetic variants in ATF6 could modulate 
the inflammatory response is intriguing and warrants further study. Addition-
al evidence that the UPR is a mediator of inflammation has been recently re-
ported.  In an attempt to identify novel pathways through which oxPAPC 
induces inflammatory genes in endothelial cells, the ATF4 (downstream of 
PERK) and XBP1 branches of the UPR pathway were found to mediate vascu-
lar inflammation and endothelial cell dysfunction in atherosclerosis (46, 47). 
 
 
ER stress and atherosclerosis 
The paragraphs above suggest an indirect effect of ER stress and activation of 
the UPR on the progression of atherosclerosis, via a modulating effect on 
many of its risk factors. However, endoplasmic reticulum stress is also directly 
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implicated in the progression of atherosclerosis. At least two pathways have 
been suggested through which ER stress catalyses the atherosclerotic process. 
The first is related to ER stress induced vascular inflammation and possibly 
disturbances in lipid fluxes in atherosclerotic lesions, (46, 47) as mentioned 
previously. Another well-described pathway has been described in macro-
phages.  Free cholesterol accumulation in macrophages in atherosclerotic le-
sions causes macrophage apoptosis and foam cell formation, a process that is 
believed to drive the progression of atherosclerosis. The ER has been identified 
as the culprit organelle for cholesterol-induced apoptosis. In contrast to the 
plasma membrane, the ER membrane is fluid, low in cholesterol (48), and par-
ticularly sensitive to the effects of free cholesterol enrichment. Even modest 
levels of free cholesterol were sufficient to activate the PERK-arm of the UPR 
in macrophages, and PERK-/- macrophages were hypersensitive to free choles-
terol loading (29). Cholesterol loading depleted the calcium stores in the ER. 
Subsequent activation of the UPR and changes in PERK activation led to acti-
vation of CHOP/GADD153, which finally induces apoptosis (29). 
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Part 2 
 
Gene expression profiling: An unbiased approach for 
dissecting complex diseases 
A pre-adipocyte gene expression study on patients with FCHL and healthy 
control subjects is the basis of this thesis (Chapter 3). An inherent limitation of 
gene expression profiles from “in vivo” human tissue samples is the difficulty 
to discriminate between primary genetic modifications that cause FCHL, and 
secondary changes resulting from cellular adaptations to hyperlipidemia. In 
the study presented in Chapter 3, we used a novel approach in an attempt to 
enrich for primary genetic alterations, or the direct cellular consequences the-
reof. Instead of using “fresh adipocytes” for gene expression profiling, we 
isolated the pre-adipocytes from liposuction samples and cultured them for 
several weeks under standardized experimental conditions. This design is 
based on the assumption that noise in the gene expression pattern due to pre-
vious metabolic influences is repressed, while genetic effects are preserved 
and expressed in vitro. Using this approach, CD36, a gene with known func-
tions involved in fat metabolism, was implicated in the pathophysiology of 
FCHL (Chapter 3). The approach applied in Chapter 3 still has some limita-
tions: although variation in gene expression due to environmental noise was 
probably efficiently reduced, it was not feasible to discriminate between gene 
expression differences from genetic or epigenetic origin. Another drawback is 
that not all genetic alterations might have been detected in a “standardized 
cell-culture environment”. According to the current thinking, the phenotype of 
Familial Combined Hyperlipidemia (and the metabolic syndrome in general) 
is the result of complex interactions between genes and environment. There-
fore, a genetically predisposed individual, or a primary cell culture from such 
an individual, may not express its phenotype in the absence of environmental 
trigger. An interesting follow up experiment would be to measure the gene 
expression pattern in pre-adipocytes of FCHL patients and control subjects 
under various challenging conditions such as high glucose, free fatty acids, 
cholesterol loading, or with addition of compounds that induce oxidative 
stress or endoplasmic reticulum stress. 
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Integrating data from gene expression studies and 
genetic linkage analyses 
Another valuable tool for unraveling complex genetic diseases are genome 
wide linkage analyses. Especially when combined with data from gene expres-
sion studies, a complementary methodology arises, unbiased by preconceived 
ideas about pathophysiological mechanisms. In the following paragraph we 
describe how this integrated approach led to the identification of ATF6 as a 
novel susceptibility gene for type 2 diabetes and FCHL in this thesis (Chapter 
4-5). 
Correlation analyses of gene expression data from cultured human pre-
adipocytes described in Chapter 3 revealed a positive relation between GRP94 
mRNA expression levels and fasting plasma glucose levels that had been 
measured in the corresponding subjects, in vivo. A similar gene expression 
study with cultured human EBV transformed lymphoblast cell-lines (49) re-
vealed a positive correlation between GRP78 (BiP) mRNA expression levels 
and in vivo plasma glucose levels. GRP94 and GRP78 are both endoplasmic 
reticulum chaperone proteins and master regulators of the endoplasmic reticu-
lum stress response or unfolded protein response (UPR). The unexpected posi-
tive correlation could not be the result of the well-known response of GRP94 
and GRP78 expression to glucose (50), since all cells had been cultured for 
several weeks under standardized, isoglycemic conditions. Based on these 
observations we hypothesized that the intrinsic cellular UPR capacity may 
partially determine a subject’s plasma glucose level, and that genetic variation 
in UPR-genes could contribute to the development of type 2 diabetes. An at-
tractive UPR candidate gene to consider was Activating Transcription Factor 6 
(ATF6). First, ATF6 is the common transcriptional regulator of GRP78 and 
GRP94. Second, ATF6 is one of the proximal sensors of endoplasmic reticulum 
stress and a critical initiator of the unfolded protein response. Third, ATF6 
maps to chromosome 1q23.3, the most replicated chromosomal locus for type 2 
diabetes(51-57). With these facts in mind we performed a genetic association 
study and identified ATF6 as a novel type 2 diabetes susceptibility gene 
(Chapter 4). 
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Evidence for a common genetic background in DM2 
and FCHL  
The parallel use of patient groups with type 2 diabetes and FCHL to study the 
genetic background of insulin resistance and the metabolic syndrome, pro-
vided a unique opportunity to investigate whether established and novel sus-
ceptibility genes for DM2 also confer increased risk to FCHL and vice versa.  
In Chapter 5 we screened the ATF6 gene for its potential involvement in the 
genetic background of FCHL. An amino acid substitution (methio-
nine[67]valine) was associated with increased risk of hypercholesterolemia 
and elevated apolipoprotein-B levels. Consistent results were obtained in two 
independent Dutch samples with increased cardiovascular risk and Familial 
Combined Hyperlipidemia (FCHL) respectively, and replicated in 715 indi-
viduals from 61 extended Finnish FCHL families. Notably, causality could be 
ascribed to this polymorphism by means of functional experiments. The genet-
ic implication of ATF6 in both DM2 and FCHL supports the concept of a 
shared genetic background for these disorders.  
USF1 is the first identified major gene for FCHL, and accounted for the linkage 
signal on 1q21-23 in Finnish families with the disease, especially in hypertrig-
lyceridemic males (58). Triggered by the overwhelming evidence for USF1 as a 
susceptibility gene for FCHL and lipid traits (58-66), some research groups 
have explored the direct contribution of the USF1 gene on type 2 diabetes 
susceptibility (67-70). However, results thus far were equivocal and replication 
studies in statistically powerful and phenotypically well-defined cohorts were 
critically needed. Therefore, in chapter 6, we evaluated the impact of USF1 risk 
alleles in 2 large Dutch case control samples comprising more than 2000 indi-
viduals. Our results appeared robust and straightforward and supported the 
hypothesis that USF1 also contributes to the genetic background of DM2. Ad-
ditional studies in distinct populations and a meta-analysis would be helpful 
to draw decisive conclusions about USF1. 
A third example in favor of the postulated overlapping genetic background in 
FCHL and type 2 diabetes is HNF4alpha. Originally identified as one of the 
genes that cause Maturity-Onset Diabetes of the Young (71), HNF4alpha is 
now a generally accepted susceptibility gene for common type 2 diabetes as 
well (72-80). Recently, the impact of HNF4alpha was extended to the metabolic 
syndrome, due to its association with increased serum lipid levels in families 
with Familial Combined Hyperlipidemia from Finland and Mexico (81).    
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What is the impact at the population level? 
A major goal of studying the genetic background of families or individuals 
with an explicit genetic predisposition, such as in FCHL, is to also demonstrate 
any potential impact of allelic variants at the population level. Translation of 
these finding to the general population requires large prospective follow up 
studies. Until now, USF1 is the only FCHL-gene that has successfully endured 
multiple validation steps, including prospective ascertainment. In the original 
study, two USF1 polymorphisms rs2073658 and rs3737787, in strong LD with 
each other, were the most strongly associated variants (58). Subsequent repli-
cation studies in various FCHL samples of distinct ethnicities implicated the 
same polymorphisms (or variants in tight LD) in the genetic background of 
FCHL (60, 62, 66). Complementary to these findings, significant associations 
with lipid traits, parameters of adipose tissue metabolism, and the metabolic 
syndrome in populations not specifically ascertained for FCHL, further ex-
tended the potential significance of USF1 as a cardiovascular risk determinant 
(59, 61, 63, 69, 82). Finally, recent important data from a prospective follow up 
study demonstrate that USF1 risk alleles confer an approximately two fold 
increased risk to cardiovascular disease and all-cause mortality in women 
from two independent Finnish cohorts representative of the general popula-
tion (64). These latter data provide important decisive evidence and illustrate 
how a gene originally identified in high-risk families proves to be important 
also at the population level. Noteworthy, as much as ~75% of subjects carry the 
risk allele, which translates to a population attributive risk (PAR) of 14% in our 
study. This means, that if the population were monomorphic for the protective 
allele, the prevalence of type 2 diabetes would be 14% lower. Thus, although 
the impact of USF1 is modest at the level of the individual –which is true for 
most susceptibility genes that underlie complex diseases– the effect at the 
population level is substantial. 
 
 
Implications and future directions 
In this thesis three genes were addressed in relation to type 2 diabetes and 
FCHL: CD36, ATF6 and USF1. A valuable insight arising from the demon-
strated up-regulation of CD36 in FCHL-pre-adipocytes, is that genetic defects 
have measurable cellular consequences in adipose tissue. Hence, this study 
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provided proof at the cellular level for the concept of defective FCHL adipose 
tissue, which was largely underpinned by observations from epidemiological 
studies (83, 84). From a functional viewpoint the fatty acid transporter CD36 is 
a logical and attractive candidate gene for FCHL. However, in contrast to 
USF1 and ATF6, CD36 is more likely the manifestation of an underlying genet-
ic alteration, rather than harboring the defect by itself. With our long-term goal 
in mind –the genetic dissection of FCHL and type 2 diabetes- future research 
should be directed by USF1- and especially our ATF6-related research find-
ings. The cellular role of ATF6 in relation of insulin resistance is currently 
unexplored, but represents one of the research questions that we shall address 
in the near future. 
More than 2 years and many replications in various populations were needed 
for USF1 from identification as FCHL candidate gene until its present general 
acceptance as established CVD susceptibility gene. The potential effect of USF1 
on type 2 diabetes susceptibility has not even been unequivocally established 
until now. Compared to USF1, the identification of ATF6 as a candidate gene 
for FCHL and type 2 diabetes is still in its infancy. Despite the fact that the 
genetic association is robust and supported by functional data, a stringent path 
of validation similar to USF1 will be required before it meets the current high 
standards in genetic epidemiology. Nevertheless, the demonstrated involve-
ment of ATF6 in two of the largest FCHL samples worldwide, is an important 
contribution to our understanding of the complex FCHL genetics, and promis-
ing in terms of its potential impact on cardiovascular risk in the general popu-
lation. Noteworthy, the identification of ATF6 as a novel susceptibility gene 
for type 2 diabetes and FCHL coincides with preliminary insights that now 
emerge in the scientific literature, pointing out that ATF6 and the UPR in gen-
eral represents an important novel pathway linked with multiple components 
of the metabolic syndrome. A theoretical perspective on these exciting devel-
opments has been provided in part 1 of this chapter. 
 We assured the potential use of ATF6 as diagnostic marker for predictive 
genetic testing, as well as a novel cellular target for treatment modalities by 
pharmaceutical interventions1 (85). Apart from the ethical considerations, the 
debate about whether genetic markers for complex genetic diseases could be 
informative for clinical use is ongoing. In a recent study by Florez and col-
leagues it was demonstrated that the TCF7L2 risk alleles, the strongest and 
                                                           
1
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best replicated DM2 susceptibility gene to date, predict the risk of diabetes 
prospectively, beyond that conferred by clinical risk factors (86). Other re-
searchers however dispute the predictive power and applicability of genetic 
markers for complex diseases (87). Fact remains however that in current clini-
cal practice a patient’s family history for cardiovascular disease or type 2 di-
abetes considerably influences the clinicians appraisal regarding further medi-
cal policy for that patient. Therefore, it is not inconceivable that detailed genet-
ic patient information will one day be superior over the classical family histo-
ry, and assist medical doctors in their clinical judgment. 
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Summary 
Over the past two decades, a dramatic worldwide increase in the number of 
people with obesity has been observed. The obesity pandemic is the driving 
force behind the high incidence of cardiovascular disease. The term “metabolic 
syndrome” defines the clustering of various obesity-associated cardiovascular 
risk factors (hypertension, disturbed glucose homeostasis and atherogenic 
dyslipidemia) with insulin resistance as a central component A combination of 
environmental (nutrition, physical activity) and genetic factors determines the 
risk for a given individual to develop the metabolic syndrome. Two subgroups 
of patients with the metabolic syndrome, those with type 2 diabetes (DM2) 
and familial combined hyperlipidemia (FCHL), are at particularly high risk for 
premature cardiovascular disease. Nearly two-thirds of individuals with 
FCHL, and 80-90% of patients with type 2 diabetes, meet the diagnostic criteria 
of the metabolic syndrome. The marked presence of a genetic component in 
type 2 diabetes and FCHL, reflected by their familial clustering, provides us 
with two excellent models to study the genetic background of insulin resis-
tance and may benefit millions of people with the metabolic syndrome. 
 
The central aim of this thesis was to identify novel genes and molecular path-
ways that underlie the pathophysiology of insulin resistance. In particular 
DM2 and FCHL were used as two complementary genetic models for insulin 
resistance. Since DM2 and FCHL are postulated to share some of their genetic 
components, our side by side research design also provided a unique oppor-
tunity to investigate whether established and novel DM2 susceptibility genes 
confer also increased risk to FCHL and vice versa.  
 
In chapter 2 we discussed the various approaches that can be employed to 
dissect the genetic background of complex diseases, and the contribution of 
each method to our present understanding of the genetic background of fa-
milial combined hyperlipidemia (FCHL) and type 2 diabetes (DM2)  
The first experimental chapter (Chapter 3) is the basis of this thesis. It describes 
a gene expression study conducted on cultured pre-adipocytes from patients 
with FCHL and healthy control subjects. The use of cultured human cells in-
stead of freshly isolated adipocytes allowed us to suppress adaptive gene ex-
pression differences and preserve the (epi)genetic effects. This approach re-
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vealed increased CD36-expression and CD36-functionality as a novel, poten-
tially important feature of FCHL adipose tissue, which may be of genetic ori-
gin 
Combined information from gene-expression data in chapter 3, another FCHL 
expression array with immortalized lymphoblast cell lines, and data from 
genetic linkage analyses led to the identification of a new candidate gene for 
type 2 diabetes: Activating Transcription Factor 6 (ATF6). The potential signi-
ficance of ATF6 is extended in Chapter 5 were we demonstrate association of 
an exonic variant in ATF6 with FCHL in three independent samples from 
Dutch and Finnish origin. In vitro studies support the genetic data and une-
quivocally implicate the ATF6 exon polymorphism as a causal variant. To-
gether, results from chapter 4 and 5 provide proof for the postulated shared 
genetic background in FCHL and type 2 diabetes, and highlight the endop-
lasmic reticulum stress response, a novel pathway in the pathophysiology of 
insulin resistance and dyslipidemia. Chapter 6 evaluates the well-established 
FCHL-susceptibility gene Upstream Stimulatory Factor 1 (USF1), for its poten-
tial role in type 2 diabetes in two large Dutch case control samples comprising 
more than 2000 individuals. In Chapter 7 we put all data in perspective, discuss 
their potential relevance for diagnostic or screening purposes, and integrate 
them with emerging insights in the field of insulin resistance, with emphasis 
on the endoplasmic reticulum stress response. 
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Samenvatting 
Het aantal mensen met overgewicht neemt wereldwijd explosief toe. Deze 
pandemie is de drijvende kracht achter de hoge incidentie van hart- en vaat-
ziekten. Mensen met overgewicht lijden vaak aan het zogenaamde “metabool 
syndroom”, een cluster van cardiovasculaire risicofactoren (hypertensie, hy-
perglycemie, en een atherogeen lipoprotein phenotype) met als centrale com-
ponent “insuline resistentie”. Het risico om als individu het metabool syn-
droom te ontwikkelen —en daarmee  dus een sterk verhoogd risico op hart- en 
vaatziekten— wordt bepaald door een combinatie van levensstijl (voeding, 
lichaamsbeweging) en erfelijkheid. Twee subgroepen met het metabool syn-
droom hebben een bovengemiddelde erfelijke belasting, en daarmee een nog 
hoger risico op hart- en vaatziekten: het betreffen patiënten met familiair ge-
combineerde hyperlipidemie (FGH) en type 2 diabetes (DM2). Deze twee pati-
entengroepen zijn vanwege hun duidelijke genetische component een uitste-
kend model om de erfelijke aspecten van insuline resistentie en het metabool 
syndroom te onderzoeken. Bijna 2/3 van de patiënten met FGH en zelfs 80-90% 
van de DM2-patienten voldoen aan de criteria van het metabool syndroom. 
Een beter begrip van de genetische variaties die ten grondslag liggen van deze 
aandoeningen is dus niet alleen van belang voor deze twee specifieke popula-
ties, maar heeft een mogelijke draagwijdte voor miljoenen patiënten met het 
metabool syndroom. 
 
De centrale doelstelling van dit proefschrift was het identificeren van nieuwe 
genen en cellulaire routes die aan de basis liggen van insuline resistentie. 
Hiervoor werden DM2 en FGH gebruikt als twee complementaire genetische 
modellen voor insuline resistentie. Omdat verondersteld wordt dat DM2 en 
FGH een gedeeltelijk overlappende genetische achtergrond hebben, bood onze 
onderzoeksopzet bovendien de unieke mogelijkheid om het effect van be-
staande en nieuwe “diabetesgenen” te verifiëren in FGH, en omgekeerd.  
 
In hoofdstuk 2 zijn de verschillende mogelijke benaderingen beschreven die 
gebruikt kunnen worden voor de ontrafeling van complexe genetische aan-
doeningen, en de bijdrage van elke methode aan de huidige inzichten in de 
genetische achtergrond van DM2 en FGH. 
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Hoofdstuk 3 vormt de experimentele basis van deze thesis. Hier werd een 
genexpressiestudie uitgevoerd met gekweekte pre-adipocyten (voorlopers van 
vetcellen) van patiënten met FGH en gezonde controlepersonen. De keuze 
voor gekweekte pre-adipocyten in plaats van verse adipocyten, direct uit de 
patiënt, maakte het mogelijk om adaptieve genexpressieverschillen te onder-
drukken, en alleen de genetische en epigenetische effecten te selecteren. Mid-
dels deze aanpak werd in cellen afkomstig van FGH patiënten een verhoogde 
expressie van CD36, en toegenomen vetzuurtransport via dit molecuul, aange-
toond. Dit is wellicht een reflectie van insulineresistentie bij FGH, die reeds in 
een zeer vroeg stadium detecteerbaar is en mogelijk een genetische oorsprong 
heeft. 
Het combineren van informatie uit genexpressiestudies (o.a. uit hoofdstuk 3) 
en genetisch koppelingsonderzoek, heeft geleid tot de identificatie van een 
nieuw kandidaatgen voor type 2 diabetes in hoofdstuk 4: Activatie Transcrip-
tie Factor 6 (ATF6). De mogelijke relevantie van ATF6 werd in hoofdstuk 5 
nog verder uitgebreid door aan te tonen dat een veelvuldig voorkomende 
aminozuursubstitutie in dit gen geassocieerd is met FGH, en vooral invloed 
heeft op plasma (LDL-)cholesterol en apolipoprotein B. Deze vinding werd 
robuust gerepliceerd in drie onafhankelijke Nederlandse en Finse patiënten-
cohorten. Samen met een serie in vitro experimenten wijzen deze data eendui-
dig het polymorfe aminozuur 67 in het ATF6-eiwit aan als de causale variant. 
Hoofdstukken 4 en 5 bieden gezamenlijk enig bewijs voor de veronderstelde 
overlappende genetische achtergrond van type 2 diabetes en familiair gecom-
bineerde hyperlipidemie. Nog belangrijker is dat de data een nieuwe cellulaire 
route impliceerden voor insuline resistentie en dyslipidemie: “de endoplasma-
tisch reticulum stress response”. 
Eveneens in functie van de mogelijke genetische overlap tussen type 2 diabe-
tes en FGH, werd in hoofdstuk 6 het gevestigde en meest gerepliceerde FGH 
risico gen USF1 bestudeerd in relatie tot zijn mogelijke betrokkenheid bij type 
2 diabetes. Een bescheiden, maar significante associatie met type 2 diabetes 
werd hierbij aangetoond. In hoofdstuk 7 plaatsten we alle verkregen data in 
perspectief, bediscussieerden hun mogelijke relevantie in een tijdperk waar 
“gepersonaliseerde geneeskunde” steeds belangrijker wordt, en focusten op 
nieuwe inzichten in de rol van endoplasmatisch reticulum stress in bijna alle 
componenten van het metabool syndroom. 
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It is not the strongest or the smartest that survive,  
but those most able to adapt to change. 
Charles Darwin 
